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Alzheimer’s disease (AD) is a severe age-related neurodegenerative disorder and is 
the most common form of dementia. Although the pathogenesis of AD remains 
unknown, the deterioration of the cerebrovascular system constitutes a risk factor 
associated with the development of the disease. Notably, brain hypoperfusion, a 
feature of healthy ageing brain and AD, occurs prior to the onset of cognitive decline 
in AD and correlates with the severity of dementia. Although there is a clear link 
between hypoperfusion and cognitive alterations in AD, a causal relationship remains 
to be established. It was hypothesised that chronic cerebral hypoperfusion leads to 
the accumulation of parenchymal and vascular amyloid-β (Aβ), triggering the 
development of vascular lesion (microinfarcts (MIs) and haemorrhages) and altering 
the neurovascular unit (NVU) integrity. Second to this, it was hypothesised that 
reductions in Aβ levels by immunotherapy targeted to amyloid in young mice, reduce 
amyloid levels, and prevent vascular lesions improving cognitive performance. Three 
studies were conducted to test these hypotheses. 
 
In the first study, the aim was to characterise age-dependent changes in amyloid-
related pathology in a transgenic mouse model (Tg-SwDI). The temporal amyloid 
precursor protein (APP) expression, accumulation of parenchymal and 
cerebrovascular Aβ and Aβ-related microglial and astrocytic activation in the cortex, 
hippocampus and thalamus of the Tg-SwDI mice at 3, 6 and 9 months of age was 
compared to wild-type controls. Significantly higher APP expression (p < 0.05), as 
well as Aβ aggregation (p < 0.001) as the animals aged was found in the Tg-SwDI 
mice in all the brain regions analysed, which was accompanied by extensive and 
progressive activation of microglial (p < 0.001) and astrocytic (p < 0.01) cells. These 
data provided a basis to design the next studies, as it was planned to induce 
hypoperfusion in these mice before significant Aβ deposition occurs. 
 
In the second study, the aim was to investigate the effect of hypoperfusion on Aβ 
dynamics and subsequently, to study the contribution of hypoperfusion and Aβ 
pathology to the development of MIs and haemorrhages, and to the potential 
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alteration of astrocyte and tight junction (TJ) integrity. To address this, mild chronic 
cerebral hypoperfusion was induced in Tg-SwDI and wild-type mice by bilateral 
common carotid stenosis for 1 and 3 months. A significant increase in soluble 
Aβ40/42 levels was initially found after 1 month of hypoperfusion in the parenchyma 
(Aβ40, p = 0.0239; Aβ42 p = 0.0198) in parallel with elevated APP levels and APP 
proteolytic cleavage products (p < 0.05). Thereafter, following 3 months, a 
significant increase in insoluble Aβ40/42 levels was determined in the parenchyma 
(Aβ40, p = 0.0024; Aβ42 p = 0.008) and vasculature (Aβ40, p = 0.0046; Aβ42 p = 
0.0118) of Tg-SwDI mice. There was no change in the levels of Aβ co-localised to 
vessels following 1 month of hypoperfusion; however Aβ levels were significantly 
increased in cerebral vessels after 3 months (p = 0.0483). The proportion of Aβ 
containing vessels was significantly higher in the small vessels of the hypoperfused 
animals compared to sham mice (p < 0.05). MIs associated with microglial 
proliferation were present in the Tg-SwDI mice and the burden was exacerbated by 
hypoperfusion at 1 and 3 months (p < 0.05). Significantly higher levels of NADPH 
Oxidase-2 (NOX2) were found in the transgenic mice compared to the wild-type 
controls at both time-points analysed (p < 0.05), and this was exacerbated after 1 
month of hypoperfusion in the Tg-SwDI mice (p < 0.05). There was a positive 
correlation between NOX2 and soluble parenchymal Aβ levels (r = 0.6643, p = 
0.0019). A minimal effect on the development of haemorrhages at these time-points 
was observed. In parallel to this, astrocyte activation was significantly higher in the 
Tg-SwDI mice compared to the wild-type controls at both time-points studied (p < 
0.05); however, no effect of hypoperfusion was observed. Also, significantly higher 
levels of aquaporin-4 (AQP4) in the Tg-SwDI mice compared to the wild-type 
controls following 1 month of hypoperfusion were found (p < 0.001). There was a 
positive correlation between AQP4 and soluble parenchymal Aβ levels (r = 0.4735, p 
= 0.0095). Claudin-5 levels were significantly higher in the Tg-SwDI mice compared 
to the wild-type controls at both time-points analysed (p < 0.0001), and this was 
exacerbated following 1 month of hypoperfusion in the transgenic model (p < 0.05). 
A positive correlation between claudin-5 and vascular Aβ levels was observed (r = 
0.6113, p = 0.0004). Together, these data suggest a synergistic contribution of 
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amyloid and hypoperfusion pathologies to the tissue damage and implicate a role of 
oxidative stress and inflammation. 
 
In the third study, the aim was to determine the effects of passive amyloid 
immunisation on Aβ levels, development of MIs and haemorrhages and behavioural 
performance in the Tg-SwDI mice. To address this, the mice underwent weekly 
intraperitoneal injections with either 3D6 or 10D5 antibodies during 3 months. 
Although there were no significant changes between control and 10D5/3D6 treated 
mice in amyloid levels, appearance of MIs and cognitive performance, it was noted 
that there was a trend towards a reduction in amyloid levels and MI area in the 
10D5/3D6 treated mice compared to the control animals. Furthermore, there was no 
evidence of microhaemorrhages in response to the immunisation. These results 
demonstrate that Aβ immunotherapy with the antibodies 3D6 and 10D5 may 
potentially decrease parenchymal and vascular amyloid accumulation, reducing the 
appearance of MIs and notably without triggering the development of 
microhaemorrhages. 
 
Collectively, the findings presented in the current thesis demonstrate that chronic 
cerebral hypoperfusion increases parenchymal and vascular Aβ levels and point 
towards a mechanism in which the cascade of events including inflammation and 
oxidative stress, triggered synergistically by hypoperfusion and Aβ, resulted in the 
widespread development of MIs and NVU changes which may further induce the 
alteration of cognition networks. A mixed therapy, aimed at improving 
cerebrovascular health and targeting the accumulation of Aβ, represents a promising 
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Alzheimer’s disease (AD) is a devastating progressive neurodegenerative disorder 
and constitutes the most frequent form of dementia accounting for 60-80% of all 
cases (Alzheimer’s Association, 2014). With an increasing prevalence, AD, first 
described in 1906 by the German psychiatrist Alois Alzheimer (Alzheimer, 1907; 
Devi and Quitschke, 1999), represents the most important neurodegenerative disease 
in the elderly population. It is estimated that 5.2 million Americans were affected by 
the disease in 2014, of which > 96% are above age 65. In the UK, 505,813 persons 
were affected by the disease in 2014. A number of prevalent cases of more than 35 
million across the world is currently estimated and it is predicted that this number 
will triple by 2050 (Wimo and Prince, 2010; Huang and Mucke, 2012, Alzheimer’s 
Association, 2014). AD constitutes a major emotional and financial burden to carers 
and society as patients require constant and extensive care. Thus, considering the 
worldwide population ageing, this disease has become an enormous challenge to 
public health. 
 
Clinically, AD is generally characterised by a progressive memory loss, with 
episodic memory impairment being the most relevant, constituting one of the earliest 
signs of the disease (Gold and Budson, 2008). The memory alterations are followed 
by the deterioration of other cognitive functions; in more advanced stages of the 
disease, behavioural changes such as depression and language difficulties are 
noticeable (Weintraub et al., 2012). Currently, there is a lack of a sensitive, early 
diagnosis to identify the patients before they display the clinical symptoms and the 
disease can only be confirmed by examination of post-mortem brains (Urbanelli et 









The neuropathological hallmarks of the disease include the accumulation of two 
types of misfolded proteins: intraneuronal deposits of hyperphosphorylated micro-
tubule-associated tau protein called neurofibrillary tangles (NFTs) and amyloid-β 
(Aβ) aggregates in brain parenchyma and in the blood vessel walls (Terry, 1994; 
Trojanowski and Lee, 2000). The distribution of NFTs follows a typical pattern of 
lesions, being accumulated early in the entorhinal cortex, followed by hippocampal 
accumulation and then association cortex. This consistent temporal distribution 
constitutes the basis of the Braak and Braak staging system for AD diagnosis (Braak 
and Braak, 1991). Although NFT accumulation is highly associated with neuronal 
and synapse loss, the causative role of these aggregates in neuronal cell death 
remains ill understood (Serrano-Pozzo et al., 2011). Nevertheless, a high correlation 
has been found between the degree of NFTs and the severity of dementia in AD 
(Arriagada et al., 1992; Bierer et al., 1995). Different degrees of Aβ aggregation may 
lead to a variety of Aβ structures in the AD brain and two types of assemblies are 
most commonly observed: diffuse plaques, which are also a common feature of the 
normal ageing brain with no evidence of associated cognitive alterations (Morris et 
al., 1996), and the dense-core plaques which are formed by a central mass of fibrillar 
Aβ with radial filaments that are surrounded by degenerating neurites and are 
associated with microglial and astrocyte activation (Serrano-Pozzo et al., 2011). In 
contrast to the NFTs, the temporal distribution pattern of Aβ plaques is less 
consistent, however they are mostly observed in the isocortex. Although the evidence 
has failed to demonstrate a correlation between plaque extent and cognitive 
alterations in AD (Arriagada et al., 1992; Giannakopoulos et al., 2003), more recent 
studies have attributed these alterations to different Aβ structures rather than amyloid 
plaques (see section 1.1.5). Although vascular amyloid accumulation can be found in 
the normal ageing brain, it is highly prevalent in the AD brain and constitutes another 
pathological feature of the disease (see section 1.1.7).  
 
Atrophy of the brain as the result of neuronal cell death and widespread synaptic loss 
also represents a typical observation in AD. The regional distribution of cerebral 
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atrophy can be determined in vivo by using imaging approaches such as magnetic 
resonance imaging (MRI) or by post-mortem histological analysis. Differential 
topographic patterns of atrophy are associated with different diseases and extensive 
involvement of the temporal lobe, predominantly in the hippocampus and entorhinal 
cortex, have been observed in the early stages of AD (Braak and Braak, 1991). 
Indeed, high resolution MRI has been shown to be useful to study the progression of 
the disease and predict further cognitive decline in AD (de Leon et al., 1993; Rusinek 
et al., 2003; Desikan et al., 2009). 
 
1.1.3. Amyloid-β metabolism.  
 
Aβ peptide is derived from the proteolytic cleavage of the amyloid precursor protein 
(APP). APP is a single transmembrane protein with three major isoforms generated 
from alternative splicing and defined by the number of amino-acids they contain 
(695, 751 and 770) (Chasseigneaux and Allinquant, 2012). APP is ubiquitous, 
however APP695 is highly expressed in neuronal cells and low expression of this 
isoform is found in other type of cells (Haass et al., 1991). The biological function of 
this protein remains unclear, however in vitro and in vivo studies have demonstrated 
that APP and the soluble fragments released during its processing including Aβ, are 
implicated in several processes including the development of the nervous system, 
gene regulation, cell adhesion, synaptic plasticity, axonal transport and 
synaptogenesis (Gralle and Ferreira, 2007; Chasseigneaux and Allinquant, 2012).  
 
APP can be metabolised by two different pathways, undergoing different proteolytic 
cleavages in each of them. Cleavage by α-secretase produces the soluble APP α 
(sAPPα) and an 83 amino acid long C-terminal fragment. In the alternative or 
amyloidogenic pathway, sequential cleavage of APP by β and γ-secretases generates 
the soluble APP β (sAPPβ), the APP intracellular domain (AISD) and the full length, 
4kDa Aβ protein (Figure 1.1) (Hartmann et al., 1997). γ-secretase can cut at various 
sites within the APP, leading to the formation of Aβ peptides fluctuating from 38 to 
43 amino-acids, although the most common forms are Aβ40 and Aβ42, which under 
normal physiological conditions are found in an Aβ42:Aβ40 ratio of ~1:9 in the brain 













Figure 1.1. Schematic representation of APP processing. APP is cleaved via two 
alternative pathways. In the non-amyloidogenic pathway, cleavage by α secretase 
releases the sAPPα. In the amyloidogenic pathway cleavage by β and γ secretases 











Increases in total Aβ levels or changes in the Aβ42:Aβ40 ratio are associated with 
the pathogenesis of AD (Pauwels et al., 2012). In vitro studies have shown that Aβ is 
able to spontaneously bind to another monomer to rapidly form aggregates, hence in 
AD brains, as well as in cerebrospinal fluid from AD patients, it is possible to find a 
range of Aβ species including monomers, oligomers, proto-fibrils and fibrils. Aβ42, 
which is more susceptible to self-aggregation into fibrils and more cytotoxic, is the 
main peptide found in extracellular deposits in the brain whilst Aβ40 is mostly found 
in vascular aggregates (Jarrett et al., 1993; Younkin, 1995; Dahlgren et al., 2002). 
 
In healthy brains, Aβ is effectively metabolised with little accumulation and the 
maintenance of normal brain levels of Aβ depends on the correct balance between its 
production and elimination. There are several pathways through which Aβ is cleared 
from the brain. These include cellular uptake through different receptors such as the 
microglial scavenger receptor A-1 (scara1) and degradation (Li et al., 2012), 
clearance along the interstitial fluid drainage pathway (Weller et al., 2008), 
lipoprotein receptor-related protein (LRP) and receptor for advanced glycation 
endproducts (RAGE) mediated flux across the blood brain barrier (BBB) (Zlokovic, 
2004), and through proteolytic degradation by Aβ-degrading enzymes (Iwata et al., 
2001; Farris et al., 2003) (Figure 1.2). 
 
1.1.4. Risk factors. 
 
There are two different forms of the disease. The early onset (< 65 years) autosomal-
dominant familial Alzheimer’s (FAD) is rare and represents less than 5% of the 
cases. This form of the disease is caused by mutations in the APP gene, or mutations 
in the presenilin 1 (PS1) 1 or presenilin 2 (PS2) (which are the catalytic subunits of 
the γ-secretase) genes, leading to altered Aβ metabolism and increased deposition of 
the protein, representing the major known genetic risk factor for AD (Goate et al., 
1991; Citron et al., 1992; Hendriks et al., 1992; Mullan et al., 1992; Suzuki et al., 




















Figure 1.2. Mechanisms of Aβ clearance. The maintenance of normal brain levels 
of Aβ depends on the correct balance between its production and elimination. The 
different clearance pathways by which Aβ is eliminated from the brain are illustrated 
in the figure, which shows Aβ clearance following amyloid immunotherapy (image 










The most common form of the disease is the sporadic late onset (>65 years) AD, the 
cause of which remains unknown, probably due to the multifactorial nature of the 
disease; however it has been related to several risk factors. Ageing is the most 
important known risk factor for sporadic AD and notably, the risk doubles every 5 
years after the age of 65 years (Qiu et al., 2009). The major genetic risk factor 
recognised to be associated with the late onset AD is the presence of the ε4 allele of 
the apolipoprotein E gene (apoE4), which increases the risk by three times in 
heterozygotes and by 15 times in homozygotes (Farrer et al., 1997). It is estimated 
that 40-60% of people affected with the disease display at least one copy of the ε4 
allele (Hauser and Ryan, 2013). Although the underlying mechanism behind this 
higher susceptibility remains currently unclear, immunohistochemistry studies have 
shown that brains from patients expressing apoE4 protein present enhanced amounts 
of Aβ aggregates compared to patients lacking the protein, particularly Aβ40 
deposits in brain parenchyma and microvessels (Rebeck et al., 1993; Schmechel et 
al., 1993; Greenberg et al., 1995; Gearing et al., 1996) suggesting that the presence 
of the apoE4 genotype might be associated with increased Aβ deposition or altered 
clearance of the protein.  
 
More recent studies have revealed an association between mutations in the triggering 
receptor expressed on myeloid cells 2 (TREM2) and a significant increase in the risk 
of AD, with an odds ratio (OR) > 3 (Guerreiro et al., 2013; Jonsson et al., 2013). 
TREM2 is involved in microglial signalling and plays an important role in 
phagocytosis activation as well as suppressing cytokine production and inflammation 
(Takahashi et al., 2005). Although the percentage of the population affected by these 
mutations is unknown, it has been reported that a single mutation in the gene that 
encodes this receptor predisposes to AD, which strongly supports a role for 
inflammation in AD. Mutations in TREM2 may possibly not be directly related with 
the onset of AD; however it might enhance the susceptibility to the disease 
progression by triggering alterations in microglial function. Interestingly, a study 
performed in aged APP23 transgenic mice showed upregulation of TREM2 in 
amyloid plaque-associated microglia compared to plaque-free tissue, which provides 
evidence of the involvement of this receptor in microglia-Aβ interaction. 
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Furthermore, there is a positive correlation between TREM2 expression 
and Aβ phagocytosis (Frank et al., 2008; Melchior et al., 2010). Thus, mutations in 
this receptor may lead to altered Aβ uptake by microglia. In the other hand, given the 
anti-inflammatory function of TREM2, mutations in this protein may also contribute 
to the progression of AD pathology by promoting neuroinflammation.  
 
Although TREM2 has been the only gene found to be linked with increased risk of 
AD following the associations between the ε4 allele of the apoE gene and the 
disease, enormous efforts have been made to find further genetic association. Thus, 
the International Genomics of Alzheimer's Project has been created and large genetic 
screens are ongoing (Guerreiro and Hardy, 2014). The most relevant susceptibility 
loci identified by genome-wide association studies include the bridging integrator 1, 
phosphatidylinositol binding clathrin assembly protein, clusterin and complement 
component receptor 1, among others (Lambert et al., 2013). Environmental factors 
including head injury, diabetes, low educational level and vascular risk factors 
(VRFs) have also been suggested to play a role in the development of the disease 
(Rosendorff et al., 2007; Van Den Heuvel et al., 2007; Sharp and Gatz, 2011; 
Milone, 2012). However although several risk factors have been associated with the 
pathophysiology of sporadic AD, the exact cause of the disease remains unrevealed 
probably due to the heterogeneous nature of the disease where ageing in concert with 
susceptibility genes and environmental factors combine in complex interactions that 
lead to the development and progression of the disease. 
 
1.1.5. Amyloid hypothesis of Alzheimer’s disease. 
 
Aβ peptide was first isolated and characterised from human leptomeningeal arteries 3 
decades ago (Glenner and Wong, 1984). Following this discovery, the protein was 
identified as the main component of senile plaques in brain tissue from AD patients 
and aged individuals with Down’s syndrome (DS) (Masters et al., 1985). 
Subsequently, it was demonstrated that Aβ is generated from the proteolytic cleavage 
of APP and the APP gene was first cloned and mapped to a locus on chromosome 21 
(Kang et al., 1987). DS patients, who carry an extra copy of this chromosome, 
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manifest early onset dementia and exhibit neuropathological features of AD (Millan 
Sanchez et al., 2012). Similar to what occurs in patients affected by mutations in 
APP, PS 1 or PS 2, trisomy of chromosome 21 leads to altered Aβ metabolism and 
an increased Aβ42:Aβ40 ratio (Teller et al., 1996). Furthermore, there is evidence 
showing an association between mutations in the PS gene and increased DS 
offspring, which has been suggested to be related with chromosome missegregation 
due to mitosis alterations (Geller and Potter, 1999; Lucarelli et al., 2004). 
 
Later, the identification of the mutations in the APP gene causing a familial form of 
the disease (Levi et al., 1990; Van Broeckhoven et al., 1990; Fernandez-Madrid et 
al., 1991; Goate et al., 1991; Naruse et al., 1991; Hendriks et al., 1992; Mullan et al., 
1992), led to the amyloid cascade hypothesis of AD. This was first proposed in 1991 
(Hardy and Allsop, 1991) and states that Aβ peptide is the central player in AD 
pathogenesis and that aggregation and deposition of this protein in brain directly 
induce synaptic injury in addition to inflammation and oxidative damage leading to 
widespread cell death and finally dementia. According to this hypothesis, all other 
neuropathological hallmarks of the disease such as NFTs are the consequence of Aβ 
deposition, which is the result of an imbalance between Aβ production and clearance 
(Selkoe, 1991; Hardy and Higgins, 1992). 
 
Although the amyloid cascade hypothesis has been the focus of AD research since it 
was first proposed in the early 1990s and has proven useful to understand the 
progression and pathogenesis of the disease, there are concerns regarding some 
aspects of this hypothesis. One of the criticisms is that many transgenic mouse 
models showing substantial Aβ accumulation and neuropil abnormalities do not have 
extensive neuronal loss (Irizarry et al., 1997). Moreover, transgenic mice that 
undergo Aβ accumulation have shown cognitive alterations before Aβ deposition in 
the brain (Hsiao et al., 1996). Similarly, spatial learning deficits occur independently 
of plaques in Aβ overexpressing mice (Koistinaho et al., 2001). Finally, the main 
objection of the hypothesis is the lack of a strong correlation between the degree of 




However, these studies are based on immunohistochemical analyses where smaller, 
oligomeric Aβ species are undetected and importantly, biochemical studies have 
revealed a good correlation between the load of these soluble species and the degree 
of neurodegeneration (Lue et al., 1999; McLean et al., 1999). Indeed, recent findings 
support the oligomer hypothesis of AD, which states that soluble Aβ oligomers are 
the main etiologic agent that participates in the initiation of the neurodegenerative 
process in AD, by triggering a cascade of pathogenic events involving inflammation 
and oxidative injury (Klein et al., 2004; Glabe and Kayed, 2006; Haass and Selkoe, 
2007). 
 
Over the years since the amyloid cascade hypothesis was first proposed it has been 
refined to incorporate an increasing awareness of the mechanisms by which Aβ leads 
to the development of the disease. The amyloid hypothesis has also been updated to 
include vascular dysfunction which was incorporated as an additional component to 
further explain the pathophysiology of AD (Hardy, 2009). The rationale behind this 
will be explained further in the next section. 
 
1.1.6. Vascular hypothesis of Alzheimer’s disease.   
 
Although the pathogenesis of AD remains unknown, VRFs including ageing, 
hypertension, diabetes, stroke, atherosclerosis and heart failure, lead to the 
deterioration of the cerebrovascular system, which constitutes a risk factor associated 
with the development of the disease (Breteler, 2000; Kalaria and Ince, 2000; De la 
Torre, 2002; de Leeuw et al., 2006; van Norden et al., 2012; Muresanu et al., 2014). 
Indeed, cerebrovascular pathology can be found in almost all cases of AD examined 
post-mortem. These lesions include cerebral amyloid angiopathy (CAA) (see section 
1.1.7), haemorrhage, endothelial and vascular smooth muscle deterioration, 
infarction, and white matter (WM) alterations related to small vessel disease 
(Vinters, 1987; Kalaria, 1996). BBB damage due to microvascular alterations is also 
present in AD brains. These alterations include reduced endothelial mitochondrial 
content, increased vessel diameter, disruption of the basement membranes, reduced 
total microvascular density, pericyte degeneration and astrocyte end-feet swelling 
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(Zlokovic, 2008). All the pathologies above mentioned may disrupt the integrity of 
the cerebral blood vessels leading to reduced brain perfusion (Attems and Jellinger, 
2014). Furthermore, reduced cerebral blood flow (CBF), a feature of healthy ageing 
brain and AD, occurs prior to the onset of cognitive decline in AD (Alsop et al., 
2010; Chao et al., 2010) and correlates with the severity of dementia (Johnson et al., 
1998; Huang et al., 2002; Yoon et al., 2012) (see section 1.2).  
 
Vascular dementia (VaD), also called vascular cognitive impairment (VCI), 
represents the second most common cause of dementia in the elderly after AD. It is 
thought to be caused by cerebrovascular alterations that lead to reduced CBF, which 
can contribute to cognitive decline by altering neuronal networks related to memory, 
cognition and behaviour (Jellinger, 2007). Several VRFs have been related to the 
development and progression of the disease (Battistin and Cagnin, 2010). 
 
Importantly, neuropathological studies have demonstrated that a considerable 
proportion of patients who meet the clinical criteria for VaD also present with 
coexisting AD pathology (Kosunen et al., 1996). Hence, the concept of mixed 
dementia, referring to the conditions where cognitive decline can be attributed to 
both cerebrovascular alterations and AD related pathology, has emerged (Jellinger, 
2007). Indeed, a study using a sensitive imaging technique to detect brain amyloid, 
revealed that about 30% of VaD diagnosed patients showed significant Aβ 
deposition (Lee et al., 2011a). The clinical and pathological resemblances between 
these two presumably different diseases (Kalaria and Ballard, 1999), as well as 
compelling evidence demonstrating that VRFs are associated with increased risk of 
AD, have contributed to the development of the vascular hypothesis of AD, first 
proposed in 1993. This hypothesis was built on the idea that during ageing, different 
factors can induce progressive structural alterations to the microvasculature, resulting 
in chronic cerebral hypoperfusion that alters the normal supply of nutrients such as 
oxygen and glucose, critical to the correct functioning of the brain, eventually 





Intervention trials aimed at treating hypertension have shown reduced risk of 
developing dementia (Forette et al., 1998; Forette et al., 2002; Tzourio et al., 2003); 
however, other studies have failed to replicate those trials (Applegate et al., 1994; 
Shepherd et al., 2002). In addition, it was demonstrated that multicomponent 
vascular care using pharmacological treatment for hypercholesterolemia and 
hypertension as well as non-pharmacological interventions such as exercise and 
dietary advice, slowed the progression of WM alterations in AD patients with 
cerebrovascular lesions (Richard et al., 2010). However, the same group showed in 
an earlier study, that a similar treatment did not slow cognitive decline in this type of 
patients (Richard et al., 2009). It can be possible that the damage induced by VRFs 
starts to occur years before the appearance of the symptoms and eventually becomes 
irreversible.   
 
1.1.7. Cerebral amyloid angiopathy, a convergence point for both theories. 
 
CAA, defined as Aβ deposition in cerebral blood vessels (Figure 1.3), can occur both 
sporadically and hereditarily. CAA has a prevalence of 90-100% in AD diagnosed 
patients and is present in about 30% of non-demented elderly (Attems, 2005; Love et 
al, 2009; Weller et al, 2009). CAA has been classified into two different types based 
on the presence or absence of capillary Aβ, both showing different pathological, 
morphological and genetic features. CAA-type 1, which is most frequently found in 
AD cases and is strongly associated with  apoE4, shows Aβ aggregation in capillaries 
whereas CAA-type 2 does not and is only present in bigger blood vessels (Attems 
and Jellinger, 2004; Thal et al., 2008). 
 
Different theories for the pathogenesis of CAA have been developed. One of them 
suggested that the source of vascular amyloid was blood (Glenner et al., 1984). 
Another proposed source was vascular smooth muscle cells (Wisniewski and Weigel, 
1994). However, cerebral capillaries which lack smooth muscle cells also present Aβ 
accumulation (Herzig et al., 2006). In contrast, increasing evidence suggests that 
vascular amyloid has a neuronal origin, followed by drainage along the perivascular 










Figure 1.3. Cerebral amyloid angiopathy. Image shows a blood vessel 
(immunostained with anti-collagen IV, red) covered by Aβ (stained with 6E10 
antibody, green) (Scale bar = 30 µm). The tissue sample corresponds to Tg-SwDI 
mouse brain (a). Thioflavin S staining of human brain tissue from an AD case 





vessel walls (Weller et al., 1998; Burgermeister et al., 2000; Van Dorpe et al., 2000; 
Herzig et al., 2004; Jucker, 2006; Weller et al., 2008; Vidal et al., 2009). Indeed, 
CAA can be observed in transgenic mouse models overexpressing human Aβ only in 
neurons (Calhoun et al., 1999). 
 
Several animal and human studies have demonstrated the association of CAA with 
structural and functional alterations of the cerebrovasculature such as thickening or 
thinning of the tunica media depending on the stage of the CAA, fibrinoid necrosis, 
microaneurysm and dilatation of arteries, which leads to the disruption of vascular 
function and contributes to cognitive impairment (Maeda et al., 1993; Zekry et al., 
2003; Auriel and Greenberg, 2012). 
 
A number of mechanisms by which CAA may have an impact on cognition have 
been proposed. It has been suggested that blockage of perivascular drainage 
pathways due to accumulation of vascular Aβ may alter the clearance of metabolites 
from the brain as well as induce impaired transport of nutrients across the BBB 
(Weller et al., 2008; Carrano et al., 2012; Hartz et al., 2012) triggering altered brain 
homeostasis that leads to cognitive alterations. Moreover, alteration of CBF due to 
CAA related capillary occlusion has been demonstrated in transgenic mouse models 
and AD patients (Thal et al., 2009) and notably, reduced cerebral perfusion has been 
linked with microinfarction (Shibata et al., 2004) which may also contribute to 
cognitive decline (Damasceno, 2012). Additionally, severe CAA has been associated 
with neuronal loss (Zarow et al., 1999). 
 
Interestingly, cerebral microbleeds (Figure 1.4), which occur as a consequence of 
vascular damage, are closely linked to vascular amyloid deposition (Greenberg et al., 
2009; Schrag et al., 2010) and have been proposed as a potential connection between 
the amyloid and vascular hypotheses of AD. In the proposed model, cerebrovascular 
pathology and Aβ may synergistically contribute to cause AD through the 














Figure 1.4. Cerebral microbleeds. Prussian blue staining of Tg-SwDI mouse brain 
tissue showing a microbleed (a) and adjacent double immunostained section showing 
CAA at the same site (b) (Scale bars = 50 µm) (images taken from Davis et al., 
2004). Human brain tissue from an AD case showing a microbleed (see arrow) 








1.1.8. Transgenic mouse models of AD.  
 
Numerous mammalian species including cat, sheep, goat, dog and monkey have been 
reported to develop neurodegenerative features similar to those found in human 
ageing and AD (Braak et al., 1994; Heuer et al., 2012; Vite and Head, 2014). 
Rodents constitute excellent research models and some of the advantages that they 
present include short generation time and small size that allows an easy handling, 
housekeeping and testing. However, to date only one rodent has been shown to 
display some of the pathological hallmarks of AD (Inestrosa et al., 2005). Hence, the 
lack of neuropathology markers of the disease in rodent brains and the finding of 
AD-related genes, have provided the basis for the creation of transgenic mouse 
models. Although FAD only represents less than 5% of the cases, the disease shares 
evident resemblances with the sporadic form of the disease including its pathology. 
 
A number of transgenic mouse lines have been created in order to recapitulate the 
key neuropathological hallmarks of AD. The first mouse model, named PDAPP, was 
generated in 1995. These mice express high levels of human APP containing the 
V171F mutation under the control of the platelet derived growth factor-β promoter, 
and show progressive accumulation of Aβ, neuronal loss and inflammation (Games 
et al., 1995). Later, several models expressing the human APP harbouring FAD 
mutations have been produced using similar approaches to those used to produce the 
PDAPP including the Tg2576, one of the most commonly used models (Hsiao et al., 
1996). Another of these models is the Tg-SwDI. This line expresses the human APP 
gene with the Swedish, Dutch and Iowa mutations, under the control of the mouse 
Thy-1.2 promoter (Figure 1.5). The Swedish mutation has been described to enhance 
the production and secretion of Aβ due to increased β-secretase (BACE) activity 
(Mullan et al., 1992; Cole and Vassar, 2007). Both, Dutch and Iowa mutations are 
associated with development of cerebrovascular amyloid deposition (Van 
Broeckhoven et al., 1990; Grabowski et al., 2001). Thus, robust age-dependent 
accumulation of Aβ in the parenchyma and predominantly in the wall of cerebral 
vessels is the pathological hallmark of this mouse model (Davis et al., 2004). Despite 


















Figure 1.5. Schematic representation of the transgenic construct used to 
generate the Tg-SwDI mouse model. The figure shows the 9-kilobase construct 
carrying the 770 isoform of the human APP gene, harbouring the Swedish 
K670N/M671L, Dutch E693Q and Iowa D694N mutations, under the control of the 















model is particularly relevant for the study of different aspects related to Aβ 
deposition particularly CAA. Therefore, this mouse line has been used to study 
mechanisms relevant to human AD and it has also been useful in the development of 
new therapeutic approaches (Vasilevko et al., 2007; Goñi et al., 2013). This line was 
used to conduct the investigation exposed in the present thesis and the 
characterisation of the model is presented in the chapter 3. Moreover, mouse models 
expressing the mutated PS1 or PS2, which exhibit enhanced production of Aβ42 
species have also been generated, although they do not develop amyloid plaques 
(Duff et al., 1996). However, these mice undergo neurodegeneration despite the lack 
of plaques (Chui et al., 1999). Furthermore, a triple transgenic model (3xTgAD), 
expressing mutated PS1, APP and tau proteins, was shown to develop age-dependant 
synaptic dysfunction before the accumulation of amyloid plaques and NFTs (Oddo et 
al., 2003).  
 
As mentioned above, AD is a multifactorial disorder with multiple components 
contributing to the onset and progression of the disease, therefore an ideal model 
should include the full spectrum of clinicopathological hallmarks of the disease 
which includes deposition of tau and Aβ in the brain, neuronal and synapse loss, 
inflammation, oxidative stress, cerebrovascular damage, memory loss and 
behavioural alterations  (Vinters, 1987; Terry, 1994; Kalaria, 1996; Trojanowski and 
Lee, 2000; Wilkinson and Landreth, 2006; Gold and Budson, 2008; Serrano-Pozzo et 
al., 2011; Weintraub et al., 2012). Yet, despite their undoubted value, the main 
caveat of the transgenic models is that they usually display only some very specific 
aspects of the disease (Elder et al., 2010) therefore the study of the interaction 
between all of these components becomes difficult. Nevertheless, they have been 
extremely valuable to understand the contribution of each of these elements and the 
different facets of the disease in isolation. Hence, the development of these models 
constitute one of the most important research tools in the field and has been critical 
in the understanding of the pathophysiology of the disease as well as in the 
preclinical testing of potential treatments (Schenk et al., 1999; Schroeter et al., 2008; 
Elder et al., 2010). The selection criteria of a model, depends on the specific 
questions to be addressed in the particular study. A summary of commonly used 
transgenic mouse models is listed in Table 1.1. 
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1.1.9. Alzheimer’s disease therapies. 
 
AD progresses as a complicated mixture of numerous genetic and environmental 
factors, therefore the exact etiopathogenesis of the disease is ill understood (see 
section 1.1.4). For this reason, the search for a treatment or cure has been extremely 
complicated. However, considering the increasing frequency of the disease as the 
worldwide population ages and the social and economic burden that this implies, the 
development of an effective intervention for AD represents a critical clinical need 
(Wimo et al., 2010).  
  
The only approved drugs that are currently available, which are limited to modestly 
improve symptoms, target cholinergic and glutamatergic neurotransmission and were 
developed based on the cholinergic hypothesis of AD, which states that the disease is 
caused by reduced synthesis of acetylcholine (Francis et al., 1999). These include an 
N-methyl-D-aspartate receptor antagonist and four cholinesterase inhibitors; yet, 
their neuroprotective activity is still under discussion (Mangialasche et al., 2010; 
Howard et al., 2012; Hyde et al., 2013). 
 
Current therapies are only limited to delay the progression of symptoms, but do not 
have effective disease modifying effects (Lannfelt et al., 2014). However, different 
strategies designed to inhibit the progression of the disease have been tested in 
clinical trials. The primary targets of these therapies include: metabolic dysfunction, 
tau and Aβ (Citron, 2010). A comprehensive review of the clinical trials carried out 
from 2002 to 2012 by Cummings and colleagues revealed that 413 trials were 
performed, 36.6% of which tested drugs intended to improve cognition, 35.1% using 
disease modifying molecules and 18% corresponded to immunotherapies. The 
overall outcomes were dramatic, with a 99.6% failure rate for approval (Cummings 
et al., 2014).  
 
Approaches targeting tau have been recently started to be tested in animal models as 
a potential treatment for AD. In 2007, the first report on tau immunotherapy in mice 
was published (Asuni et al., 2007). The study demonstrated that injection of a 
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phosphorylated tau epitope in P301L mice, which develop NFTs, amyotrophy and 
motor alterations, reduced the aggregation of the protein and improved the 
behavioural performance. Subsequently, active and passive immunisation studies 
performed in different tau mutant transgenic mouse models have shown similar 
results, where decreased tau pathology and reversed cognitive deficits have been 
demonstrated (Boimel et al., 2010; Boutajangout et al., 2010; Bi et al., 2011, 
Boutajangout et al., 2011; Chai et al., 2011; Troquier et al., 2012; d'Abramo et al., 
2013; Castillo-Carranza et al., 2014). Additionally, Methylthioninium (MT) is a 
diaminophenothiazine that has been shown to prevent tau aggregation in vitro and 
dissolve paired helical filaments from AD brain tissue (Wischik et al., 1996). The 
results of the first phase 2 clinical trial of MT in patients with mild to moderate AD, 
revealing the minimum safe and effective dose of the drug, have recently been 
published and suggest that MT could have therapeutic utility in AD (Wischik et al., 
2015). 
 
Supported by compelling evidence involving Aβ in the pathogenesis of AD (Selkoe, 
1991; Hardy and Higgins, 1992), AD drug development has based primarily on the 
amyloid hypothesis, and the majority of randomised controlled trials (RCTs) have 
been designed to target this protein. These include drugs that reduce Aβ production, 
drugs that prevent Aβ aggregation and drugs aimed at promoting the clearance of the 
protein (Mangialasche et al., 2010). In the first group, drugs designed to inhibit or 
modulate β and γ-secretases have been tested in several clinical trials. One of these 
compounds, Tarenflurbil, was demonstrate to reduce Aβ42 production and prevent 
cognitive alterations in transgenic mouse lines of AD (Eriksen et al., 2003; Kukar et 
al., 2007). More interestingly, in a phase II RCT Tarenflurbil was proven to be safe 
and effective in terms of global function in patients with mild to moderate AD 
(Wilcock et al., 2008). However, the treatment failed to show efficacy in a phase III 
trial (Green et al., 2009). Another phase III RCT was ended due to the adverse side 
effects induced by the γ-secretase inhibitor Semagacestat, which triggered worsening 
of cognitive decline (Schor, 2011). By inhibiting γ-secretase, many other substrates 
for the enzyme such as Notch are affected therefore the treatment might disturb 
several vital pathways (Barten et al., 2006). Following a comprehensive analysis of 
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the data from the trial with Semagacestat, Bart De Strooper suggested that better 
understanding of the basic biology of secretases would allow to successfully using 
them as a pharmacological target for the treatment of AD (De Strooper, 2014). 
Among the drugs that enhance Aβ clearance, Aβ immunotherapy constitutes one of 
the most promising strategies (Panza et al., 2012; Li et al., 2013; Sarazin et al., 
2013). 
 
1.1.10. Aβ immunotherapy.  
 
In 1996 it was first demonstrated that anti-Aβ antibodies could prevent the 
aggregation of Aβ and inhibit fibril formation in vitro (Solomon et al., 1996; 
Solomon et al., 1997). Later, in 1999 the first report showing decreased amyloid 
pathology in vivo following active immunisation of PDAPP mice with synthetic 
Aβ42 aggregates was published (Schenk et al., 1999). These results were 
encouraging as suggested that Aβ immunotherapy could represent the first disease 
modifying strategy to treat humans with AD.  
 
AN1792 was the first active immunotherapy strategy tested in humans, using the full 
length Aβ42 as immunogen; however, it was discontinued in phase II due to the 
development of meningoencephalitis in a subset of AD patients (Gilman et al., 2005). 
Although, despite the adverse secondary effects, decreased Aβ deposition was found 
in the brains of treated patients (Nicoll et al., 2003) and long-term follow-up of the 
interrupted study revealed reduced cognitive decline in patients with antibody 
response to the treatment (Holmes et al., 2008; Vellas et al., 2009). Hence, numerous 
preclinical studies of active immunotherapy started to be developed and 
demonstrated reduction of Aβ levels and  improvement of cognitive abilities 
following immunisation in transgenic mouse models of AD (Janus et al., 2000; 
Lemere et al., 2000; Weiner et al., 2000; Maier et al., 2006; Lemere and Masliah, 
2010; Panza et al., 2012). However, several Aβ peptide antigens failed to stimulate 





In 2000 the first passive Aβ immunotherapy experiments were performed in 
transgenic mice. The results demonstrated that 10D5 and 3D6 antibodies, specific for 
n-terminal epitopes of Aβ, were able to enter the brain following systemic 
administration, and trigger Aβ clearance through Fc receptor-mediated microglial 
phagocytosis (Bard et al., 2000). Subsequently, several preclinical studies were 
performed and showed that antibodies against different epitopes of Aβ were able to 
reduce Aβ levels and improve cognitive abilities (DeMattos et al., 2001; Dodart et 
al., 2002; Bard et al., 2003; Hartman et al., 2005; Spires-Jones et al., 2009; Lemere 
and Masliah, 2010). However, the high incidence of secondary effects including the 
development of haemorrhages in transgenic models following passive immunisation 
(Pfeifer et al., 2002b; Wilcock et al., 2004; Racke et al., 2005; Wilcock et al., 2006; 
Burbach et al., 2007; Karlnoski et al., 2008; Schroeter et al., 2008), provided some 
reason of caution. Bapineuzumab, which constitutes the humanised form of the 3D6 
antibody, was the first antibody tested in humans. The treatment showed reduced Aβ 
load, however it was associated with high incidence of amyloid related imaging 
abnormalities, and the program was terminated in phase III due to failure of the 
treatment to reach clinical endpoint (Panza et al., 2011; Tayeb et al., 2013). 
Solanezumab, another antibody designed to target monomeric Aβ, failed to meet 
clinical endpoint in two phase III trials, yet encouraging results were found in a 
subgroup of mild AD patients, which showed slowed cognitive decline (Carlson et 
al., 2011; Tayeb et al., 2013), therefore a third phase III study was started in mild AD 
patients.  
 
In addition, second generation active immunotherapies and new anti-Aβ antibodies 
are currently being tested in patients at very early stages of the disease (Panza et al., 
2014). A summary of active and passive immunotherapy clinical trials are shown in 
Tables 1.2 and 1.3 respectively.  
 
Interestingly, several findings have suggested that tau is implicated in Aβ-related 
neurodegeneration (Rapoport et al., 2002; Santacruz et al., 2005; Roberson et al., 
2007). Furthermore, it was demonstrated that Aβ immunotherapy influenced tau 





























































































































































tau aggregates in neuronal processes were observed (Boche et al., 2010). However, 
the treatment did not affect NFTs that were accumulated in the neuronal cell bodies. 
Hence, the authors suggest that this could explain the persistent cognitive decline in 
the patients after the treatment. It was recently reported that the mechanism by which  
Aβ immunotherapy alters tau aggregation involves reduced expression of GSK-3β, a 
kinase implicated in tau phosphorylation (Amin et al., 2014). 
 
In conclusion, encouraging clinical trials are currently ongoing, yet more efficiently 
designed trials are needed. The trials have arguably been conducted late and when 
there is extensive pathology and degeneration. AD is a multifactorial disease, 
therefore increased collaboration between basic and clinical researchers, with the aim 
of better understanding of the complex interacting networks influencing the onset 
and progression of the disease is required, as therapeutic strategies aiming at 
modifying several targets rather that one, might probably take the AD drug 
development field closer to the design of a successful treatment (Mangialasche et al., 
2010; Schneider et al., 2014). 
 
1.2. Links between chronic cerebral hypoperfusion and AD.  
 
1.2.1. Cerebral blood flow.  
 
The brain is totally dependent on an uninterrupted blood supply to function. The 
regulation of CBF, to deliver oxygen and glucose to meet the metabolic demand of 
specific brain regions, known as functional hyperaemia, is determined by local brain 
activity (Ainslie and Tftrailszeng, 2010). This regulation of CBF supply is carried 
out by the highly co-ordinated communication between different brain cells 
comprising the neurovascular unit (NVU) (Lok et al., 2007). Under physiological 
conditions, functional hyperaemia depends on cerebral perfusion pressure (CPP) and 
cerebrovascular resistance (CVR), thus, any fluctuations in CPP would be 
compensated by changes in CVR to maintain that way a relatively constant CBF, a 
process known as autoregulation (Aaslid et al., 1989). This mechanism of 
autoregulatory vasodilation is dependent on several elements including neurogenic, 
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myogenic, endothelial-derived, chemical and hormonal factors (Farkas and Luiten, 
2001). 
 
In humans, CBF in an adult is about 60 ml of blood per 100 grams of brain tissue per 
minute. However, it is estimated that CBF drops with age, in a rate of about 0.5% per 
year, with a decrease of about 20% between ages of 20 to 60 years (Leenders et al., 
1990; Zou et al., 2009; Chen et al., 2011a). 
 
1.2.2. Cerebral hypoperfusion.   
 
Normally, the oxygen extraction fraction (OEF), defined as the proportion of oxygen 
extracted from the circulation by the brain is 40% (Leenders et al., 1990). When the 
capacity of autoregulatory vasodilation fails to maintain the CBF on the normal 
range, the OEF increases to maintain the metabolic rate of oxygen, a phenomenon 
termed misery perfusion, also known as cerebral hypoperfusion (Baron et al., 1981). 
When severe interruption of blood perfusion occurs due to blockage of a vessel, OEF 
reaches its limit, leading to an imbalance between blood supply and metabolic 
activity of the brain, this process is known as ischemia and results in regional 
neuronal damage. Chronic, modest reduction of CBF can alter brain function and has 
been involved in the development of dementia (Farkas et al., 2007). 
 
Several VRFs have been associated with the onset of chronic brain hypoperfusion 
including aging, stroke, diabetes, hypertension, heart failure, coronary artery disease, 
atherosclerosis, smoking and alcoholism (de la Torre, 2002; Qiu et al., 2003; Novak 
et al., 2006; Beason-Held et al., 2007; Singh-Manoux et al., 2009). It has been 
hypothesised that VRFs may lead to endothelial cell dysfunction, resulting in nitric 
oxide (NO) uncoupling, which may alter the dynamic regulation of CBF and as 
consequence lead to chronic cerebral hypoperfusion. Indeed, oxidative stress induced 
by hypertension can alter endothelial cell release of NO leading to decreased CBF. 
Similarly, diabetes can contribute to CBF alterations by inducing endothelial cell 
damage and endothelin-1 mediated altered NO production, which impairs normal 
vasodilation (de la Torre, 2012). 
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1.2.3. Cerebral hypoperfusion in the early stages of AD.  
 
Neuroimaging studies have revealed regional cerebral hypoperfusion within the 
temporo-parietal cortex of AD patients (Prohovnik et al., 1988; Hirao et al., 2005; 
Matsuda, 2007). The reduced CBF is evident in the early stages of the disease 
(Franceschi et al., 1995; Ishibashi et al., 1998) suggesting a primary role in the 
development of dementia. It is hypothesised that during normal ageing, VRFs lead to 
the deterioration of the cerebrovascular system, resulting in reduced CBF, which can 
contribute to neurodegeneration and have an impact on cognitive decline (see section 
1.1.6) (O'Brien et al., 2003; de la Torre, 2004). Notably, epidemiological data 
demonstrate that all risk factors for AD have shown to induce hypoperfusion (de la 
Torre, 2000a). Moreover, several neuropsychological and imaging studies looking at 
the relationship between stroke and dementia have demonstrated an increased 
incidence of dementia in people who had cerebral infarcts compared to those with no 
such lesions (Kokmen et al., 1996; Vermeer et al., 2003; Hachinski, 2011; Tolppanen 
et al., 2013). Interestingly, circulating Aβ levels are elevated in ischemic stroke 
patients and immunohistochemical analysis has shown association between Aβ 
deposition and hypoxic/ischemic lesions (Jendroska et al., 1995; Lee et al., 2005; Qi 
et al., 2007). 
 
The reduction in cerebral perfusion precedes the onset of cognitive decline in AD, 
correlates with the severity of dementia (Kalaria and Ince, 2000) and evidence from 
longitudinal epidemiological and neuroimaging studies (Ruitenberg et al., 2005; 
Fernando et al., 2006; Farkas et al., 2007) suggests that underlying chronic cerebral 
hypoperfusion contributes to cognitive decline. Furthermore, the use of imaging 
techniques to detect changes in brain perfusion has permitted the prediction of 
individuals who will undergo cognitive decline (Alsop et al., 2010). Mild cognitive 
impairment (MCI), which is thought to be the transition between normal ageing and 
dementia (Morris and Cummings, 2005), is characterised by reduced perfusion 
compared to healthy controls; however this reduction has been demonstrated to be 
more significant in AD patients, which has allowed to predict the conversion from 
MCI to dementia (Johnson et al., 2005; Chao et al., 2010). 
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Cerebral hypoperfusion in AD is thought to be linked with both structural and 
functional alterations that may culminate with irreversible brain damage. However 
due to the co-existence of reduced CBF with a spectrum of pathology including 
amyloid plaques, CAA, tau aggregates, atrophy and microinfarcts (MIs), the role of 
hypoperfusion on the onset and progression of AD is not clear and whether reduced 
CBF is a cause or consequence of the disease is still debated (Mazza et al., 2011). 
However, the investigation of experimentally induced chronic cerebral 
hypoperfusion in animal models has revealed similar structural, metabolic, 
biochemical and cognitive alterations to those observed in AD brains (Kalaria, 2000; 
de la Torre, 2008), including microvascular damage, altered protein synthesis, 
oxidative stress, inflammation, altered Aβ production, tau hyperphosphorylation, 
axon-glial disruption, WM lesions, cerebral infarction and memory impairment (de la 
Torre et al., 1992a; De Jong et al., 1999; Shibata et al., 2004; Coltman et al., 2011; 
Reimer et al., 2011; Liu and Zhang, 2012; Okamoto et al., 2012; Zhao et al; 2014). 
Based on the differential effects of reduced CBF in animal models depending on the 
age at which they underwent hypoperfusion, and also on the synergistic effect of age 
and severity of hypoperfusion on the associated alterations (de la Torre et al., 1992b; 
de la Torre et al., 1997; Pappas et al., 1997), the critically attained threshold of 
cerebral hypoperfusion hypothesis of AD was proposed. This hypothesis suggests 
that the combination of advanced ageing with the manifestation of VRFs might result 
in reduced cerebral perfusion that reaches a critical threshold, which can culminate 
with structural capillary damage and altered microcirculation patterns in the brain, 
and would impair the normal supply of oxygen and glucose, leading to the 
progressive breakdown of metabolic pathways. This cascade of events, that would 
require many years to develop before clinical symptoms can be detected, is suggested 
to eventually trigger the pathology that characterises AD (de la Torre, 1999; de la 
Torre, 2000b). 
 
Substantive evidence supports the impact of cardiovascular risk factors on the 
development of dementia, and offers the possibility to use them as therapeutic targets 
for the prevention and intervention of the progression of cognitive decline (de la 
Torre, 2012). Indeed, treatment of heart failure has shown to improve CBF and 
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cognitive performance (Zuccalà et al., 2005). However, although treatment using 
antihypertensive drugs has been demonstrated to prevent or delay cognitive 
deterioration and dementia (Forette et al., 1998; Forette et al., 2002; Tzourio et al., 
2003; Cherubini et al., 2010; Kitagawa, 2010), some studies have not been able to 
reproduce these results (Applegate et al., 1994; Shepherd et al., 2002). Moreover, a 
recent study revealed a poor correlation between VRFs including hypertension and 
the development of cerebral WM hyperintensities (Wardlaw et al., 2014). In addition, 
although multicomponent pharmacological strategies targeting hypercholesterolemia 
and hypertension have been shown to reduce WM alterations in AD patients, no 
changes in cognitive performance following this treatment were demonstrated 
(Richard et al., 2009; Richard et al., 2010). Hence, the early identification of VRFs, 
before symptoms arise, is crucial to stop the progression of underlying disease 
(Solomon et al., 2009).  
 
In summary, chronic cerebral hypoperfusion constitutes a self-perpetuating 
condition, and when cognitive decline is irreversible, a cure for AD seems 
improbable. However, if VRFs are identified in time during clinical examination, 
early intervention could prevent further cerebrovascular deterioration, altered 
metabolism and reduced cerebral perfusion that precede cognitive deterioration.  
 
1.2.4. Animal models of cerebral hypoperfusion. 
 
The study of the effect of chronic cerebral hypoperfusion on cognitive alterations in 
AD patients is complicated by the existence of multiple factors that may lead to 
reduced CBF and the heterogeneous nature of the pathology. Thus, several animal 
models of brain hypoperfusion have been developed in order to reconstruct this 
pathological condition and explore in isolation its impact on the onset of cognitive 
decline in ageing and AD. Due to economical and ethical acceptability issues, most 
hypoperfusion experiments have been established in rodents. 
 
Transient or permanent occlusion of the middle cerebral artery (MCAO) constitute 
common methods developed to model focal cerebral ischemia (Tamura et al., 1981. 
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Longa et al., 1989). Neuropathological assessment following this type of injury 
demonstrates localised areas of ischemic brain damage including cortical and basal 
ganglia infarction. A well characterised model of cerebral hypoperfusion, used 
mainly in rats, correspond to the bilateral occlusion of the common carotid arteries 
(BCCAO) or two vessel occlusion, which can be performed transiently or 
permanently. This procedure has been shown to induce metabolic alterations, 
progressive neuronal loss especially in the hippocampus, widespread WM injury and 
cognitive disturbances (Wakita et al., 2002; Ohtaki et al., 2006; Farkas et al., 2007).  
 
Another model of cerebral hypoperfusion, which produces a less severe 
neuropathological outcome, has also been established by using microcoils in order to 
induce bilateral common carotid arteries stenosis (BCAS) (Figure 2.1) (Kurumatani 
et al., 1998; Shibata et al., 2004). Microcoils of different diameters lead to different 
degrees of CBF reduction (Figure 1.6). In general, WM lesions with severity that is 
inversely proportional to the diameter of the microcoil can be observed, and working 
memory deficits can be detected following placement of a 0.18 mm coil (Shibata et 
al., 2007; Coltman et al., 2011).   
 
With the purpose of understanding the underlying mechanisms by which chronic 
cerebral hypoperfusion can influence the aetiology of AD, the models described 
above have been applied to study changes associated with Aβ metabolism.  
 
In models in which CBF is severely reduced, including global and focal ischemia, 
there is evidence demonstrating that Aβ production and deposition can be promoted 
(Pluta et al., 1998; Popa-Wagner et al., 1998; Pluta., 2000; Wang et al., 2010). 
Indeed, studies of short term transient MCAO in rats, have shown increased APP 
levels surrounding the infarcted areas (Stephenson et al., 1992; Yam et al., 1997; 
Nihashi et al., 2001). However, in another study, long term follow up of rats 
subjected to transient MCAO, which also showed elevated APP along with increased 
Aβ levels at early time points, demonstrated that in some areas of the brain this was 
only a temporal change (van Groen et al., 2005). Similarly, APP upregulation and Aβ 












Figure 1.6. Cerebral blood flow values following bilateral carotid arteries 
stenosis (BCAS). Microcoils of different diameters lead to different degrees of CBF 













Studies aimed at investigating the molecular mechanisms underlying the increased 
levels of Aβ following focal ischemic insults or chronic hypoperfusion, have 
revealed enhanced APP processing associated with increased BACE activity and 
altered expression of Aβ degrading enzymes (Hiltunen et al., 2009). Notably, the 
enhanced expression of BACE and increased Aβ levels have shown positive 
correlation with cognitive impairment (Zhiyou et al., 2009). 
 
Furthermore, these models of ischemic insults or hypoperfusion have also been 
studied in transgenic mouse lines of AD, with similar results. For instance, 3xTg-AD 
mice exposed to MCAO showed increased amyloid levels associated with enhanced 
BACE expression (Koike et al., 2010). By using the same experimental stroke 
model, APPswe/PS1dE9 mice showed acute and transient Aβ aggregation into 
plaques and CAA near to the infarcted area, however no changes in APP, PSEN1 or 
Aβ degrading enzymes were observed and the authors suggest that stroke may 
potentially alter clearance pathways (Garcia-Alloza et al., 2011).  
 
Additionally, APP23 mice exposed to hypoxia exhibited increased amyloid 
deposition, which was associated with hypoxia inducible factor 1α (HIF1α)-mediated 
BACE1 upregulation, that enhanced amyloidogenic APP cleavage. However, no 
changes in APP levels were observed in this study (Sun et al., 2006; Zhang et al., 
2007). Interestingly, BCAS has shown to induce increased amyloid deposition, WM 
alterations and astrocyte proliferation in APPSwInd mice (Kitaguchi et al., 2009); 
however, in a different study, the same group has latter found suppression of Aβ 
deposition but increased soluble Aβ and neuronal loss following surgery, which was 
associated with memory impairment. Thus, the authors proposed that soluble rather 
than insoluble Aβ species might have had an influence on the cognitive alterations 
found (Yamada et al., 2011). Additionally, enhanced CAA and MIs have also been 









1.3. Neurovascular unit dysfunction in the aetiology of AD. 
 
1.3.1. Neurovascular unit structure and function. 
 
During the last decade, the study of the cerebrovasculature has been expanded to 
several types of cells, which are closely associated with the endothelium to form the 
NVU (Abbott et al., 2006). The close interaction between these cells, allows the 
dynamic response of the microcirculation to the energy demands of the brain via 
neurovascular coupling, to maintain the normal function of the central nervous 
system (CNS) (del Zoppo and Mabuchi, 2003). 
 
The NVU is structurally formed by a monolayer of endothelial cells lining the 
microvasculature, which are connected and sealed by the tight junctions (TJs) and 
delineated by the basal lamina. Surrounding the endothelium are the pericyte 
processes, which are attached to the basement membrane. Astrocytic end-feet encase 
most of the capillary wall and extend their processes to be in direct contact with 
neuronal terminals, allowing neurovascular communication. Circulating immune 
cells are also part of this functional structure and include microglia and perivascular 
macrophages, which participate in the immune response at the NVU (Figure 1.7) 
(Neuwelt et al., 2011; Zlokovic, 2011). The principal functions of the NVU complex 
include the CBF regulation in response to neuronal activation, the dynamic 
regulation of the BBB permeability to maintain brain homeostasis, neurovascular 
remodelling and immune response (Ohtsuki and Terasaki, 2007; Newelt et al., 2011). 
 
Neurovascular coupling is largely mediated by astrocytes, which react in response to 
changes in neuronal metabolism, influencing CBF to provide the correct nutrient 
supply, which occurs under normal physiological or pathological conditions 
(Volterra and Meldolesi, 2005). It has been shown that one of the mechanisms by 
which the regulation of CBF occurs, is through cerebrovascular dilation or 
constriction elicited by vasoactive molecules released by the astrocytic end-feet in 
response to calcium signalling that propagates along the astrocyte projections; this 











Figure 1.7. Cellular components of the neurovascular unit. The NVU corresponds 
to the structural and functional interaction between brain endothelial cells, pericytes, 










2004; Haydon and Carmignoto, 2006; Gordon et al., 2008). Interestingly, it has been 
proposed that the BBB transport of glucose, the major energy substrate for brain 
cells, can also be dynamically controlled depending on the regional glucose needs, 
through a mechanism similar to the neurovascular coupling. Thus, a phenomenon 
called neurobarrier coupling was proposed, in which neuronal activity influences 
BBB transport through astrocyte communication (Leybaert, 2005). 
 
The BBB constitutes a key component of the NVU. It is a physical and metabolic 
barrier formed by microvascular endothelial cells, which are connected by the TJs 
(Figure 1.8), forming a highly specialised membrane that controls the transport of 
molecules between the brain and the circulation to maintain the microenvironment 
for the correct brain function. The main roles of the BBB include molecular 
trafficking, diffusion barrier, maintenance of ionic composition and protecting the 
brain from neurotoxins and pathogens (Abbott et al., 2010; Obermeier et al., 2013). 
Transmembrane proteins including claudins and occludins, which are anchored to the 
endothelium, constitute the highly selective intercellular TJs that are necessary to 
restrict paracellular diffusion of hydrophilic molecules across the BBB (Ballabh et 
al., 2004).  
 
The mechanism that regulates the permeability of the BBB is highly dependent on all 
the components of the NVU, which interact to establish and maintain the barrier 
properties. For instance, pericytes participate in the differentiation of endothelial 
cells and can modulate capillary permeability (Bandopadhyay et al., 2001; Hurtado-
Alvarado et al., 2014). Furthermore, astrocytic end-feet (Figure 1.8), which envelop 
the capillaries, are highly polarised structures due to the high expression of the water 
channel aquaporin-4 (AQP4) and the potassium channel Kir4.1, which regulate the 
ionic and osmotic balance. Importantly, numerous studies have demonstrated that 
astrocytes can improve the barrier properties of the BBB by enhancing enzymatic 
activity, upregulating transporters and enhancing barrier tightness by increasing TJ 
formation (Janzer and Raff, 1987; Tout et al., 1993; Hayashi et al., 1997; Lee et al., 














Figure 1.8. Electron micrograph of a mouse brain capillary. The image shows an 
astrocyte end-foot surrounding the capillary and tight junctions between endothelial 











1.3.2. Neurovascular unit and neurodegeneration. 
 
When one component of the NVU fails, the dynamic crosstalk between its different 
elements can break down leading to dramatic consequences and eventually culminate 
with neurodegenerative processes. Interestingly, Bell and colleagues demonstrated 
progressive age-dependent vascular damage in pericyte-deficient mice, which led to  
cerebral hypoperfusion and BBB breakdown that preceded neuronal loss and 
cognitive alterations (Bell et al., 2010). This study emphasises the importance of the 
NVU in the process of neurodegeneration. 
 
The pathophysiology of the NVU has been linked with the aetiology of several 
neurological disorders such as amyotrophic lateral sclerosis, Parkinson’s disease, 
multiple sclerosis and AD (Waubant, 2006; Chung et al., 2010; Zlokovic, 2011; 
Garbuzova-Davis and Sanberg, 2014). A common event in these diseases is BBB 
disruption due to TJ alterations (Zlokovic, 2008; Henkel et al., 2009; Alvarez et al., 
2011a), which has been shown to be associated with altered vascular-associated 
matrix metalloproteinases (MMPs) activity (Yang et al., 2007).  
 
In vitro studies have shown increased expression levels of MMPs in astrocytes 
treated with Aβ (Deb et al., 2003). Furthermore, intracerebral injection of Aβ 
induced MMP-9 activation in mice and interestingly, the amyloid-induced cognitive 
decline was improved in MMP-9 knockout mice (Mizoguchi et al., 2009). 
Immunohistochemical examination of post-mortem AD brains has demonstrated 
enhanced expression of MMPs (Leake et al., 2000; Asahina et al., 2001) and elevated 
MMP-9 levels have also been demonstrated in biological fluids of AD patients 
including plasma and cerebrospinal fluid (Lorenzl et al., 2003; Horstmann et al., 
2010). 
 
There is evidence that uncontrolled activity MMPs, which are able to degrade 
basement membrane and TJ proteins, might play a crucial role in neurodegenerative 
processes, by increasing the permeability of the BBB leading to haemorrhage and 
cell death (Cheng et al., 2006; Yang et al., 2007; Rosenberg, 2009). Additionally, 
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altered Aβ clearance due to BBB damage may lead to amyloid accumulation which 
can enhance neurovascular dysfunction through the development of CAA (Bell and 
Zlokovic, 2009). Consequently, the development of chronic inflammatory response 
and oxidative stress may contribute to the neurovascular damage (Stanimirovic 
and Friedman, 2012). 
 
Notably, there is evidence of cell-cell signalling between the components of the 
NVU, in an attempt of reorganisation and remodelling, following brain injury 
(Iadecola, 2004; del Zoppo, 2009). However, this adaptive response triggered in 
order to induce recovery, can be either disturbed or perpetuated and promote 
worsening of the damage. For instance, it has been shown that activation of HIF-1 
following hypoxic injury, induces the expression of several genes that can promote 
cell survival and tissue adaptation by increasing the blood supply and oxygen 
delivery, yet the enhanced BBB permeability may consequently trigger changes in 
brain ionic and osmotic homeostasis that can lead to oxidative stress and promote 
damage. Moreover, HIF-1 can also trigger inflammatory responses and angiogenesis 
which can contribute to perpetuate cerebral deterioration. These cascade of events 
can lead to dramatic structural and functional changes in the NVU, including BBB 
leakage, edema and altered neurovascular coupling (Semenza, 2011; Stanimirovic 
and Friedman, 2012; Chen et al., 2013). 
 
1.4. Thesis hypothesis and aims. 
 
Together, the evidence presented above suggests a possible mechanism in which, as 
the result of chronic cerebral hypoperfusion, increased Aβ deposition could be 
implicated in the pathogenesis of AD by inducing neurovascular damage and 
downstream cognitive impairment. Nevertheless, there are several gaps regarding the 
pathways that are initiated by hypoperfusion and culminate with degenerative 
processes that may lead to cognitive decline in AD (Figure 1.9).  
 
At the outset of the thesis, it was hypothesised that chronic cerebral hypoperfusion 























Figure 1.9. Events linking chronic cerebral hypoperfusion with cognitive 
decline. Diagram shows the gaps between the different events that are initiated by 
chronic cerebral hypoperfusion and culminate with degenerative processes that may 


















development of MIs and haemorrhages and altering the NVU integrity. Second to 
this, it was hypothesised that Aβ immunotherapy decrease amyloid levels and reduce 
degenerative processes (MI and haemorrhages) improving cognitive performance. 
 
The specific aims were as follows: 
 
1. To characterise the temporal APP expression, accumulation of parenchymal and 
cerebrovascular Aβ and Aβ-related microglial and astrocytic activation that the Tg-
SwDI model exhibits, in order to provide a basis to design the next studies. 
 
2. To determine parenchymal and cerebrovascular Aβ levels in response to chronic 
cerebral hypoperfusion. A further aim was to investigate the effects of hypoperfusion 
and Aβ pathology on the development of MIs and haemorrhages and the potential 
alteration of astrocyte and tight junction integrity. 
 
3. To determine the effects of passive immunisation with both 10D5 and 3D6 
antibodies on Aβ40/42 levels in the parenchyma and cerebrovasculature of the Tg-
SwDI mice. A further aim was to determine whether treatment with these antibodies 
induces changes in the appearance of MIs and haemorrhages and whether the 






























































Transgenic mutant mice Tg-SwDI, that overexpress human APP, harbouring the 
Swedish K670N/M671L, Dutch E693Q and Iowa D694N mutations under the 
control of the Thy1 promoter, generated on a C57Bl/6J background (Davis et al., 
2004), were purchased from Jackson Laboratories. They were subsequently bred in 
house. For the experiments presented on chapters 3 and 4, male homozygous animals 
were used. For the experiments presented on chapter 5, male heterozygous animals 
were used. Wild type mice (C57Bl/6J) were purchased in Charles River Laboratories 
and were used as comparative controls. The age of the animals for each study is 
specified in each chapter. 
 
Mice were housed on a 12 hour light/dark cycle and had access to food and water ad 
libitum. All procedures were authorised under the project licence number 60/4350 
held by Prof. Horsburgh, approved by the UK Home Office and the University of 
Edinburgh's Ethical Review Committee and adhered to regulations specified in the 
Animals (Scientific Procedures) Act (1986). 
 
2.2. Chronic cerebral hypoperfusion.  
 
Chronic cerebral hypoperfusion was induced as previously described (Reimer et al., 
2011). Mice were initially anaesthetised with 5% isoflurane in oxygen and then 
maintained under 1.5% isoflurane. Microcoils (0.18 mm internal diameter; Sawane 
Spring Co. Japan) were applied permanently to both common carotid arteries (Figure 
2.1) with a 30 minute interval between the insertion of the first and second microcoil. 
Sham animals underwent identical surgical interventions without application of the 
microcoils. Mice were randomly assigned to the hypoperfused or sham group. The 
recovery of the mice was closely monitored with weight and general health recorded 
regularly. Animals that lost more than 20% of their pre-surgical weight or had poor 
recovery were culled. The surgeon was blind to the genotype of the mice and the 












Figure 2.1. Bilateral common carotid artery stenosis. (A) Schematic diagram of 
microcoil. (B) Schematic diagram of microcoil in place around the common carotid 










surgical intervention and genotype of the mice until the final data analysis. The 
surgery was carried out by Dr Philip Holland. 
 
 
The expression of Thy1.2 promoter-driven genes has previously shown not to be 
affected by ischemic/hypoxic injury (McCarran and Goldberg, 2007; Underhill and 
Goldberg, 2007). 
 
Mice were sacrificed 1 or 3 months after the surgery. Group sizes are listed in Table 
2.1. 
 
2.3. Administration of antibody for amyloid immunotherapy. 
 
Mice were injected intraperitoneally weekly with either 10D5 (10 mg/kg), 3D6 (3 
mg/kg) or vehicle (TYII-15) (10 mg/kg) during 12 weeks. The animals were injected 
in the morning and checked in the afternoon for any adverse signs during the whole 
experimental period and observations were recorded on recovery sheets. Adverse 
effects were not observed. Mice were randomly assigned to the vehicle or treatment 
group. The researcher was blind to the antibody that was being injected and the 
studies downstream of the treatment were conducted by a researcher blind to the 
treatment that the mice underwent until the final data analysis.  
 
2.4. Transcardial perfusion. 
 
Animals used for biochemical studies were saline perfused. Animals used for 
immunohistochemical studies were saline perfused followed by perfusion fixation as 
described below. 
 
2.4.1. Saline perfusion. 
 
Mice were deeply anesthetised under 5% isoflurane in an anaesthetic chamber. 
Subsequently, animals were removed from the chamber and a mask was used to 
maintain the anaesthesia at 2% during the procedure. A midline incision was made 
and the diaphragm exposed and cut to expose the heart. A needle was inserted into  
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Table 2.1. Cohort sizes used for biochemical and immunohistochemical 
analyses, following chronic cerebral hypoperfusion. 
 








Biochemistry 1 10 9 8 6 
Biochemistry 3 6 6 8 7 
Immunohistochemistry 1 9 10 12 11 



























the left ventricle and clamped in place and a small incision was made in the right 
atrium to allow drainage of the blood. Mice were perfused with 20 ml of 0.9% 
heparinised phosphate buffered saline (PBS) (pH 7.4) at a rate of 2 ml/minute. 
 
2.4.2. Perfusion fixation. 
 
The surgical approach was as above (2.4.1). Mice were perfused firstly with 20 ml of 
saline buffer followed by perfusion of 20 ml of 4% paraformaldehyde (PFA) in 0.1 
M phosphate buffer (PB) (pH = 7.4) to fix brain tissue. 
 
2.5. Tissue processing for histopathology. 
 
After perfusion, brains were removed from the skull, cut along the longitudinal 
fissure and both hemi-brains were post-fixed in 4% PFA at 4 °C prior to vibratome 
sectioning or paraffin embedding.  
 
2.5.1. Processing for vibratome sections. 
 
Following post-fixing for 24 hours in 4% PFA, the left hemibrain was then washed 
for 1 hour in PB and free-floating 30 µm thick sagittal sections were produced with a 
vibratome (Hydrax V50, Zeiss). Sections were collected and stored in cryoprotective 
medium (30% glycerol, 30% ethylene glycol in PB) at -20ºC until use for 
immunohistochemical studies. 
 
2.5.2. Processing for paraffin embedding. 
 
Following post-fixing for 48 hours in 4% PFA, the right hemibrain was washed for 1 
hour in PB followed by automatic paraffin processing using a Tissue Tek VIP 2 
(Sakura) tissue processor, as described in Table 2.2. Briefly, hemibrains were 
dehydrated by several incubations with increasing concentration of alcohol followed 
by a final incubation in xylene. Next, the tissue was incubated in paraffin wax until 
embedded into paraffin blocks. Sections of 6 µm thickness were produced with a  
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Table 2.2. Automatic processing for paraffin embedding.  
 
Solution Duration (hours) Temperature (ºC) 
70% Ethanol 1 35 
90% Ethanol 1 35 
100% Ethanol 1 35 
100% Ethanol 1.5 35 
100% Ethanol 2 35 
100% Ethanol 1 35 
Xylene 1 35 
Xylene 1 35 
Xylene 1 35 
Paraffin wax TT 111 1 60 
Paraffin wax TT 111 1 60 
Paraffin wax TT 111 1 60 














microtome (Leica RM2135) and mounted onto superfrost plus slides (VWR 
International) for histological or immunohistochemical studies. Specific details 
including orientation of the tissue sections are specified in the methods section of the 




For all immunohistochemistry experiments, previous assessment of the optimal 
concentration of each antibody was carried out by testing various dilutions. Negative 
controls, in which identical treatment was performed without addition of the primary 
antibody, were used in all the experiments to determine non-specific staining. 
 
Primary and secondary antibodies used are listed in Table 2.3. 
 
2.6.1. Fluorescent labelling. 
 
Free-floating vibratome sections were rinsed in PBS followed by Tris buffer (TB) pH 
7.6. Sections were mounted onto superfrost plus slides (VWR International) and left 
to air-dry at RT overnight. 
 
Paraffinised tissue slices, were deparaffinised with heat (60 °C) for 30 minutes 
followed by incubation in xylene.  
 
Either vibratome or paraffin tissue sections were re-hydrated through a series of 
alcohols (100%, 90% and 70% ethanol) and then equilibrated in PBS for 10 minutes.  
 
Retrieval was performed by submerging slices in 10 mM citrate buffer (pH 6) and 
heated at 100 °C under pressure for 10 minutes. Subsequently, sections were rinsed 
in PBS and retrieval using 2 mM proteinase K, in buffer TE for 10 minutes at RT, 
was performed. Samples were then washed in PBS and blocked for 2 hours at RT 
with 20% normal serum 0.5% BSA followed by incubation with the primary 
antibody solution overnight at 4 °C. Samples were then washed in PBS and  
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incubated with the secondary antibody solution for 2 hours at RT. Sections were 
washed with PBS followed by TB and left to air-dry at RT away from light. Finally, 
coverslips were mounted using Vectashield HardSet mounting medium and sections 
were stored at 4°C.  
 
2.6.2. Immunoperoxidase labelling. 
 
Tissue was deparaffinised with heat (60 °C) for 30 minutes followed by incubation in 
xylene. Samples were later incubated in 100% ethanol and then covered with 3% 
H2O2 for 30 minutes. Sections were rinsed with running water and citrate retrieval 
was performed by submerging slices in 10 mM citrate buffer (pH 6) and heated at 
100 °C under pressure for 10 minutes. Subsequently, tissue sections were washed in 
PBS, blocked with 10% serum 0.5% BSA for 1 hour at RT and then incubated with 
the primary antibody overnight at 4 °C. Samples were washed in PBS and incubated 
with the secondary antibody solution for 1 hour at RT. Slides were washed in PBS 
followed by incubation with Vectastain Elite ABC reagent (Vector Labs). Sections 
were washed in PBS and incubated with diaminobenzidine solution (Vector Labs). 
Finally, tissue sections were rinsed with running water, dehydrated through a series 
of alcohols (70%, 90%, 100% ethanol) and incubated in xylene. Coverslips were 
mounted using DPX mounting medium (Thermo Fisher).  
 
2.7. Histological detection of microinfarcts and haemorrhages. 
 
2.7.1. Haematoxylin and eosin staining. 
 
In order to determine the presence of MIs, sections were stained with haematoxylin 
and eosin (H&E) to visualise the presence of ischemic tissue damage. Paraffin 
sections were deparaffinised in an oven at 60°C for 30 minutes followed by 
incubation in xylene for 15 minutes. Samples were re-hydrated by incubation 
through a series of alcohols (100%, 90%, 70% ethanol) and running water. Sections 
were immersed in Shandon haematoxylin solution (Thermo Fisher) for 3 minutes and 
then rinsed briefly in running water. Differentiation of the staining was achieved by 
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incubation in acid alcohol solution (1% HCl in 70% ethanol) for 4 seconds and then 
sections were rinsed in running water for 2 minutes. Samples were immersed in 
Scott’s tap water solution (2% MgSO4, 0.35% NaHCO3) for 2 minutes and then 
washed in running tap water for another 2 minutes. Slides were incubated in eosin Y 
(Thermo Fisher) solution for 2 minutes and then briefly rinsed in water. Sections 
were dehydrated by incubation through a series of alcohols (70%, 90%, 100% 
ethanol) followed by incubation in xylene. Finally, coverslips were mounted using 
DPX mounting medium (Thermo Fisher). 
 
2.7.2. Prussian blue staining. 
 
In order to detect the presence of haemorrhages, paraffin sections were 
deparaffinised in an oven at 60°C for 30 minutes followed by incubation in xylene 
for 15 minutes. Samples were re-hydrated by incubation through a series of alcohols 
(100%, 90%, 70% ethanol) and running water. Sections were immersed in Perls 
solution (2% potassium ferrocyanide, 2% hydrochloric acid) for 10 minutes and then 
rinsed in running water. Slides were counterstained using 0.1% nuclear fast red 
(Vector) for 5 minutes and washed in running water. Dehydration was performed by 
incubation through a series of alcohols (70%, 90%, 100% ethanol) followed by 
incubation in xylene. Finally, coverslips were mounted using DPX mounting 
medium (Thermo Fisher). 
 
2.8. Analysis of immunohistochemistry. 
 
Fluorescence labelled sections were analysed using a laser scanning confocal 
microscope (Zeiss LSM 510, Germany).  
 
Images from Perls, H&E and immunoperoxidase labelled sections were acquired 
using a QImaging QICAM MicroPulisher 3.3 camera (QImaging, Surrey, BC, 
Canada) connected to an Olympus BX51 microscope (Olympus UK, Southendon-




All measurements were carried out using Image J software (v1.42q). Specific details 
including brain region imaged and type of analysis performed are specified in the 
methods section of the corresponding chapter. 
 
 
2.9. Generation of parenchymal and vessel enriched fractions. 
	
Following saline perfusion, the brains were removed and cut along the midline. The 
right hemi-brain was stored at -80⁰C until used for total protein extraction. The left 
hemi-brain was homogenised with a fit dounce homogeniser with 1 ml of PBS on 
ice, using 15 strokes. The homogenate was centrifuged at 250 x g for 10 minutes at 
4⁰C. The pellet was re-suspended in 3 ml of 17.5% ficoll (Sigma) and centrifuged at 
3,200 x g for 25 minutes. The pellet (containing the vessel enriched fraction) was 
collected and the supernatant (containing the parenchymal fraction) was centrifuged 
again at 3,200 x g for 25 minutes. The pellets from both spins were re-suspended in 1 
ml of 1% BSA in PBS and centrifuged at 2,000 x g for10 minutes. The pellet was 
washed with 1 ml of PBS and stored at -80⁰C. The supernatant containing the 
parenchymal fraction was mixed with 6 ml of PBS and centrifuged at 3,200 x g for10 
minutes. The supernatant was discarded and the pellet stored at -80⁰C. 
Characterisation of the vessel enriched fraction was performed and shown in Figure 
2.2. Immunostaining using antibodies against collagen IV and Aβ was performed to 
observe the presence of blood vessels and Aβ in aliquots from vessel enriched 
fractions, extracted from wild-type and Tg-SwDI mice. Western blot analysis of 
protein extracts from both parenchymal and vessel enriched fractions revealed 
significantly higher levels of vascular related proteins (smooth muscle actin (SMA) 
and occludin) in vessel enriched compared to parenchymal fractions. 
 
2.10. Protein extraction and quantification. 
 










Figure 2.2. Characterisation of the vessel enriched fraction. Representative 
images showing aliquots from vessel enriched fractions, extracted from wild-type (a) 
and Tg-SwDI mice (b) immunostained with anti-collagen IV and anti-Aβ antibodies 
(scale bar = 40 µm). Western blot analysis of protein extracts from both parenchymal 
(SO) and vessel (S1) enriched fractions was used to determine the expression levels 
of SMA and occludin, represented in the graphs; tubulin was used as loading control. 






Sequential protein extraction was performed in order to obtain both soluble and 
insoluble protein fractions.  
 
The tissue was homogenised with homogenisation buffer (20 mM tris base pH 7.4, 
250 mM sucrose, 1 mM EDTA, 1 mM EGTA, 1X protease inhibitor cocktail 
[Calbiochem]) and centrifuged at 100,000 x g for 1 hour at 4⁰C. The supernatant  
(containing the soluble protein fraction) was carefully transferred to a new tube and 
stored at -80⁰C.  
 
The pellet was resuspended and homogenised in guanidine buffer (5 M guanidne, 50 
mM Tris/HCL) and mixed for 3 hours at room temperature (RT). The solution was 
diluted 1:10 with ice-cold reaction buffer (0.2 g/L KCL, 0.2 g/L KH2PO4, 8 g/L 
NaCl, 1.15 g/L Na2HPO4, 5% BSA, 0.03% tween 20, 1X protease inhibitor cocktail) 
and centrifuged at 16,000 x g for 20 minutes at 4⁰C. The supernatant (containing the 
insoluble protein fraction) was stored at -80⁰C. 
 
2.10.2 Total protein extraction. 
 
Total protein extraction was performed by homogenising the tissue in RIPA buffer 
(50 mM Tris, pH 7.5, 1% NP-40, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 0.5% 
sodium deoxycholate, 1X protease inhibitor cocktail), followed by sonication for 5 
seconds at 10% amplitude (Branson digital sonifier). Samples were centrifuged at 
5000 x g for 5 minutes and the supernatant was collected and stored at -80⁰C. 
 
2.10.3. Protein quantification. 
 
Protein levels were quantified with the Pierce BCA Protein Assay Kit (Thermo 
Scientific). Manufacturer’s instructions were used to perform the assay. Absorbance 
was read on a LT-4000 MS microplate reader (Labtech, East Sussex, UK). 
 




For all ELISA experiments, previous assessment of the optimal sample dilution was 
carried out by testing various dilutions in order to obtain absorbance values within 
the range of the standard curve. Levels of Aβ1-40, Aβ1-42, Scara1, AQP4 and 
NADPH Oxidase-2 (NOX2) were assessed using ELISA. In all experiments, 
manufacturer’s instructions were used to perform the assays. Details of antibodies 
used are detailed in Table 2.4. Specific details including type of sample used and 
kit’s source, are specified in the methods section of the corresponding chapter.  
 
2.12. Western blotting. 
 
APP, APP-CTF’s, LRP, GFAP and claudin-5 levels were determined by using 
western blot. Details of antibodies used are detailed in Table 2.5. The type of sample 
used is specified in the methods section of the corresponding chapter.  
 
Samples were prepared by mixing the protein extracts with 1X NuPAGE loading 
buffer (Invitrogen) and 1% NuPAGE reducing agent (Invitrogen) followed by 
incubation at 70˚C for 10 minutes in a water bath. Samples and molecular weight 
marker (Li-Cor, Cambridge, UK) were loaded and fractionated by electrophoresis 
using 4–12% sodium dodecyl sulphate polyacrylamide gels (Invitrogen) in MES 
running buffer (Invitrogen) at 100V. Subsequently, proteins were electroblotted at 
30V for 1.5 hours on to polyvinylidene fluoride (PVDF) membranes (Hybond-P, GE 
Healthcare) using a XCell II Blot Module (Invitrogen). PVDF membranes were 
incubated with agitation in blocking buffer (Li-Cor) for 1 hour at RT, followed by 
incubation overnight at 4 ˚C with the primary antibody, which was diluted in a 
solution containing blocking buffer and 0.1% tween-20. Membranes were washed 3 
times in PBS 0.1% tween-20, during 10 minutes each wash. Subsequently, 
membranes were incubated with the secondary antibody during 45 minutes and 
washed as previously described with a final wash for 5 minutes in distilled water. 
Membranes were air-dried and stored away from light. The immunoreactive bands 
were visualised using the Odyssey Infrared Imaging System (LiCor Biosciences, 
Lincoln, NE, USA) and densitometric analysis of the scans was performed by using 
the odyssey software (version 3.0; Li-Cor, Cambridge, UK). 
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Table 2.4. Antibodies used for ELISA.  
 
Antibody Target Source 
anti- Aβ1-40 Amyloid-β 1-40  Invitrogen 
anti-  Aβ1-42 Amyloid-β 1-42  Invitrogen 
anti- Scara1 Scavenger receptor A Cusabio 
anti- AQP4 Aquaporin-4 Invitrogen 



































Table 2.5. Primary antibodies used for western blotting. 
 
Antibody Label Species 
raised in 
Clone Source Dilution 
anti-APP APP Mouse Monoclonal Millipore, MAB348 1:1000 
anti-          
APP-CTF’s 
APP-
CTF’s Rabbit Polyclonal 
Calbiochem, 
171610 1:1000 
anti-LRP1 LRP1 Rabbit Monoclonal Abcam, ab92544 1:20000 
anti-GFAP Astrocytes Rabbit Polyclonal Dako, ZO334 1:5000 
anti-  



























2.13. Barnes maze.  
 
Spatial learning memory was assessed by using the Barnes maze (Figure 2.3). The 
maze consists of a 91.5 cm diameter, 115 cm height circular white platform (San 
Diego Instruments) with 20 circular holes around the perimeter of the platform. A 
small, dark escape chamber is attached to one of the holes. Visual cues including 
different shaped and coloured objects hanging in plain sight of the animals are placed 
around the maze to optimise cognitive performance. The platform is brightly lit by 
overhead lighting. A 10.5 cm diameter cylinder is used to retain the animals on the 
platform before the trial begins. A camera fixed above the maze was used to track the 
movement patterns of the animals by using the ANY-maze video tracking Software 
(v4.99). 
 
The aim of the Barnes maze is to measure the ability of the animals to learn and 
remember the location of the escape chamber using the configuration of the cues. 
 
2.13.1. Acclimation phase. 
 
Prior to the beginning of the experiment, the mice were acclimated to the holding 
room and the maze room over a period of three days. During this phase, the animals 
were kept outside the maze room during one hour and then taken into the room. Mice  
were placed into the holding cylinder during ten seconds and then brought back to 
their home cage. 
 
The animals were handled by the same experimenter throughout the study.  
 
2.13.2. Habituation phase. 
 
One day after the acclimation phase, mice were kept outside the maze room during 










Figure 2.3. Assessment of spatial learning and memory performance using the 






Animals were allowed to freely explore the maze during three minutes, whilst 
aversive white noise was being played. After conclusion of the three minutes, if the 
mice stayed on the surface of the table, they were trained to enter to the escape 
chamber by being gently guided into the box and allowing them to stay inside for one 
minute with the white noise off. 
 
To avoid the use of olfactory cues to find the escape box, the surface of the maze and 
the box were cleaned with a 70% ethanol solution between animals. 
 
2.13.3. Spatial acquisition phase. 
 
The training was performed over a period of five days, where two trials per day were 
ran. The mice were kept outside the maze room during one hour and then taken into 
the room to start the test. Animals were placed into the holding cylinder during ten 
seconds and the white noise started to play. The cylinder was lifted and the mice 
were given three minutes to find the escape box. After conclusion of the three 
minutes, if the mice did not find the exit hole, they were trained to enter to the escape 
chamber by being gently guided into the box and allowing them to stay inside for one 
minute with the white noise off.  
 
The escape box was located in the same position of the maze for each animal 
throughout the training phase; however it was shifted 90 degrees between each 
mouse to avoid the use of olfactory cues in order to find the escape chamber. Also, 
the surface of the maze and the escape box were cleaned with a 70% ethanol 
solution. 
 
Animals were divided into two groups. After every animal from the first group 







2.13.4. Probe trial. 
 
48 hours after the last training trial, the probe trial was conducted. The mice were 
kept outside the maze room during one hour and then taken into the room to start the 
test. Animals were placed into the holding cylinder during ten seconds and the white 
noise started to play. The cylinder was lifted and the mice were given 90 seconds to 
freely explore the maze with the escape box removed. The surface of the maze was 




During the training (spatial acquisition) phase, the latency to escape (time required 
by the mouse to enter the escape box) and primary latency (time required by the 
mouse to explore the escape box regardless of whether they entered) were directly 
measured by the tracking software. The number of errors, defined as the exploration 
of incorrect holes, was recorded and quantified manually by the experimenter 
observing via the computer screen. Total errors (number of errors made before 
entering the escape box) and primary errors (number of errors made prior to the 
initial contact with the escape hole) were recorded. During the probe trial, the 
percentage of time spent in each quadrant was directly measured by the tracking 
software. The number of total and primary errors were recorded and quantified 
manually by the experimenter. 
 
This test was carried out in collaboration with Dr Luke Searcy, who set up the maze 
and participated in the experimental procedure. 
 
2.14. Statistical analysis.  
 
All statistical analyses were performed using Graph Pad Prism 5.0 software (La 
Jolla, CA, USA). For experiments with two samples, a two-tailed un-paired Student’s 
t-test was applied. For experiments with more than two samples, a one-way ANOVA 
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test was applied. For experiments with more than two samples but two variables, a 
two-way ANOVA test was applied. Bonferroni test was used as a post hoc-test. 
 
Data are presented as the mean ± standard error of the mean. Unless otherwise 
indicated, a probability (p) value of < 0.05 was considered to be statistically 
significant. 
 


































































Several transgenic lines have been developed in an attempt to generate models that 
mimic specific aspects of human AD and they constitute a potent tool for the 
research in AD field; the Tg-SwDI is one of these models. This mouse line expresses 
a 9-kilobase construct carrying the 770 isoform of the human neuronal APP gene, 
harbouring the Swedish K670N/M671L and vasculotropic Dutch E693Q and Iowa 
D694N mutations, under the control of the mouse Thy-1.2 promoter (Figure 1.5), 
which drives the gene expression specifically in the brain. A report describing this 
model was published in 2004 by Davis and colleagues, where age-dependant Aβ 
accumulation, primarily in the cerebral microvasculature of these mice is 
demonstrated. Diffuse plaque-like structures in the parenchyma are also described to 
occur (Davis et al., 2004). These mice present astrogliosis and microglial activation, 
which is associated with vascular amyloid (Miao et al., 2005). Functional and 
structural deterioration of the cerebrovasculature has been detected in this model 
starting at 3 months of age (Park et al., 2013; Park et al., 2014). 
 
Vascular accumulation of Aβ has been associated with the development of cerebral 
haemorrhages (Vonsattel et al., 1991) and microinfarction (Okamoto et al., 2009; 
Soontornniyomkij et al., 2010), which are a common histopathological finding in 
post-mortem studies of AD patients and may contribute to the cognitive decline (Ellis 
et al., 1996; Cordonier and van der Flier, 2011; van Rooden et al., 2014). Indeed, 
these type of cerebral lesions are also present in the Tg-SwDI mice and are a focus of 
the work presented in the chapter 4 of the present thesis, where the effect of chronic 
cerebral hypoperfusion on Aβ accumulation, and subsequent contribution to the 
development of these lesions was investigated. Interestingly, Tg-SwDI mice have 
shown to undergo cognitive alterations including learning and memory deficits 
detected in the Barnes maze task, which correlate with subicular accumulation of Aβ 
in the microvasculature (Xu et al., 2007). However, the contribution of haemorrhages 
and MIs to the cognitive impairment in these mice is unknown. This is studied in the 
chapter 5 of this thesis, where the effect of reducing amyloid load, on the 
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development of MIs and haemorrhages and potential behavioural improvement in the 
Tg-SwDI mice were investigated. 
 
Although the model has previously been characterised (Davis et al., 2004), the 
rederivation of mice and subsequent breeding can often lead to changes from the 
original phenotype. Thus it was deemed important to characterise the amyloid and 
Aβ-related pathology with increasing age. Since it was planned to induce the 
hypoperfusion in these mice before significant Aβ deposition is observed it was also 
important to define when the onset of amyloid accumulation was initiated. 
 
3.1.1. Hypothesis and aim of study. 
 
It was hypothesised that the Tg-SwDI model undergoes increasing parenchymal and 
vascular Aβ accumulation associated with inflammation over time. 
 
The aim of this study was to characterise the temporal APP expression, accumulation 
of parenchymal and cerebrovascular Aβ and Aβ-related microglial and astrocytic 
activation that the Tg-SwDI model exhibits, compared to wild-type animals, in order 




















3 groups of 3, 6 and 9 months old male Tg-SwDI mice were used. Male wild-type 
(C57Bl/6J) mice were used as comparative controls. Animal numbers were as 
follows: 
 
3 months, n = 8 wild-type and 8 Tg-SwDI; 6 months, n = 10 wild-type and 10 Tg-
SwDI and 9 months, n = 15 wild-type and 15 Tg-SwDI. 
 
The researcher was blind to the genotype of the mice until the final data analysis. 
 
3.2.2. Perfusion and tissue processing. 
 
Animals underwent saline perfusion followed by perfusion fixation as described in 
section 2.4.2. Brains were processed for paraffin embedding and coronal sections 




Immunohistochemistry was carried out as described in section 2.6. Tissue sections at 
anatomical level corresponding to -1.70 mm from bregma (Franklin and Paxinos, 
1997) were used. APP expression, Aβ deposition, microglial activation and 
astrogliosis were conducted using immunoperoxidase labelling. Vascular Aβ 
accumulation was performed using fluorescent labelling.  
 
3.2.4. Image analysis.  
 
For the analysis of APP expression, Aβ deposition, microglial activation and 
astrogliosis, one image from the cortex, one from the hippocampus and one from the 
thalamus were acquired as described in section 2.8, at 4x magnification. Quantitative 
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measurement of the staining was assessed by measuring the percentage of the stained 
area compared to the total area. 
 
For the analysis of vascular Aβ, four images of the thalamus per brain were acquired 
as described in section 2.8 with a 40x objective at a 1024 x 1024 pixel resolution. 
Colocalisation analysis between blood vessels and Aβ was done by calculating the 
ratio between the area occupied by colocalising pixels and the percentage of collagen 
IV (red channel) stained area. 
 
3.2.5. Statistical analysis.  
 
The data was analysed for statistical significance using two-way analysis of variance 
(ANOVA) (with age and genotype as factors) followed by the Bonferroni post-test.  
 
Results from vascular Aβ measurements were analysed for statistical significance 
using unpaired t-test with p < 0.05. 
 



















3.3.1. Temporal expression of APP in Tg-SwDI mouse brain.   
 
In order to visualise the expression of APP, immunostaining was performed using an 
antibody that recognises an epitope within amino acids 66-81 of APP (N-terminus) 
and therefore binds to both murine and human APP. This protein is normally 
concentrated in neurons and this was observed in both Tg-SwDI and wild-type mice, 
however the staining was much more evident in the tissue sections from transgenic 
animals (Figure 3.1). As shown in Figure 3.2, the expression of the protein increased 
as the animal aged in all the brain regions analysed. As comparison, representative 
images from 9 months old wild-type mice are shown (Figure 3.2, j-l).  
 
The image analysis showed that APP immunostaining was significantly higher in the 
Tg-SwDI mice when compared to wild-type controls starting at 6 months of age in 
the cortex and hippocampus and by 9 months in the thalamus (Figure 3.3).  
 
These results indicate that the Tg-SwDI model presents an age-dependent increase in 
APP expression levels in the brain. 
 
3.3.2. Amyloid-β deposition. 
 
In order to study Aβ deposition in the Tg-SwDI mouse brain, immunostaining was 
conducted using the antibody 6E10, epitope of which is situated within amino acids 
3-8 of Aβ and therefore recognises all isoforms of the protein.  
 
As shown in Figure 3.4, there was a progressive and robust accumulation of Aβ in 
cortex, hippocampus and thalamus of the transgenic animals. The accumulation of 
the protein increased as the animal aged, showing extensive aggregation by 9 
months, markedly in the thalamus (Figure 3.4, i). Aβ plaque-like deposits started to 


















Figure 3.1. Amyloid precursor protein expression in the Tg-SwDI model. Tissue 
sections from 9 months old transgenic and wild type animals were immunostained 
with a marker of APP. Representative images taken in the cortex (a, c) and 





















Figure 3.2. Temporal expression of APP in the Tg-SwDI model. Transgenic and 
wild type animals were sacrificed at 3, 6 and 9 months of age and histological 
analysis of the cortex (a, d, g, j), hippocampus (b, e, h, k) and thalamus (c, f, i, l) was 
performed. Sections were immunostained and APP was visualised using a marker 














Figure 3.3. APP expression increases over time in the transgenic mouse model 
Tg-SwDI. Quantitative analysis of APP immunostaining was assessed by measuring 
the percentage of stained area, represented in the graphs. The data presented are the 
means ± S.E.M.; two-way ANOVA: cortex: significant effect of genotype (F(1,57) = 
28.49, ***p < 0.0001), Bonferroni post-test (**p < 0.01) (a); hippocampus: 
significant effect of genotype (F(1,58) = 31.23, ***p < 0.0001), Bonferroni post-test 
(*p < 0.05; ***p < 0.001) (b); thalamus: significant effect of age (F(2,58) = 11.96, 
***p < 0.0001), significant effect of genotype (F(1,58) = 20.47, ***p < 0.0001), 
significant interaction (F(2,58) = 11.30, ***p < 0.0001), Bonferroni post-test (***p < 












Figure 3.4. Temporal Aβ deposition in the transgenic mouse model Tg-SwDI. 
Transgenic and wild type animals were sacrificed at 3, 6 and 9 months of age and 
histological analysis of the cortex (a, d, g, j), hippocampus (b, e, h, k) and thalamus 
(c, f, i, l) was performed. Sections were immunostained and amyloid was visualised 







diffuse aggregates were present in all the brain regions analysed, as shown at higher 
magnification (Figure 3.4, insets). 
 
As expected, amyloid aggregation was absent in wild-type controls; representative 
images from 9 month old wild-type mice are shown (Figure 3.4, j-l). 
 
The image analysis showed that Aβ deposition was significantly higher in the Tg-
SwDI mice when compared to wild-type controls starting at 6 months of age in the 
cortex and hippocampus and by 9 months in the thalamus (Figure 3.5). 
 
This result indicates that the Tg-SwDI model presents an age-dependent increase in 
Aβ deposition in the brain. 
 
3.3.3. Microglia activation. 
 
Microglia constitutes the principal cell component of the active immune defence in 
the CNS. An inflammatory response has been associated with amyloid deposition 
and particularly to CAA in transgenic mouse models and in AD patients (Morgan et 
al., 2005; Chung et al., 2011; Zabel et al., 2013; Baron et al., 2014).  
 
In order to determine whether this mouse line undergoes microglial activation, an 
immunohistochemical study was conducted using the antibody Iba1, which 
recognises the ionized calcium-binding adaptor molecule 1, a protein that is 
upregulated during the activation of microglia (Ito et al., 1998). 
 
As shown in Figure 3.6, microglial activation increased in the Tg-SwDI model as the 
animal aged in all the brain regions analysed. In comparison, there was minimal 
microglia in wild-type mice compared to Tg-SwDI mice at the same ages. 
Representative images of microglia from 9 month old wild-type mice are shown to 










Figure 3.5. Aβ deposition increases over time in the transgenic mouse model Tg-
SwDI. Quantitative analysis of Aβ deposition was assessed by measuring the 
percentage of stained area, represented in the graphs. The data presented are the 
means ± S.E.M.; two-way ANOVA: cortex: significant effect of age (F(2,58) = 10.59, 
***p = 0.0001), significant effect of genotype (F(1,58) = 43.15, ***p < 0.0001), 
significant interaction (F(2,58) = 9.040, ***p = 0.0004), Bonferroni post-test (***p < 
0.001) (a); hippocampus: significant effect of age (F(2,56) = 16.80, ***p < 0.0001), 
significant effect of genotype (F(1,56) = 73.33, ***p < 0.0001), significant interaction 
(F(2,56) = 14.07, ***p < 0.0001), Bonferroni post-test (***p < 0.001) (b); thalamus: 
significant effect of age (F(2,58) = 50.91, ***p < 0.0001), significant effect of 
genotype (F(1,58) = 67.87, ***p < 0.0001), significant interaction (F(2,58) = 44.52, ***p 










Figure 3.6. Temporal increase of microglial activation in the transgenic mouse 
model Tg-SwDI. Transgenic and wild type animals were sacrificed at 3, 6 and 9 
months of age and histological analysis of the cortex (a, d, g, j), hippocampus (b, e, 
h, k) and thalamus (c, f, i, l) was performed. Sections were immunostained and 









Quantitative measurement of percentage area stained with Iba1 revealed that 
microglial activation was significant only by 9 months of age in cortex and 
hippocampus of the transgenic animals when compared to the wild-type controls 
(Figure 3.7, a and b, respectively), whereas in the thalamus extensive and significant 
activation of microglial cells was found by 6 months (Figure 3.7, c). Note that this 
pattern of activation follows the load of amyloid across the different brain regions. 
 
Furthermore, comparison of the results obtained from both Aβ and Iba1 
immunostaining analyses revealed a positive correlation between both proteins 
(Figure 3.8), suggesting that amyloid accumulation in this model is associated to the 
initiation of an inflammatory process. 
 
3.3.4. Astrocyte activation. 
 
In order to determine astrocyte reactivity in the Tg-SwDI model, immunostaining 
was conducted using a marker that recognises the glial fibrillary acidic protein 
(GFAP), an intermediate filament protein that is highly expressed in astrocytes and 
upregulated during astrogliosis, therefore used to study astrocyte activation. 
 
As shown in Figure 3.9, there was strong astrocyte activation in cortex, hippocampus 
and thalamus of the transgenic animals. GFAP upregulation was progressive in the 
cortex and thalamus and was markedly high in young mice in the hippocampus. As 
comparison, representative images from 9 months old wild-type mice are shown 
(Figure 3.9, j-l). The image analysis showed that GFAP immunostaining was 
significantly higher in the Tg-SwDI mice when compared to wild-type controls 
starting at 6 months of age in the cortex and thalamus and as early as 3 months in the 
hippocampus (Figure 3.10).  
 










































Figure 3.7. Microglial activation increases over time in the transgenic mouse 
model Tg-SwDI. Quantitative analysis of Iba1 signal was assessed by measuring the 
percentage of stained area, represented in the graphs. The data presented are the 
means ± S.E.M.; two-way ANOVA: cortex: significant effect of age (F(2,58) = 9.332, 
***p = 0.0003), significant effect of genotype (F(1,58) = 8.358, **p = 0.0054), 
significant interaction (F(2,58) = 5.998, **p = 0.0043), Bonferroni post-test (***p < 
0.001) (a); hippocampus: significant effect of age (F(2,57) = 26.12, ***p < 0.0001), 
significant effect of genotype (F(1,57) = 19.17, ***p < 0.0001), significant interaction 
(F(2,57) = 4.333, *p = 0.0177), Bonferroni post-test (***p < 0.001) (b); thalamus: 
significant effect of age (F(2,58) = 31.32, ***p < 0.0001), significant effect of 
genotype (F(1,58) = 56.99, ***p < 0.0001), significant interaction (F(2,58) = 10.71, ***p 


















Figure 3.8. Aβ deposition correlates with increased microglial activation. 
Pearson correlation:Scatter plot shows a positive correlation between percentage of 
Iba1 stained area and percentage of Aβ stained area, Pearson correlation test: r = 






















Figure 3.9. Temporal increase of astrocyte activation in the transgenic mouse 
model Tg-SwDI. Transgenic and wild type animals were sacrificed at 3, 6 and 9 
months of age and histological analysis of the cortex (a, d, g, j), hippocampus (b, e, 
h, k) and thalamus (c, f, i, l) was performed. Sections were immunostained and 








Figure 3.10. Astrocyte activation increases over time in the transgenic mouse 
model Tg-SwDI. Quantitative analysis of GFAP signal was assessed by measuring 
the percentage of stained area, represented in the graphs. The data presented are the 
means ± S.E.M.; two-way ANOVA: cortex: significant effect of age (F(2,52) = 7.469, 
**p = 0.0014), significant effect of genotype (F(1,52) = 46.43, ***p  < 0.0001), 
Bonferroni post-test (***p < 0.001) (a); hippocampus: significant effect of genotype 
(F(1,52) = 53.72, ***p < 0.0001), Bonferroni post-test (**p < 0.01; ***p < 0.001) (b); 
thalamus: significant effect of age (F(2,52) = 21.94, ***p < 0.0001), significant effect 
of genotype (F(1,52) = 85.31, ***p < 0.0001), significant interaction (F(2,52) = 18.40, 
***p < 0.0001), Bonferroni post-test (***p < 0.001) (c).   
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3.3.5. Cerebral amyloid angiopathy. 
 
In order to temporally characterise the accumulation of Aβ in the cerebral 
vasculature of Tg-SwDI mice, colocalisation analysis of Aβ with blood vessels was 
performed in the thalamus, which has been described to be one of the brain areas 
showing higher levels of CAA in this model (Davis et al., 2004).  
 
As shown in Figure 3.11, the vessels (red channel) were visualised with a specific 
marker of collagen IV, a type of collagen found in the basement membrane carrying 
out a structural function within the vasculature. The antibody 6E10 was used to 
visualise Aβ (green channel).  
 
Quantitative analysis of the colocalisation of Aβ with vessels as an index of vascular 
Aβ revealed that the load of vascular Aβ was significantly increased as the animals 
aged, as well as the number of amyloid containing vessels (Figure 3.11, d and e 
respectively), suggesting that Aβ deposition increases and distributes uniformly in 



























































Figure 3.11. Vascular Aβ increases over time in the transgenic mouse model Tg-
SwDI. Double immunostaining was performed using anti-collagen IV (vessels) and 
6E10 (Aβ). Colocalisation analysis of the merged images was made by calculating 
the proportion of vessels (red channel) colocalising with Aβ (green channel) (d). The 
proportion of Aβ containing vessels was quantified and represented in the graph (e). 
The data presented are the means ± S.E.M., one-way ANOVA: p < 0.05, n= 32  











3.4. Discussion.  
 
The aim of this study was to temporally characterise the Aβ and Aβ-related 
pathology in the Tg-SwDI mouse model. Increasing APP expression was found as 
well as Aβ aggregation as the animals aged in the cortex, hippocampus and thalamus, 
which was accompanied by extensive and progressive activation of microglial and 
astrocytic cells. 
 
3.4.1. APP expression and Aβ accumulation. 
 
The results from this study, in agreement with the original publication describing the 
Tg-SwDI model (David et al., 2004) show an age-dependent regional accumulation 
of amyloid predominantly in the thalamus. Furthermore, in agreement with the 
results obtained from Van Nostrand group, vascular amyloid is particularly 
prominent in the model (Davis et al., 2004). However, there are details in the 
temporal accumulation of amyloid and APP that differ from the results obtained by 
Davis and colleagues (Davis et al., 2004). For example, the authors of this paper 
observed that human APP expression levels were modest and lower compared to the 
endogenous mouse APP. In contrast, in the present study higher levels were observed 
in the transgenic mice when compared to the wild-type controls. One possible 
explanation for this difference, apart from the fact that different approaches were 
used to determine this (western blot in the published study and 
immunohistochemistry in the current study), is that the antibody used in the present 
study recognises both murine and human APP, which could be the reason why higher 
levels were observed in the Tg-SwDI animals. Moreover, an important difference 
between both studies that needs to be considered when comparing this data is that all 
the published analyses conducted by Van Nostrand group (Davis et al., 2004) were 
done in heterozygous Tg-SwDI mice and differently, the current study was 
performed using homozygous animals. This could be another explanation for the 
contrasting results between the two studies. Also, it is important to note that the 
authors observed that APP levels remained consistently low over time, and 
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differently, the results from the current study revealed a significant and progressive 
increase in the levels of the protein as the animals aged. 
 
In parallel with the increasing APP levels, age-dependent progression of Aβ 
accumulation was observed. These findings are in line with those from Davis and 
colleagues who, despite the low levels of APP found, also demonstrated early onset 
and robust temporal accumulation of Aβ (Davis et al., 2004). Quantification of the 
regional accumulation of Aβ revealed that by 12 months, vascular accumulation was 
strong in the thalamus and subiculum. In agreement, the present study found higher 
accumulation of the protein in the thalamus compared to the cortex and 
hippocampus; consequently, quantitation of vascular Aβ was performed focusing 
only in this region. Again, similarly to what was described by the authors, age-
dependent increase of amyloid associated to the cerebrovasculature was found in the 
present study.  
 
3.4.2. Aβ-related inflammation. 
 
Inflammation has been largely studied in relation to amyloid deposition and has been 
described to positively correlate, particularly with vascular Aβ (Akiyama et al., 2000; 
Mrak and Griffinbc, 2001; Patel et al., 2005, Zabel et al., 2013; Baron et al., 2014). 
Microglia and astrocytes are key players involved in the development of 
inflammation and both cells have been shown to be associated with microvascular 
amyloid deposits (Grabowski et al., 2001; Eng et al., 2004). Hence, a further aim of 
this study was to explore the Aβ-related microglial and astrocyte activation in the Tg-
SwDI model.  
 
The results obtained suggest that amyloid deposition occurred before microglial 
activation in cortex and hippocampus. In both regions there was significant Aβ 
deposition by 6 months of age but microglial activation was observed only by 9 
months. In contrast, although amyloid deposition was significantly higher in the 
transgenic mice compared to controls by 9 months of age in the thalamus, microglial 
activation occurred earlier in this region, by 6 months. As mentioned above, vascular 
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Aβ deposition has been previously described to be higher in thalamus than other 
regions in the brain of this transgenic mouse line. Hence, it is possible that the 
regional difference of microglial activation observed in the present study may be 
related to the vascular Aβ deposition, which has been shown to be associated with a 
stronger immune response than parenchymal amyloid accumulation. Indeed, a 
previous study performed with homogenates of parenchymal and vessel enriched 
fractions extracted from human post mortem brains from AD patients with 
parenchymal and vascular Aβ and AD patients with only parenchymal amyloid, 
revealed higher expression levels of inflammatory markers in the samples from  
subjects  that had CAA compared to those who presented only parenchymal amyloid. 
Moreover, inflammation was markedly associated with vessels containing amyloid 
compared to those that did not presented CAA (Zabel et al., 2013). The analysis of 
astrocyte activation in the present study revealed progressive astrogliosis over time in 
the transgenic mice compared to the wild-type controls. These results are in line with 
a study conducted by Miao and colleagues, where large number of reactive astrocytes 
and activated microglia were observed in the Tg-SwDI model. Furthermore, 
reduction of cerebrovascular amyloid, obtained by breeding Tg-SwDI mice with 
apoE knock-out mice, resulted in decreased number of microglia and astrocytes 
emphasising the link between CAA and inflammation (Miao et al., 2005).  
 
Compelling evidence has demonstrated that microglial activation and astrogliosis are 
associated with increased production of pro-inflammatory cytokines, neurotoxins and 
ROS, which have been suggested to contribute to cognitive decline in AD (Combs et 
al., 2001; Mrak and Griffin, 2001; Streit, 2004). Interestingly, anti-inflammatory 
treatment with minocycline reduced the neuroinflammation and induced 
improvement of the behavioural performance in the Tg-SwDI model without 
changing Aβ levels (Fan et al., 2007). This evidence highlights the important role of 
inflammation in the mechanisms by which amyloid leads to cognitive alterations in 
the model. It is important to note that microglia and astrocytes play an important role 
at the NVU. In transgenic models of AD, the response of these cells is heterogeneous 
and can potentially be protective as well as detrimental. This is further discussed in 
the next chapter. 
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3.4.3. Neurovascular alterations. 
 
Numerous transgenic mouse lines have been generated to recapitulate the main 
neuropathological futures of AD and have been widely used in the field. Although 
the creation of these mouse models is based on the genetic mutations that lead to the 
development of the disease, which constitute less than 5% of the cases, both familial 
and sporadic AD present markedly similar pathology. Since AD constitutes a 
multifactorial disorder, each model displaying particular hallmarks of the disease is 
useful to understand a very specific aspect of the pathology. The transgenic Tg-SwDI 
model, expressing the mutant human APP, mimics several features of the Dutch- and 
Iowa-type familial CAA, and integrates the early onset of Aβ accumulation with high 
association of the protein to the cerebrovasculature. Despite the fact that the Tg-
SwDI model fails to recapitulate other features of AD pathology including NFTs and 
neuronal death, it provides a robust experimental paradigm for the in vivo study of 
different aspects related to Aβ deposition, in particular to CAA. 
 
Furthermore, this mouse line is particularly interesting in the study of AD as notably, 
CAA is present in almost all cases of the disease. Several studies have demonstrated 
that vascular Aβ deposition induces structural alterations to the blood vessels such as 
loss of smooth muscle cells, detachment of the tunica media and fibrinoid necrosis 
(Maeda et al., 1993; Zekry et al., 2003; Auriel and Greenberg, 2012), leading to 
functional deterioration of the cerebrovascular system. A study conducted in young 
Tg-SwDI mice (3-4 months) revealed that these animals present impaired functional 
hyperaemia and endothelium-dependent responses, assessed by laser-Doppler 
flowmetry, even before displaying substantial vascular amyloid accumulation (Park 
et al., 2013). A more recent study published by the same group, looking at the 
functional correlates of vascular damage induced by CAA in the same model, 
demonstrated that the neurovascular dysfunction in these mice is age-dependant and 
occurs in parallel to the structural alteration of the cerebrovasculature. These 
alterations included fragmentation of smooth muscle cells and disrupted pericyte 
morphology. Thus, although it wasn’t a focus of the present study, it would be 
expected, given the increasing load of vascular amyloid, that there would be both 
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structural and functional alterations to the vasculature in these mice. Importantly, 
early but not late treatment with the reactive oxygen species (ROS) scavenger 
Mn(III)tetrakis(4-benzoic acid)porphyrin Chloride, resulted in the complete rescue of 
the cerebrovascular dysfunction, implicating oxidative stress in the mechanisms of 
CAA-induced neurovascular dysfunction in these animals (Park et al., 2014). 
 
3.4.4. Summary and conclusions. 
 
In summary, the current study has shown the temporal APP expression, accumulation 
of parenchymal and cerebrovascular Aβ and Aβ-related microglial and astrocytic 
activation that the Tg-SwDI mice exhibit. Although this mouse line do not reproduce 
the full spectrum of human AD pathology, including neuronal loss and tau tangles, 
both being important hallmarks of the disease, the pathology that this mice present 
shares evident resemblances with the pathology of human AD brains. The most 
important similarities between the model and the human AD pathology include the 
presence of amyloid aggregates and the inflammation triggered by Aβ accumulation 
(McGeer et al,. 1989). Notably, CAA is one of the features of human AD brains 
(Attems, 2005) and as shown in the present study, the Tg-SwDI mice display early 
and robust accumulation of the protein in the vessel wall. 
 
This model represents a useful tool for the next studies within this thesis, which were 
aimed at investigating the effects of chronic cerebral hypoperfusion on Aβ deposition 
in the parenchyma and the cerebrovasculature and subsequently, its contribution to 
the appearance of structural changes in the NVU and to the development of MIs and 
haemorrhages. The data presented in the current chapter were useful in providing a 
basis to design the following studies since by assessing Aβ deposition in the 
parenchyma and the cerebrovasculature at different (early and late) time points, 
insights into the temporal and regional accumulation of the protein, as well as the 
Aβ-related pathology, in the Tg-SwDI mice were gained. This allowed us to induce 
the chronic cerebral hypoperfusion before substantial amyloid accumulation was 
observed, and therefore we were able to examine whether the reduced CBF may 

















Chapter 4. The Effect of mild chronic cerebral 
hypoperfusion on Aβ accumulation and its 













Misfolding, aggregation and accumulation of Aβ in brain parenchyma and blood 
vessel walls are major hallmarks of AD brains and constitute critical stages for the 
pathogenesis of the disease. Importantly, several studies have shown that cerebral 
hypoperfusion can modulate Aβ metabolism, but this is ill-defined with reports 
showing that hypoperfusion can both increase (Kitaguchi et al., 2009; Okamoto et 
al., 2012; ElAli et al., 2013) and suppress (Yamada et al., 2011) Aβ deposition. 
Although the mechanistic basis by which hypoperfusion alters Aβ metabolism has 
not yet been established, there is evidence that a severe reduction of CBF may induce 
increased APP expression and processing leading to enhanced generation of Aβ 
(Kalaria et al., 1993; Bennett et al., 2000; Shi et al., 2000; van Groen et al., 2005; 
Zhiyou et al., 2009). On the other hand, it has been suggested that cerebrovascular 
alterations leading to brain hypoperfusion can induce defective vascular Aβ 
clearance. Such alterations impair the efficient perivascular lymphatic drainage, 
triggering Aβ accumulation in the vessel walls with further blockage of the drainage 
pathways, leading to accumulation of the protein in the brain (Weller et al., 1998; 
Weller et al., 2008; Sagare et al., 2013). Thus, the pathways by which cerebral 
hypoperfusion is implicated in the pathogenesis of AD may be directly associated to 
the induction of accelerated accumulation of amyloid. However, the mechanistic 
basis by which this occurs remains unclear.  
 
Cerebral microinfarction is a common histopathological finding in post-mortem 
studies of AD patients (Brundel et al., 2012; van Rooden et al., 2014) and has often 
been linked to CAA. However, the analysis of the association between CAA and the 
development of MIs remains inconclusive, with data showing positive (Olichney et 
al., 1995; Haglund et al., 2006; Okamoto et al., 2009; Soontornniyomkij et al., 2010) 
weak (van Rooden et al., 2014) and no correlation (Launer et al., 2008; Kövari et al., 
2013) between these parameters, suggesting that vascular amyloid might play a role, 
but cannot be considered as the only contributor factor for the development of these 
lesions. Interestingly, microinfarction has been shown to occur in areas of brain 
hypoperfusion in AD patients and this has also been demonstrated in mouse models 
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of cerebral hypoperfusion (Suter et al., 2002; Shibata et al., 2004; Okamoto et al., 
2012). Additionally, evidence has shown that vascular accumulation of Aβ 
constitutes the main cause of cerebral haemorrhage in the elderly (McCarron et al., 
2000; Rosand et al., 2000; Charidimou et al., 2012) and there is a positive correlation 
between the severity of CAA and the presence of haemorrhages (Vonsattel et al., 
1991).  
 
Furthermore, dysfunction of the NVU occurs during normal ageing and has been 
proposed to contribute to the neurodegenerative process in AD (Iadecola, 2004; 
Zlokovic, 2011). Interestingly, cerebral hypoperfusion, which is also a future of the 
normal ageing brain, is associated with the altered activity of ion pumps at the BBB 
(Zlokovic, 2008). This altered activity at the BBB due to reduced blood flow may 
promote the accumulation of toxins in the brain (ElAli and Hermann, 2011) leading 
to a metabolically altered microenvironment that contribute to neurovascular 
dysfunction. This evidence supports some aspects of the vascular hypothesis of AD 
which states that, during ageing, VRFs alter the NVU leading to chronic cerebral 
hypoperfusion and BBB dysfunction contributing to cognitive decline (de la Torre 
and Mussivand, 1993). In addition, there is increasing experimental evidence 
showing alterations in specific structures of the NVU including astrocytes (Wilcock 
et al., 2009; Moftakhar et al., 2010; Merlini et al., 2011; Yang et al., 2011; Fukuda 
and Badaut, 2012) and TJs (Marco and Skaper, 2006; Hartz et al, 2012) triggered by 
the accumulation of Aβ. 
 
Taken together, this evidence suggests that the mechanism by which VRFs can 
contribute to the development of AD may be through the alteration of the 
neurovasculature, in parallel with the induction of Aβ accumulation which may 
exacerbate those alterations and perpetuate neurovascular dysfunction. Nevertheless, 







4.1.1. Hypothesis and aim of study. 
 
It was hypothesised that chronic cerebral hypoperfusion leads to the accumulation of 
parenchymal and vascular Aβ, triggering the development of MIs and haemorrhages 
and altering the NVU integrity.  
 
The specific aims of this study were as follows: 
 
1. To determine parenchymal and cerebrovascular Aβ levels in response to 
hypoperfusion, at two different time points post-surgery (1 and 3 months). A detailed 
examination of the isoforms and species of Aβ and type of blood vessel associated to 
its accumulation was carried out. If increased Aβ levels were to be found, a further 
aim was to determine the mechanism by which this happens. Therefore, the effect of 
hypoperfusion on APP and receptors involved in Aβ clearance (LRP and Scara1) 
were studied. 
 
2. To investigate the effects of hypoperfusion and Aβ pathology on the development 
of MIs and haemorrhages, and the potential alteration of astrocyte and tight junction 
integrity. Furthermore, potential links between hypoperfusion, Aβ and NOX2 with 

















4.2.1. Animals and surgery. 
 
Male, 3 months old Tg-SwDI and wild-type (C57Bl/6J) mice were used. One cohort 
was used for biochemical studies and a second cohort was used for 
immunohistochemical studies.  
 
Animals underwent bilateral common carotid artery stenosis or sham surgery as 
previously described in section 2.2. Mice were sacrificed 1 or 3 months after the 
surgery. Group sizes are listed in Table 2.1. 
 
4.2.2. Perfusion and tissue processing. 
 
Animals used for immunohistochemical studies were saline perfused followed by 
perfusion fixation as described in section 2.4.2. The left hemi-brain was processed 
for vibratome cutting and sagittal sections were produced as described in section 
2.5.1. The right hemi-brain was processed for paraffin embedding and sagittal 
sections were produced as described in section 2.5.2.  
 
Animals used for biochemical studies were saline perfused as described in section 
2.4.1. The left hemi-brain was used to generate parenchymal and vessel enriched 
fractions as described in section 2.9. The right hemi-brain was used to prepare total 
brain homogenates. Protein extraction and quantification were performed as 




Immunohistochemistry was carried out as described in section 2.6. Tissue sections at 
anatomical level corresponding to 1.92 mm from midline (Franklin and Paxinos, 
1997) were used. Aβ, collagen IV, SMA and AQP4 immunostainings were 
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conducted using fluorescent labelling. Iba1 immunostaining was performed using 
immunoperoxidase labelling.  
 
4.2.4. Histological detection of MIs and haemorrhages. 
 
The detection of MIs was done by using H&E staining, which was performed as 
previously described in section 2.7.1. Haemorrhages were identified using Prussian 
blue staining as described in section 2.7.2. Tissue sections at anatomical level 
corresponding to 1.92 and 1.56 mm from midline (Franklin and Paxinos, 1997) were 
used. 
 
4.2.5. Image analysis. 
 
For the analyses of Aβ/collagen 4, SMA/collagen 4 and AQP4/collagen 4 
immunostainings, four images of the thalamus per brain were acquired as described 
in section 2.8 with a 40x objective at a 1024 x 1024 pixel resolution. Parenchymal 
Aβ was determined by subtracting the percentage of stained area occupied by the 
colocalised pixels to the percentage of stained area of the green channel (Aβ). 
Colocalisation analysis between blood vessels and Aβ was done by calculating the 
Manders coefficient. To classify blood vessels into small or large, the width of the 
vessels containing or not SMA was measured using ImageJ. To determine the 
proportion of Aβ containing vessels, colocalisation analysis between vessels and Aβ 
was performed and the proportion of Aβ containing (small or large) vessels was 
quantified; each vessel branch was considered as a single vessel. Colocalisation 
analysis between blood vessels and AQP4 was performed by calculating the ratio 
between the area occupied by colocalising pixels and percentage of collagen IV (red 
channel) stained area. 
 
For the study of MIs, two sections per brain were analysed and one image of the 
thalamus per section was acquired as described in section 2.8, at 10x magnification. 
MIs were defined as sharply delimited areas of tissue pallor that were accompanied 
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by microglial proliferation identified by Iba1 immunostaining in adjacent sections. 
The area covered by infarcted tissue was measured. 
 
For the study of haemorrhages, two sections per brain were scanned. Haemorrhages 
were identified by the presence of ferric iron deposits on Perls stained sections. The 
presence or absence of haemorrhages in each mouse was recorded. 
 
4.2.6. Enzyme-linked immunosorbent assay. 
 
Levels of both Aβ40 and Aβ42 (Invitrogen) were determined in the soluble and 
insoluble protein fractions extracted from the parenchymal and the vessel enriched 
fractions. NOX2 (Cusabio), Scara1 (Cusabio) and AQP4 (Invitrogen) levels were 
assessed in total proteins extracted from brain homogenates. In all experiments, 
manufacturer’s instructions were used to perform the assays. 
 
4.2.7. Western blot. 
 
Western blotting was performed as described in section 2.12. Total proteins extracted 
from brain homogenates were used to detect APP, APP-CTF’s and GFAP. Protein 
extracts from vessel enriched fractions were used to detect LRP and claudin-5. 
 
4.2.8. Statistical analysis. 
 
The samples obtained from the two different time-points analysed (1 and 3 monhs) 
were used in independent assays, therefore the results obtained from the two different 
groups were statistically analysed independently. 
 
Results from parenchymal and vascular Aβ measurements (Imaging and ELISA), 
APP, CTFs and LRP western blot assays and scara1 ELISA measurement, were 




For NOX2 and AQP4 ELISA measurements, GFAP and claudin-5 western blot 
assays, AQP4/collagen 4 colocalisation analysis and MIs study, statistical 
comparison was carried out using two-way ANOVA (with age and genotype as 
factors), followed by the Bonferroni post-test. For the association analyses, the 
































4.3.1. Soluble Aβ levels are increased in response to cerebral hypoperfusion and 
precede fibrillar Aβ accumulation in the parenchyma. 
 
In order to determine whether chronic cerebral hypoperfusion can increase Aβ 
accumulation in the parenchyma of Tg-SwDI mice, confocal microscopy was used to 
quantify Aβ deposition. However, no significant changes were observed between 
sham and hypoperfused groups following either 1 or 3 months (Figure 4.1). To 
further investigate whether chronic hypoperfusion may have an effect on the 
different pools of Aβ within the parenchyma, the levels of soluble and insoluble Aβ 
were quantified by ELISA. After 1 month of hypoperfusion, significantly increased 
levels of both Aβ40 and Aβ42 were found in the soluble protein fraction, when 
compared to the sham control. In contrast, the insoluble protein fraction remained 
unchanged. After 3 months of hypoperfusion, there were no significant changes 
between the sham and hypoperfused groups in the soluble fraction, however 
increased concentration of both Aβ40 and Aβ42 was observed in the insoluble 
fraction (Figure 4.2). 
 
Although no changes were found by using the immunochemical approach, the 
ELISA constitutes a more sensitive detection method that allows the quantification of 
very low amounts of amyloid and therefore permitted the detection of the differences 
between the groups. These data suggest that hypoperfusion can modify Aβ 
metabolism, triggering an early increase of the protein followed by aggregation into 
insoluble fibrils in the parenchyma. 
 
4.3.2. Delayed accumulation of vascular Aβ in response to cerebral 
hypoperfusion. 
 
As shown in the previous chapter of the present thesis, Tg-SwDI mice exhibited 
minimal vascular accumulation of Aβ at 3 months of age. To examine whether 









Figure 4.1. Parenchymal Aβ deposition following chronic cerebral 
hypoperfusion in Tg-SwDI mice. Double immunostaining was performed using 
markers of collagen (red) and Aβ (green). Parenchymal Aβ was determined using 
ImageJ, by subtracting the percentage of stained area occupied by the colocalised 
pixels (white area) to the percentage of stained area of the green channel. The result 
is represented in the graphs. The data presented are the means ± S.E.M. (unpaired t-
test p > 0.05, 1 months n=19, 3 months n=18). Representative images from sham and 










Figure 4.2. Chronic cerebral hypoperfusion induces early increase in soluble Aβ 
levels followed by fibrillar Aβ accumulation in the parenchyma of the 
transgenic mouse model Tg-SwDI. Tg-SwDI animals were sacrificed after 1 (a) 
and 3 (b) months of chronic cerebral hypoperfusion. Following sequential protein 
extraction, the levels of soluble and insoluble Aβ40/42 were quantified in the 
parenchymal fraction by ELISA. Graphs represent the levels of the protein 
normalised to total protein concentration. The data presented are the means ± S.E.M., 
*p < 0.05 (unpaired t-test, 1 months n=19, 3 months n=12). 
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cerebrovasculature of these mice, confocal microscopy was used to quantify Aβ 
colocalisation with the vasculature. After 1 month of hypoperfusion there were no 
changes in the levels of Aβ colocalised to vessels between sham and hypoperfused 
mice in the thalamus (Figure 4.3, a). Conversely, following 3 months of 
hypoperfusion, the levels of Aβ colocalised to vessels significantly increased in the 
hypoperfused animals, compared to the sham group (Figure 4.3, b-d, see arrows).  
 
To further examine the pools of Aβ, ELISA measurement of protein extracts from 
the vessel enriched fraction was performed to determine quantitatively the levels of 
vascular Aβ40 and Aβ42. In agreement with the imaging analysis, no significant 
changes were observed between hypoperfused and sham animals after 1 month of 
hypoperfusion; however, following 3 months there was a significant increase in the 
levels of both Aβ40 and Aβ42 in the insoluble fraction of the hypoperfused group 
when compared to the sham animals (Figure 4.4).  
 
Collectively, these results indicate that hypoperfusion promotes the build-up of 
fibrillar Aβ in the cerebrovasculature, process that is preceded by accumulation of 
the protein in the parenchyma.  
 
4.3.3. Vascular Aβ deposition induced by chronic cerebral hypoperfusion occurs 
in small blood vessels. 
 
To further explore whether the increased levels of vascular Aβ observed after 3 
months of cerebral hypoperfusion were accumulating in small or large blood vessels, 
double immunostaining was used with a marker of collagen IV, to visualise all types 
of blood vessels and a marker of SMA, only present in larger vessels (Figure 4.5, a). 
In order to differentiate between the different types of vessels, image analysis of 
confocal micrographs was performed and vessels were classified into small (<6µm), 
corresponding to capillaries and large (>6µm), corresponding to bigger vessels 
including arterioles and arteries. Subsequently, the proportion of Aβ colocalising 
vessels (Figure 4.5, b) was calculated in each group. As represented in the graphs, 










Figure 4.3. Chronic cerebral hypoperfusion accelerates Aβ/vasculature 
colocalisation in the transgenic mouse model Tg-SwDI. Double immunostaining 
was performed using markers of collagen (red) and Aβ (green). Colocalisation 
analysis of the merged images was made by calculating the Manders coefficient with 
ImageJ, represented in the graphs. The data presented are the means ± S.E.M., *p < 
0.05 (unpaired t-test, 1 months n=19, 3 months n=18). Representative images from 
sham and 3 months hypoperfused mice, indicating Aβ/vasculature colocalisation are 










Figure 4.4. Chronic cerebral hypoperfusion accelerates vascular Aβ 
accumulation in the transgenic mouse model Tg-SwDI. Tg-SwDI animals were 
sacrificed after 1 (a) and 3 (b) months of chronic cerebral hypoperfusion. Blood 
vessel enriched fractions were generated, followed by sequential protein extraction. 
Subsequently, Aβ40/42 levels were quantified by ELISA. Graphs represent the levels 
of the protein normalised to total protein concentration. The data presented are the 












Figure 4.5. Vascular Aβ deposition induced by chronic cerebral hypoperfusion 
occurs in small blood vessels of Tg-SwDI mice. Double immunostaining was 
performed using markers collagen (red) and SMA (green) (a); subsequently, 
colocalisation analysis of the merged images was made with ImageJ (b). Graphs 
represent the proportion of Aβ containing vessels (c, d). The data presented are the 








small vessels of the hypoperfused animals compared to sham mice (Figure 4.5, c) 
and not in the large vessels (Figure 4.5, d), suggesting that hypoperfusion triggered 
Aβ accumulation predominantly in the capillaries. 
 
4.3.4. Chronic cerebral hypoperfusion increases APP levels and processing. 
 
Based on the previous findings showing that cerebral hypoperfusion increased Aβ 
levels, a process that started in the parenchyma, followed by accumulation in the 
vasculature, it was next determined whether this process was mediated by increased 
APP production or processing. To this end, western blot analysis of brain protein 
extracts was performed using specific antibodies that recognise APP and its carboxyl 
terminal fragments (CTFs), produced after proteolytic cleavage by the specific 
enzymes BACE1 that generates the CTFβ, and α-secretase that results in the 
formation of the CTFα (Figure 4.6). Interestingly, the immunoblotting analysis 
revealed a significant increase in the levels of APP, CTFβ and CTFα in the 
hypoperfused animals following 1 month, when compared to the sham group (Figure 
4.6, a, c-e). However, after 3 months of hypoperfusion no difference was observed 
between the two groups (Figure 4.6, b, f-h), suggesting that the increased Aβ levels 
observed, might be the result of enhanced APP synthesis and processing, triggered at 
early stages during chronic cerebral hypoperfusion. 
 
4.3.5. LRP and scara1 levels are not affected by chronic cerebral hypoperfusion. 
 
To further assess whether, along with the increased production and processing of 
APP, altered clearance of Aβ could have contributed to the accumulation of the 
protein induced by hypoperfusion at 3 months, the levels of LRP-1 and levels of 
scara1 were determined.  
 
Immunoblots showed there were no significant changes in the levels of LRP 












Figure 4.6. Chronic cerebral hypoperfusion increases APP levels and processing 
in the transgenic mouse model Tg-SwDI. Western blot analysis of brain protein 
extracts after 1 (a, c-e) and 3 (b, f-h) months of hypoperfusion was performed to 
determine the expression levels of APP, CTFβ and CTFα. Specific bands were 
quantified by densitometric analysis and expressed relative to total tubulin protein, 
represented in the graphs. The data presented are the means ± S.E.M., *p < 0.05 









4.7). Similarly, ELISA quantitation of scara1 indicated that hypoperfusion did not 
alter the levels of the receptor (Figure 4.8).  
 
These data suggests that the hypoperfusion-induced increase in Aβ levels observed in 
the Tg-SwDI mice was not mediated either by changes in vascular clearance through 
LRP or by altered macrophage clearance through scara1. 
 
4.3.6. MIs, associated with microglial proliferation, are precipitated by chronic 
cerebral hypoperfusion. 
 
The effect of both Aβ and chronic cerebral hypoperfusion, on the development of 
MIs, was examined by studying cerebral hypoperfusion in wild-type and Tg-SwDI 
mice following 1 and 3 months and comparing to sham mice (Figure 4.9). 
Histological examination of tissue sections using H&E staining was performed and 
the area covered by MIs was quantified.  
 
Representative images showing normal (Figure 4.9, a) and infarcted (Figure 4.9, b) 
tissue are shown. Adjacent sections to those used for MI analysis were 
immunostained using Iba1 to investigate further evidence of microglial infiltration 
within the infarcted area. Microglial proliferation in the lesion area was evident in 
the hypoperfused tissue (Figure 4.9, d) compared to the control (Figure 4.9, c). There 
was no evidence of MIs in sham wild-type mice but small areas of infarcted tissue 
were observed in sham Tg-SwDI animals (Figure 4.9, e,f). However, after 
hypoperfusion there was an increase in MIs and this was exacerbated in Tg-SwDI 
mice. Following 1 month, no MIs were observed in the wild-type group; however, 
there was a significant increase in the infarcted area in Tg-SwDI hypoperfused 
(0.021 mm2 ± 0.007) compared to sham (0.0079 mm2 ± 0.004) mice. After 3 months, 
a small infarcted area was found in the wild-type hypoperfused animals (0.0026 mm2 
± 0.02), however it did not reach significance when compared to the sham controls. 












Figure 4.7. LRP levels are not affected by chronic cerebral hypoperfusion in the 
transgenic mouse model Tg-SwDI. Western blot analysis of proteins extracts from 
vessels enriched fractions after 1 (a, c) or 3 (b, d) months of hypoperfusion was 
performed to determine the expression levels of LRP in Tg-SwDI mice; specific 
bands were quantified by densitometric analysis and expressed relative to total 
tubulin protein, represented in the graphs. The data presented are the means ± S.E.M. 





























Figure 4.8. Scara1 levels are not affected by chronic cerebral hypoperfusion in 
the transgenic mouse model Tg-SwDI. Scara1 levels were quantified in protein 
extracts from brain homogenates using ELISA after 1 (a) and 3 (b) months of 
hypoperfusion; graphs represent the levels of the protein normalised to total protein 
concentration. The data presented are the means ± S.E.M. (unpaired t-test, p > 0.05, 1 



























Figure 4.9. Aβ promotes the development of MIs, which is exacerbated by 
chronic cerebral hypoperfusion and associated with microglial proliferation. 
Representative images showing normal (a) and infarcted (b) tissue using H&E 
staining; insets show a higher magnification of the image. Iba1 staining was used to 
visualise microglial proliferation (c, d) (scale bar = 100 µm). Histopathological 
analysis was performed using H&E staining in tissue sections from Tg-SwDI and 
wild-type animals following 1 (e) and 3 (f) months of hypoperfusion; the area 
covered by infarcted tissue was measured and is represented in the graphs. The data 
presented are the means ± S.E.M., two-way ANOVA: significant effect of genotype 
(F(1,38) = 14.52, ***p = 0.0005), Bonferroni post-test (*p < 0.05) (e); significant 
interaction (F(1,34) = 5.446, *p = 0.0257), significant effect of surgery (F(1,34) = 10.14, 
**p = 0.0031), significant effect of genotype (F(1,34) = 21.82, ***p < 0.0001), 
Bonferroni post-test (**p < 0.05) (f). Scatter plot shows a positive correlation 


























infarcted area in the Tg-SwDI hypoperfused (0.024 mm2 ± 0.005) compared to sham 
(0.0073 mm2 ± 0.003) mice. There was a positive correlation between the MI area 
and the microglia burden (Figure 4.9, g).  
 
Together, these data indicate that MIs are present in Tg-SwDI mice and that the 
burden is exacerbated with chronic cerebral hypoperfusion. 
 
Histopathological analysis revealed that there were no haemorrhages following 1 
month of hypoperfusion. After 3 months of hypoperfusion, haemorrhages were 
detected in only one wild-type mouse, and in 3 Tg-SwDI mice (Figure 4.10). Thus, 
chronic hypoperfusion and presence of amyloid at these time-points had minimal 
effects on the development of haemorrhages.  
 
4.3.7. Chronic cerebral hypoperfusion increases NOX2 levels in the transgenic 
mouse model Tg-SwDI. 
 
In order to examine the effect of both Aβ and chronic cerebral hypoperfusion on the 
development of oxidative stress, ELISA measurement of brain protein extracts was 
assayed to determine the levels of NOX2 in wild-type and Tg-SwDI mice following 
hypoperfusion (Figure 4.11). Significantly higher levels of the protein were found in 
the transgenic mice compared to the wild-type controls at both time-points analysed, 
and this was exacerbated after 1 month of hypoperfusion in the Tg-SwDI mice.  
 
Conversely, following 3 months, there were no significant changes between sham 
and hypoperfused animals. Interestingly, increased levels of NOX2 positively 
correlated with the levels of soluble parenchymal Aβ, and no correlation between 
NOX2 and vascular Aβ was found (Figure 4.11, c, d). 
 
These data suggest that soluble amyloid may induce an oxidative response which is 














Figure 4.10. Proportion of mice with haemorrhages following chronic cerebral 
hypoperfusion. Histopathological analysis was performed using Perls staining in 
tissue sections from Tg-SwDI and wild-type animals following 1 and 3 months of 
hypoperfusion. Representative images showing normal (a) and haemorrhagic (b) 
tissue are shown (scale bar = 100 um). The number of mice with haemorrhages was 





















Figure 4.11. Aβ increases NOX2 levels, which is exacerbated by chronic cerebral 
hypoperfusion. NOX2 levels were quantified in protein extracts from brain 
homogenates using ELISA after 1 (a) and 3 (b) months of hypoperfusion. Graphs 
represent the levels of the protein normalised to total protein concentration. The data 
presented are the means ± S.E.M., two-way ANOVA: significant effect of surgery 
(F(1,29) = 4.288, *p = 0.0474), significant effect of genotype (F(1,29) = 16.79, ***p = 
0.0003), Bonferroni post-test (*p < 0.05) (a); significant effect of genotype (F(1,23) = 
4.719, *p = 0.0404) (b). Pearson correlation: Scatter plots show a positive correlation 
between NOX2 levels and soluble parenchymal Aβ40 levels, r = 0.6643, p = 0.0019 
(c) and no correlation between NOX2 levels and vascular Aβ40 levels, r = 0.0853, p 








4.3.8. Effect of both chronic cerebral hypoperfusion and Aβ on astrocyte 
integrity. 
 
The effect of both brain hypoperfusion and amyloid on astrocyte activation was 
examined after chronic cerebral hypoperfusion in wild-type and Tg-SwDI mice 
following 1 and 3 months and compared to sham mice (Figure 4.12). Western blot 
was used to assess the total levels of reactive gliosis by quantifying GFAP levels. 
Significantly higher levels of GFAP were found in the Tg-SwDI mice compared to 
the wild-type controls. Although the levels of the protein were slightly increased in 
the transgenic hypoperfused mice and in the wild-type group after 3 months of 
hypoperfusion, this was not significantly different from the sham controls.   
 
To further investigate the effects of Aβ and hypoperfusion on astrocytes, the next 
studies focussed on AQP4, an astrocyte end-foot marker. The measurement of total 
levels of AQP4 in brain protein extracts was performed using an ELISA (Figure 
4.13). There were significantly higher levels of AQP4 in the Tg-SwDI mice 
compared to the wild-type controls following 1 month of hypoperfusion (Figure 4.13, 
a). In contrast, after 3 months, no significant changes where found between the 
groups (Figure 4.13, b). 
 
Interestingly, association analyses showed a positive correlation between AQP4 
levels and the levels of soluble parenchymal Aβ. However there was no correlation 
between AQP4 and vascular Aβ levels (Figure 4.13, c, d). Furthermore, a highly 
significant positive correlation between AQP4 and NOX2 levels was found (Figure 
4.13, e). 
 
Subsequently, in order to determine vascular AQP4 coverage, confocal microscopy 
was used to quantify AQP4 colocalisation with the vasculature (Figure 4.14) As 
expected, AQP4 immunostaining (Figure 4.14, b) was predominantly localised at the 
cerebrovasculature, yet image analysis revealed that neither amyloid nor 
hypoperfusion affected the vascular AQP4 coverage at both time points analysed 











Figure 4.12. Increased astrocyte activation in the Tg-SwDI mouse model. 
Western blot analysis of protein extracts from brain homogenates after 1 (a) and 3 (b) 
months of hypoperfusion was performed to determine the expression levels of 
GFAP, represented in the graphs; GAPDH was used as loading control. The data 
presented are the means ± S.E.M., two-way ANOVA: 1 month: significant effect of 
genotype (F(1,29) = 4.786, *p = 0.0369); 3 months: significant effect of genotype 


















Figure 4.13. Hypoperfusion increases AQP4 levels, which correlates with levels 
of Aβ and NOX2. AQP4 levels were quantified in brain protein extracts using 
ELISA after 1 (a) and 3 (b) months of hypoperfusion. Graphs represent the levels of 
the protein normalised to total protein concentration, the data presented are the 
means ± S.E.M., two-way ANOVA: significant effect of genotype (F(1,29) = 7.976, *p 
= 0.0101), significant effect of surgery (F(1,29) = 5.605, *p = 0.0248), significant 
interaction (F(1,29) = 7.584, **p = 0.0085), Bonferroni post-test (***p < 0.001). 
Pearson correlation: Scatter plots show a positive correlation between soluble 
parenchymal Aβ40 and AQP4 levels (**p = 0.0095, r = 0.4735) (c) no correlation 
between vascular Aβ40 and AQP4 levels (p = 0.7866, r = -0.05255) (d) and positive 

















Figure 4.14. AQP4/vasculature colocalisation. Double immunostaining was 
performed using markers of collagen (a) and AQP4 (b), colocalising pixels of the 
merged images are shown in white (c) (scale bar= 50 µm). The proportion of vessels 
covered by AQP4 after 1 (d) and 3 (e) months of hypoperfusion is represented in the 
graphs. The data presented are the means ± S.E.M. two-way ANOVA, p > 0.05 (1 









4.3.9. Effect of both chronic cerebral hypoperfusion and Aβ on tight junction 
levels. 
 
The levels of claudin-5, one of the main proteins comprising the TJs, were 
investigated in response to chronic cerebral hypoperfusion and the potential 
contribution of Aβ to this change was determined by studying Tg-SwDI and wild-
type hypoperfused mice and compared to sham animals. Western blot analysis of 
protein extracts from vessel enriched fractions was performed to quantify the levels 
of the protein.  
 
As shown in Figure 4.15, claudin-5 levels were significantly higher in the Tg-SwDI 
mice compared to the wild-type controls at the 2 time-points analysed, and this was 
exacerbated following 1 month of hypoperfusion in the transgenic model. In contrast, 
no significant changes between sham and hypoperfused animals were found after 3 
months. Notably, association analyses showed positive correlation between claudin-5 
and vascular Aβ levels, and no correlation between claudin-5 and soluble 




























Figure 4.15. Increased claudin-5 levels in Tg-SwDI mice are exacerbated by 
hypoperfusion. Western blot analysis of protein extracts from vessel enriched 
fractions after 1 (a) and 3 (b) months of hypoperfusion was performed to determine 
the expression levels of claudin-5. Specific bands were quantified by densitometric 
analysis and expressed relative to total tubulin protein, represented in the graphs. The 
data presented are the means ± S.E.M., two-way ANOVA: significant effect of 
genotype (F(1,29) = 33.47, ***p < 0.0001), Bonferroni post-test (*p < 0.05) (c); 
significant effect of genotype (F(1,23) = 56.33, ***p < 0.0001) (d). Pearson 
correlation: Scatter plots show a positive correlation between claudin-5 and vascular 
Aβ40 levels (r = 0.6113, ***p = 0.0004) (e) and no correlation between claudin-5 





The present study sought to test the hypothesis that chronic cerebral hypoperfusion 
leads to the accumulation of parenchymal and vascular Aβ, triggering the 
development of MIs and haemorrhages and altering the NVU integrity. The results 
support the hypothesis and demonstrate that chronic cerebral hypoperfusion results in 
a significant increase in APP levels and processing, leading to accelerated Aβ40/42 
production and deposition in the parenchyma followed by aggregation in the 
cerebrovasculature. Notably, vascular Aβ deposition occurred predominantly in the 
microvasculature. Subsequent assessment of the neurovascular integrity revealed that 
amyloid load promotes the development of MIs and interestingly, specific pools of 
Aβ were associated with the alteration of different structures of the NVU. These 
alterations were exacerbated by hypoperfusion and associated with oxidative stress. 
 
4.4.1. Parenchymal and vascular Aβ accumulation in response to hypoperfusion. 
 
In the present study, it was demonstrated that hypoperfusion modified Aβ 
metabolism in the Tg-SwDI mice, triggering an early increase in the levels of soluble 
Aβ in the parenchyma followed by aggregation of the protein into insoluble fibrils 
and subsequently the build-up of aggregates in the cerebrovasculature. Aβ 
aggregation follows a seeding-nucleation mechanism, where the limiting step is the 
formation of small oligomeric intermediates that act as seeds to catalyse the 
polymerisation process. Thus, the increased levels of insoluble Aβ observed in the 
parenchyma after 3 months of hypoperfusion, were likely the result of the 
polymerisation of soluble Aβ, which started to increase following 1 month of 
hypoperfusion. We hypothesise that the amount of Aβ being produced in the brain of 
these mice was too high to be effectively eliminated by the clearance system at the 
BBB, therefore Aβ also started to accumulate in the vessel walls, at the clearance 
site. Indeed, previous studies in the Tg-SwDI model revealed that Dutch/Iowa mutant 
Aβ is poorly cleared from the brain into the circulation contributing to its 
accumulation (Davis et al., 2004). The results presented in this study demonstrate 
that hypoperfusion potentiated this process. Thereafter, every new Aβ molecule 
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synthesised was rapidly added to the growing fibrils at the parenchyma and 
vasculature.  
 
It has been shown that vascular smooth cells express APP and vessels isolated from 
the brain are able to produce Aβ (Kalaria et al., 1996; Burgermeister et al., 2000), 
and thus it has been suggested that vascular amyloid originates in the cerebral 
vasculature. CAA is present in brain capillaries, which lack smooth muscle cells, 
therefore the single contribution of this type of cell to the amyloid build-up, is 
unlikely. However, it has been demonstrated that Aβ can also be produced by 
endothelial cells (Kitazume et al., 2010). In contrast, compelling evidence points 
towards a mechanism in which vascular amyloid is originated in the parenchyma, 
from neuronal production and drained along the perivascular lymphatic fluid where, 
under pathologic conditions, starts to accumulate in the vessel walls (Weller et al., 
1998; Burgermeister et al., 2000; Van Dorpe et al., 2000; Herzig et al., 2004; Jucker, 
2006; Weller et al., 2008; Vidal et al., 2009). These data support our previous 
assumption that following hypoperfusion, a combination of enhanced Aβ production 
along with altered clearance of the protein across the BBB in the Tg-SwDI model 
might have contributed to its accumulation in the vasculature. Furthermore, our 
results support previous studies showing that CAA is preceded by higher levels of 
soluble amyloid suggesting that soluble Aβ is a marker of potential CAA (Suzuki et 
al., 1994b; Shinkai et al., 1995). 
 
Interestingly, in the wild-type group a significant increase in levels of parenchymal 
Aβ42 was found in the hypoperfused mice compared to the sham controls after 1 
month (Figure A1), however no vascular accumulation of the protein was detected 
(data not shown). Unlike the Tg-SwDI mice, in which both murine and the mutant 
human APP proteins are expressed, wild-type mice only express murine APP. 
Therefore, considering the substantially lower levels of the protein being produced 
and the fact that rodent Aβ is not amyloidogenic in vivo (Selkoe, 1989; Hilbich et al., 
1991; Otvos et al., 1993), it is likely that the protein was eventually effectively 
cleared instead of being accumulated and aggregated into insoluble fibrils as it 
happened in the Tg-SwDI mice. This could explain why the protein was not 
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detectable in those samples, which was not surprising as vascular Aβ corresponds 
mainly to fibrillar amyloid.  
 
4.4.2. Aβ accumulation in microvessels. 
 
Vascular accumulation of Aβ is present in the majority of AD patients and 
constitutes a risk factor for dementia (MRC-CFAS, 2001; Greenberg et al., 2002; 
Pfeifer et al., 2002a; Weller and Nicoll, 2003; Greenberg et al., 2004). In humans, 
different patterns of vascular amyloid have been described, which define different 
histopathological phenotypes in AD (Allen et al., 2014).  
 
Interestingly, the results presented in this study demonstrate that following 3 months 
of hypoperfusion, vascular amyloid accumulated predominantly in smaller blood 
vessels, lacking SMA, suggesting that hypoperfusion triggered Aβ accumulation in 
the capillaries. However, it is important to note that the width of the majority (78.2 
%) of the vessels was found to be between 0.6 and 6 µm, which were considered as 
small vessels, and only 21.8 % of vessels had a width over 6 µm. This sampling issue 
might have influenced the results, favouring statistical power due to the larger n in 
the small vessels group.  
 
One of the major clearance mechanisms of Aβ in the brain is vascular transport 
across the BBB, which is mediated primarily by the cell surface receptor LRP1 
(Shibata et al., 2000; Deane et al., 2004). Hence, according to what we suggested 
previously, it is likely that as Aβ levels started to increase in response to the reduced 
CBF, the protein was not successfully cleared through the capillary network at the 
BBB, therefore it started to accumulate in smaller vessels, at the clearance site. Yet it 
is possible that the accumulation of the protein eventually occurs within larger blood 






4.4.3. Potential mechanisms underlying the Aβ increase in response to 
hypoperfusion. 
 
Increased parenchymal Aβ levels might be the result of either overproduction or 
altered clearance of the protein, or the combination of both. In the current study, 
enhanced APP synthesis and processing, triggered at early stages during chronic 
cerebral hypoperfusion, are shown. This suggests that the increased Aβ levels 
observed might be the result of a general increase in APP metabolism, where both 
amyloidogenic and non-amyloidogenic pathways were enhanced. The latter can be 
concluded by the observation of increased levels of both CTF-β and CTF-α 
respectively. It is possible, that the time-dependant increase in basal APP levels that 
this model undergoes, might have masked the effect of hypoperfusion, explaining 
why no changes were observed following 3 months.  
 
Although the physiological function of APP is not completely understood, there is 
well documented evidence of a neuroprotective and synaptogenic role of the full-
length protein as well as the soluble fragments released during its processing 
including Aβ (Caillé et al., 2004; Han et al., 2005; Leyssen et al., 2005; 
Chasseigneaux and Allinquant, 2012). Indeed, there are number of studies showing 
that different types of brain injury including traumatic brain injury (TBI) (Itoh et al., 
2009; Corrigan et al., 2011) and also ischemic injury (Stephenson et al., 1992; 
Bennett et al., 2000; Lee et al., 2006; Zhang et al., 2007; Koike et al., 2010), both 
constituting risk factors for AD (Pluta et al., 2009; Sivanandam and Thakur, 2012) 
induce intra-axonal upregulation of APP or increase its processing. Hence, the 
explanation for the hypoperfusion-induced upregulation of APP and increased 
metabolism of the protein observed can be directly linked to its neuroprotective role. 
However, in the long term, this response may have deleterious consequences due to 
the overproduction of Aβ. In contrast, no changes in APP were found between sham 
and hypoperfused mice in the wild-type group (Figure A2). We suggest that similar 
to changes in the Tg-SwDI group, the increased Aβ levels observed might be a 
neuroprotective response to hypoperfusion. However, as basal APP levels in wild-
type mice are considerably lower, a much more sensitive method would be required 
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to detect this subtle change. Indeed, CTF-β levels were undetectable by western blot 
in those samples probably because the amyloidogenic pathway is less common in 
wild-type mice therefore a more sensitive detection assay would be needed. 
 
To further investigate whether cerebral hypoperfusion may have altered Aβ clearance 
contributing to its accumulation, this study first focused on LRP-1, the main receptor 
involved in the active outward transport of the protein across the BBB. Previous 
studies of the role of this receptor in the pathogenesis of AD have revealed a positive 
correlation between decreased levels of LRP and AD pathology (Kang et al., 1997; 
Jaeger et al., 2009; Cuzzo et al., 2011). Thus, it was hypothesised that the increased 
Aβ levels observed following hypoperfusion might be in part due to altered LRP 
levels; however the results showed no such changes. Notably, the receptor was 
upregulated following 3 months of hypoperfusion in the wild-type mice (Figure A3), 
likely in response to the increased Aβ levels, supporting the previous speculation that 
the protein was effectively cleared in this group. 
 
Another key player involved in Aβ clearance in the brain is microglia, which 
constitutes the first line of immune defence in the CNS and is in continuous 
surveillance for any potential injurious stimuli. In AD brains and in transgenic mouse 
models, as demonstrated in the previous chapter, microglia becomes activated in 
response to Aβ deposition and migrates into sites containing Aβ plaques (Morgan et 
al., 2005; Chung et al., 2011; Zabel et al., 2013; Baron et al., 2014). It is well 
established that cerebral hypoperfusion triggers proliferation and activation of 
microglial cells (Shibata et al., 2004; Farkas et al., 2004); however, the effect of 
hypoperfusion on microglial-dependant Aβ clearance has not been established. 
Microglia can bind amyloid through interaction with different receptors, however 
their role in the progression of AD is yet unknown. Previous research suggest that 
microglial cells expressing the chemokine receptor CCR2 are recruited to sites of 
cerebral amyloidosis, acting at the perivascular compartment to clear Aβ. 
Interestingly, deficiency of CC-chemokine ligand 2 (Ccl2), the main CCR2 ligand, 
induced accelerated β-amyloidosis and cognitive dysfunction in CCL2-deficient 
APP/PS1 mice (Kiyota et al., 2013). Moreover, APP-Ccr2-/- mice showed decreased 
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microglial recruitment and accelerated Aβ deposition, specially associated to the 
vasculature (El Khoury et al., 2007; Mildner et al., 2011). Despite the ability of 
microglia to be attracted by Aβ and clear the aggregates, which might delay the 
progression of AD pathology at early stages, during ageing and as AD progress, 
amyloid pathology continue to develop and the apparent dysfunction that microglia 
undergoe has been focus of interesting research. Importantly, isolated monocytes 
from AD patients show poor macrophage differentiation and Aβ phagocytosis as 
well as higher expression of intracellular cytokines compared to age-matched 
controls (Fiala et al., 2005). Furthermore, there is evidence indicating that microglia 
from old transgenic animals that develop increasing Aβ accumulation with age, 
shows downregulation of the Aβ-binding receptors scara1 and CD36, compared to 
young animals (Hickman et al., 2008). Thus, the phenotype of microglia changes as 
AD pathology develops, showing upregulation of the proinflammatory cytokines 
interleukin-1β (IL-1β) and tumor necrosis factor α (TNF-α) but decreasing their Aβ-
clearing abilities, contributing that way to the development of the disease (Hickman 
et al., 2008). In addition, based on previous studies showing that class A scavenger 
receptors mediate adhesion of microglia to Aβ fibrils (El Khoury et al., 1996), a more 
recent study performed by the same group in PS1-APP mice, has found that scara1 is 
a major microglial receptor for soluble Aβ and that its deficiency triggers reduced Aβ 
uptake and increased mortality in these mouse line (Frenkel et al., 2013). Therefore, 
we asked the question whether hypoperfusion could have altered scara1 levels 
contributing to Aβ accumulation. However, the results indicate that the 
hypoperfusion-induced increase in Aβ levels observed was not mediated by this 
change. Nevertheless, although hypoperfusion had no effects in the expression levels 
of scara1, it might induce functional alterations of the receptor and affect its binding 
to Aβ. Also, the potential alteration of other receptors involved in microglial-
mediated Aβ clearance such as CCR2 and CD36 cannot be ruled out. Further studies 
would be needed to determine this. It would also be interesting to investigate the 





4.4.4. Development of MIs and haemorrhages in response to Aβ and 
hypoperfusion. 
 
Cerebral MIs are frequently observed in AD brains (Brundel, 2012; van Rooden et 
al., 2014) and, as shown by several studies, the load of MIs correlates with impaired 
cognitive performance (Kövari et al., 2007; Troncoso et al., 2008; Arvanitakis et al., 
2011). The results of this study show that the development of MIs associated with 
microglial proliferation, can be precipitated by chronic cerebral hypoperfusion, 
suggesting microinfarction as a linkage between hypoperfusion and the development 
of degenerative processes. Additionally, there is a large in vitro and in vivo body of 
evidence demonstrating Aβ toxicity and its role in the pathoetiology of AD (Canevari 
et al., 1999; Hardy and Selkoe, 2002; Lin et al., 2001, Atwood et al., 2003; Rosales-
Corral et al., 2004; Butterfield et al., 2007; Parameshwaran et al., 2008; Wang et al., 
2013). Interestingly, vascular accumulation of Aβ, which is present in almost all 
cases of AD, has been linked with the development of MIs; however, correlation 
studies have shown inconsistent results (Olichney et al., 1995; Haglund et al., 2006; 
Launer et al., 2008; Okamoto et al., 2009; Soontornniyomkij et al., 2010; Kövari et 
al., 2013; van Rooden et al., 2014).  
 
As demonstrated in the present chapter, chronic cerebral hypoperfusion induced a 
significant increase in parenchymal and cerebrovascular Aβ production and 
deposition. To further examine the link between MIs and Aβ deposition, association 
analyses were performed using the Pearson correlation test, which revealed no 
correlation between MI load and vascular or parenchymal amyloid levels (Figure 
A5). However, the effect of hypoperfusion on the appearance of MIs was 
exacerbated in the Tg-SwDI mice compared to the wild-type group, suggesting an 
underlying influence of amyloid on the development of these lesions. One 
explanation to this result might be attributable to the fact that the association analyses 
were done using the quantification of the immunostaining, which does not 
distinguish between the different pools of Aβ. Therefore, it is possible that rather 
than insoluble aggregates, soluble Aβ oligomers, which constitute the most cytotoxic 
species of Aβ, might be involved on the development of MIs. This could also explain 
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the inconsistencies between the previously published studies mentioned above, 
showing inconsistent MI/amyloid correlation results, where no differentiation was 
made between the different pools of amyloid. Indeed, compelling evidence support 
the oligomer hypothesis, which states that soluble Aβ oligomers are the main 
etiologic agent that participates in the initiation of the neurodegenerative process in 
AD, by triggering a cascade of pathogenic events involving inflammation and 
oxidative injury (Klein et al., 2004; Glabe and Kayed., 2006; Haass and Selkoe, 
2007; Walsh and Selkoe, 2007; Maezawa et al., 2011). Since different cohorts were 
used in the present study to perform the pathology and biochemistry analyses, 
additional studies using the same cohort would be required in order to test the 
specific association between Aβ oligomers and microinfarction.  
 
Notably, although the mechanisms leading to MI formation remain unknown, 
oxidative stress and inflammation, as the result of cerebrovascular alterations, have 
been suggested as possible contributors (Miklossy, 2003; Damasceno, 2012; Chen et 
al., 2011b; Smith et al., 2012; Shih et al., 2013). NOX2 constitutes the main ROS 
source in the brain and it has a critical role in cell death following ischemic insults 
(Brennan-Minnella et al., 2014). For example, mice lacking a functional NOX2 
presented significantly reduced infarct volume following transient cerebral ischemia 
(Walder et al., 1997; Tang et al., 2008; Jackman et al., 2009). Moreover, NOX2 has 
shown to be involved in post-ischemic brain inflammation, which exacerbates the 
progression of brain injury (Chen et al., 2011b). Furthermore, increasing evidence 
demonstrates an association between Aβ-induced neuronal damage and oxidative 
stress, wish has shown to involve microglial activation (Bianca et al., 1999; Coraci et 
al., 2002; Abramov et al., 2004; Qin et al., 2006; Wilkinson and Landreth, 2006; 
Narayan et al., 2014). Notably, Aβ is able to increase the processing of IL-1β into 
mature IL-1β in microglia via ROS (Parajuli et al., 2013). In addition, Tg2576 mice 
lacking NOX2 showed improved cerebrovascular function and behavioral 
performance through reduction of oxidative stress independently of Aβ accumulation 
(Park et al., 2008) suggesting that the neurovascular alterations observed in this 
mouse model are the result of the oxidative stress induced by the accumulation of 
Aβ. Consequently, to further investigate the potential mechanistic basis of the current 
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finding of increased microinfarction following chronic cerebral hypoperfusion, the 
levels of NOX2 were assessed. Higher levels of this protein were found in the Tg-
SwDI mice compared to the wild-type controls, and this was exacerbated by 
hypoperfusion in the transgenic model, suggesting a synergistic effect, where both 
amyloid and hypoperfusion contributed to NOX2 upregulation. Thus, it is possible 
that NOX2-derived radicals may have contributed to the development of MIs. 
Interestingly, soluble parenchymal Aβ, but not vascular Aβ, correlated with 
increased NOX2 levels, supporting the previous speculation of the potential 
participation of oligomeric species in the pathoetiology of MIs.  
 
Cerebral haemorrhages constitute another common finding in AD brains (Nakata et 
al., 2002; Cordonnier et al., 2006) and have been proposed to participate in the 
pathophysiology of the disease (Cordonier and van der Flier, 2011). Hence, the 
possible contribution of hypoperfusion and amyloid to the appearance of 
haemorrhages was also explored in the present study. Although the development of 
this type of lesions was minor, it was possible to observe a higher proportion of 
animals with haemorrhages in the transgenic group exposed to a longer period of 
hypoperfusion. It can be possible that a stronger stimulus such as longer exposure 
time to reduced CBF or higher Aβ levels (i.e. older mice) might be needed to induce 
a significant increase in haemorrhagic lesions. Indeed, sustained hypoperfusion over 
six months has been shown to induce widespread vascular disruption and BBB 
breakdown, leading to the development of haemorrhages in mice (Holland et al., 
2015). 
 
4.4.5. NVU alterations in response to Aβ and hypoperfusion. 
 
The close interaction between the cells comprising the NVU controls the 
permeability of the BBB, regulates CBF and effective communication within the 
NVU is critical for normal cognitive function (Lok et al., 2007). As demonstrated in 
the present chapter, chronic cerebral hypoperfusion triggered the accumulation of Aβ 
in brain parenchyma and in the cerebrovasculature. This may contribute to perpetuate 
NVU alterations and accelerate the neurodegenerative process in AD. In order to test 
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this, the independent and combined effect of hypoperfusion and amyloid on astrocyte 
and TJ integrity was examined. The results of this study revealed significant 
differences between transgenic and control mice suggesting the involvement of Aβ 
deposition on these changes. Furthermore, it was demonstrated that slight reductions 
of CBF were able to exacerbate some of these changes, unveiling a synergistic 
contribution of both hypoperfusion and amyloid to the development of these 
alterations. 
 
Interestingly, although behaviour was not assessed in the present study, there have 
been reports demonstrating that the behavioural performance of transgenic mouse 
models of AD is worsened following cerebral hypoperfusion. Reduced CBF induced 
by the occlusion of one common carotid artery aggravated the memory deficits in 
Tg2576 mice (Lee et al., 2011b). Similarly, BCAS triggered cognitive alterations in 
J20 mice (Yamada et al., 2011). In another study, where permanent occlusion of the 
right common carotid artery was performed in APPSWE/PS1 mice, learning deficits 
were also observed (Pimentel-Coelho et al., 2013). Notably, in all these studies, the 
behavioural alterations observed were the result of a synergistic effect of both 
hypoperfusion and the underlying Aβ pathology of the mice, as the effect was either 
not observed in the wild-type controls or it was the exacerbation of a pre-existent 
deficit in the transgenic mice. Nevertheless, there is a lack of studies, where the 
combination of hypoperfusion and AD models is explored in order to identify 
possible cellular or molecular targets involved in the pathways that lead to the 
cognitive alterations. This is of particular importance for the development of 
potential novel strategies for the prevention of AD. 
 
4.4.6. Astrocyte alterations. 
 
The function of astrocytes under physiological conditions is relatively well 
characterised, with increasing evidence suggesting an active role of this type of cells 
in several brain functions. However, their participation in the diseased brain remains 
poorly understood. The study of this has been particularly difficult since astrocytic 
reaction in response to brain injury can be diverse and potentially protective as well 
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as detrimental (Kölker et al., 2001; Chen and Swanson, 2003; Sofroniew, 2005; 
Barreto et al., 2011). There are also very few markers for the different pools of 
astrocytes and most studies focus on GFAP as a marker of astrocytes. 
 
As demonstrated in previous reports, severe reduction of CBF induced by permanent 
BCCAO, has shown to induce upregulation of GFAP in the hippocampus of 
hypoperfused rats (Vicente et al., 2009). Similarly, most modest reductions of 
cerebral perfusion have shown astrogliosis in several WM areas of the brain in mice 
(Shibata et al., 2004). In contrast, the results of the present study showed no 
significant changes in GFAP levels following chronic cerebral hypoperfusion in 
wild-type mice. However, it is important to note that this discrepancy might relate to 
the different approaches used in these studies. For instance, in the present study, 
GFAP levels were determined in total brain homogenates and differently, in the 
previous studies above mentioned specific brain regions were analysed. Thus, 
although no general changes were observed in the current study, it is possible that 
potential regional changes might have been masked. Another explanation might be 
the differences in severity of CBF reductions and the extent of pathology caused. 
 
Interestingly, it has been shown that in transgenic models of AD, astrocytic reaction 
is not homogeneous and, on the contrary, astrogliosis occurs in parallel to glial 
dystrophy as AD pathology progress, and this response is spatially different 
depending on the proximity of astrocytes to amyloid deposits (Rodríguez et al., 2009; 
Olabarria et al., 2010). The current study revealed an overall increase in astrocyte 
activation in the Tg-SwDI mice compared to the wild-type controls, suggesting the 
underlying involvement of Aβ pathology on this response. This data is in line with 
previously reported findings, where reactive astrogliosis has been found to be 
associated with Aβ aggregates in cell cultures (DeWitt et al., 1998), transgenic 
models of AD (Benzing et al., 1999) and in human AD brains (Nagele et al., 2004). 
 
One of the key functions of astrocytes is the control of the ionic/osmotic balance in 
the brain through the water channel AQP4, which plays a central role in astrocyte 
plasticity in response to different types of brain of injury or stimuli. However, AQP4 
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also participates in pathophysiological conditions, as demonstrated by the reduced 
edema formation and improved neurological recovery following ischemic stroke in 
AQP4-knockout mice (Manley et al., 2000). Furthermore, there are conflicting 
reports showing either redistribution (Yang et al., 2011), downregulation (Wilcock et 
al., 2009) or upregulation (Moftakhar et al., 2010) of AQP4 associated to Aβ in 
transgenic mouse models of AD and in AD patients. However, these discrepancies 
may relate to differences in the particular experimental conditions of each study but 
more importantly to the stage of the disease or the severity of the pathology. Similar 
differences in AQP4 expression, in response to brain injury, have been shown by 
several reports. For example, increased AQP4 mRNA has been described following 
mechanical brain trauma (Vizuete et al., 1999) or focal cerebral ischemia (Taniguchi 
et al., 2000) in rats. However, a heterogeneous, time-dependent response was 
demonstrated following TBI, where a decreased AQP4 expression level was found 
followed by increased levels at later time points post injury (Ke et al., 2001). Hence, 
the, yet unknown, detrimental or beneficial role of AQP4 depends not only on the 
injury model but also on the time point studied.  
 
The results presented in the current study showed increased AQP4 levels following 
chronic cerebral hypoperfusion in the Tg-SwDI mice, yet this difference was not 
observed in the wild–type group, suggesting a synergistic effect, where both amyloid 
and hypoperfusion contributed to the upregulation of the receptor. A dynamic, early 
and transient response can be presumed, as interestingly, this change was not 
observed at the later time point studied (3 months post-surgery). As mentioned 
above, differences on AQP4 dynamics might be time-dependant and determined by 
the extent of the injury. Hence, one explanation to this result could be that, as 
demonstrated before, following BCAS, CBF began to recover over time (Shibata et 
al., 2004), therefore the degree of the stimuli changes over time. Thus, although Aβ 
pathology is higher at the later time point, the synergistic effect might be lost. 
 
A previous study showed compensatory AQP4 upregulation in response to oxidative 
damage in an AD mouse model and notably, deficiency of AQP4 in the same model 
resulted in higher oxidative stress and grater cognitive deficits (Liu et al., 2012). As 
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demonstrated in the previous chapter of the present thesis, NOX2 levels were also 
found to be upregulated in the Tg-SwDI model following 1 month of hypoperfusion, 
thus it is possible that the increased AQP4 levels observed might be a compensatory 
response to the increased oxidative stress induced by both hypoperfusion and Aβ. 
Indeed, there was a positive correlation between AQP4 and NOX2 levels. 
Interestingly, according to the association analyses performed, soluble parenchymal 
Aβ correlated with the higher AQP4 levels observed, suggesting the participation of 
this toxic amyloid species in the pathways that triggered this dynamic astrocytic 
reaction. 
 
Astrocytes interact with the cerebrovasculature and neurons through their specialised 
foot processes, where AQP4 is highly expressed. This contact is crucial for the 
correct supply of metabolites to neurons, to maintain osmotic balance, and to 
regulate the local CBF in response to neuronal activity. Dissociation between 
astrocytic end-feet and capillaries has been shown to occur following ischemic 
insults resulting in a neurodegenerative inflammatory response (del Zoppo and 
Hallenbeck, 2000; Milner et al., 2008). After ischemia, increased ion and 
neurotransmitter uptake lead to enhanced water entry to the astrocyte, resulting in 
swelling of the end-feet (Kimelberg, 1995). Thus, astrocyte swelling triggered by 
AQP4 upregulation might be a possible mechanism by which loss of end-feet-
capillary contact occurs in response to ischemic injury. Hence, given the increased 
AQP4 levels observed in the Tg-SwDI mice following hypoperfusion, it was 
hypothesised that this could lead to astrocyte-vasculature detachment. However, the 
results revealed no significant changes in the vascular AQP4 coverage, suggesting 
that the contact between end-feet and blood vessels was not altered neither by 
hypoperfusion nor by amyloid pathology. It is likely that the study was performed in 
an early stage, and such alterations were not present yet. Indeed, loss of AQP4 
polarisation has been reported following six months of hypoperfusion in mice 






4.4.7. Tight junction alterations. 
 
TJ proteins constitute an important structural component of the BBB. Alterations of 
the expression and distribution of these proteins can lead to altered brain homeostasis 
and contribute to neurodegenerative processes. Although TJ protein alteration is 
known to contribute to BBB dysregulation, previous reports on TJ protein levels in 
response to injury have shown conflicting data. For instance, a study demonstrated 
that Aβ induces enhanced endothelial permeability, however its effect on the 
expression of different TJ proteins was variable, showing downregulation of occludin 
but no changes in claudin-5 or ZO-1 (Tai et al., 2010). Other studies have shown 
decreased expression of occludin, claudin-5 and ZO-1 associated with vascular 
amyloid (Carrano et al., 2011). Conversely, Aβ treatment of isolated microvessels 
showed reductions of claudin-5 but no changes in occludin and ZO-1 levels (Hartz et 
al., 2012). 
 
Additionally, chronic cerebral hypoperfusion has been linked with dysregulation of 
the BBB (Ueno et al., 2002, Wu et al., 2006), however, the specific effect of 
hypoperfusion on TJ integrity remains unclear. Interestingly, claudin-3 was shown to 
be upregulated following hypoperfusion induced by BCCAO (Shin et al., 2008). 
Altered levels of this protein have been associated with disrupted BBB permeability 
(Coyne et al., 2003; Wolburg et al., 2003; Brooks et al., 2005). Furthermore, in vitro 
studies performed to evaluate TJ integrity in oxidative environment have revealed 
contrasting results, with evidence of decreased claudin-5 and occludin expression 
(Schreibelt et al., 2007) but also enhanced occludin levels (Lee et al., 2004) induced 
by oxidative stress. Yet, BBB impairment was observed in both cases, regardless the 
outcome of the experiment. 
 
Claudin-5 is one of the main components of the TJs, therefore it was used in the 
current study as a marker of NVU physical integrity. The results revealed 
significantly higher levels of claudin-5 in the Tg-SwDI mice compared to the wild-
type controls and this was exacerbated following 1 month of hypoperfusion in the 
transgenic mice, suggesting an underlying influence of amyloid on the development 
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of this change and a synergistic effect when both injuries (Aβ and hypoperfusion) 
were present. Interestingly, the increased levels of claudin-5 positively correlated 
with the levels of cerebrovascular Aβ and no correlation was observed with levels of 
soluble parenchymal Aβ, suggesting that the accumulation of amyloid in blood 
vessel walls was likely the triggering factor that induced the altered expression of the 
protein. 
 
Both cerebral hypoperfusion and vascular amyloid, which are associated with 
inflammation, constitute features of the AD and normal ageing brain. A number of 
studies have reported that with increased ageing, altered TJ protein expression leads 
to a “leaky” BBB condition (Mooradian et al., 2003; Sandoval and Witt, 2011; Blau 
et al., 2012). Notably, inflammation has also been shown to induce alterations in TJ 
protein levels, with increased expression of claudin-3 and claudin-5 (Brooks et al., 
2005) and reduced occludin levels (Huber et al., 2001), leading to increased BBB 
permeability. Thus, an inflammatory response triggered by hypoperfusion and Aβ 
could be a possible explanation for the increased claudin-5 expression levels 
observed in the current study. Future studies are required to determine the 
mechanisms by which this response occurs. It would also be interesting to 
complement this study by looking at other components of the TJ such as ZO-1 and 
occludin. 
 
It is important to mention that, rather than static structures, TJ complexes correspond 
to dynamic assemblies that are able to change in response to injury or stimuli in order 
to adapt to the conditions and that way maintain cerebral homeostasis. Hence, the 
dynamic properties of TJ should be taken into account when considering all the 
contradictory data observed in the literature, as subtle changes in experimental 
conditions including different time points studied, might result in different TJ 
reorganisation. 
 
It is well known that astrocytes participate in the regulation of TJ proteins expression 
and therefore have a key role in the maintenance of the BBB (Janzer and Raff, 1987; 
Abbott et al., 2006). Hence, considering the previous finding of a similar response of 
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the astrocytes, where a synergistic effect of amyloid and hypoperfusion was found to 
contribute to AQP4 upregulation, following 1 month of hypoperfusion, it is possible 
to speculate that the changes observed at the TJ level, were likely a synchronised 
compensatory response where different structures of the NVU interacted in order to 
maintain or re-establish brain homeostasis following injury. 
 
In the present study, the analysis of NVU alterations focussed on structural changes, 
and although these changes imply functional alterations it would be important to 
study this, for example by studying functional hyperaemia. 
 
4.4.8. Summary and conclusions.  
 
It is well documented that chronic cerebral hypoperfusion, an early feature of human 
AD, can alter Aβ metabolism, and this has been largely demonstrated in animal 
models of the disease (Kitaguchi et al., 2009; Okamoto et al., 2012; ElAli et al., 
2013). In the present study, by investigating amyloid levels in parenchyma and 
vasculature at different time points, we have gained insights into the kinetics of 
aggregation of Aβ in the Tg-SwDI model and how this is altered by chronic cerebral 
hypoperfusion. In this model, Aβ is produced and rapidly aggregates to form 
insoluble fibrils. Hypoperfusion exacerbated this process. Similarly, in humans 
affected with AD, the misfolding and accumulation of Aβ in brain parenchyma and 
blood vessel walls are major hallmarks and constitute critical phases for the 
pathogenesis of the disease (Terry, 1994; Trojanowski and Lee, 2000). However, if 
amyloid accumulation constitutes a cause or a consequence of chronic hypoperfusion 
in humans, it remains currently unknown. 
 
Critically, the results of this chapter demonstrate that chronic cerebral hypoperfusion 
induced a transient upregulation of APP that may have led to the increased Aβ levels 
and aggregation of the protein in the parenchyma followed by vascular accumulation. 
In the case of human AD this is not completely understood and whether increased 
APP levels, as a consequence of chronic cerebral hypoperfusion, constitutes the 
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source of the high amounts of Aβ in the brain of AD patients, has not been 
demonstrated.  
 
Furthermore, the findings presented in this chapter provide evidence of a detrimental 
interaction between reduced CBF and Aβ pathology that contributed to the 
development of cerebrovascular alterations including MIs and changes in astrocytes 
and TJs, where specific pools of Aβ were differentially involved. Although the 
existence of a similar sinergistic interaction that may contribute to the progress of the 
disease in humans remains unknown, the independent involvement of hypoperfusion 
and amyloid accumulation on the development of degenerative processes has been 
shown to occur. Specifically, similar to what was found in this study, changes in 
specific components of the NVU have been demonstrated in the brains of patients 
with amyloid accumulation (Moftakhar et al., 2010; Hartz et al, 2012). Moreover, 
comparable with our findings, microinfarction has been shown to occur in areas of 
brain hypoperfusion in AD patients (Suter et al., 2002). 
 
Altogether, these data support the importance of the role that Aβ plays in the 
pathoetiology of neurovascular deterioration, which may have implications on the 
development of AD. In addition, this evidence highlights the idea of an overlap 
between both the vascular and amyloid hypotheses of AD.  
 
The next set of studies sought to explore whether modulation of amyloid levels by 
passive amyloid immunotherapy would impact on the degenerative processes found 
in the Tg-SwDI mice. As shown above Tg-SwDI mice exhibited, even in the absence 

























Chapter 5. Effects of passive Aβ 
immunotherapy on amyloid levels and MIs in 















Aggregation of Aβ peptide into soluble oligomers or amyloid plaques in brain 
parenchyma and cerebral blood vessels constitute a critical process in the 
pathogenesis of AD (Hardy and Selkoe, 2002), and suggests Aβ as an obvious 
therapeutic target. Thus, several approaches based on targeting Aβ in order to 
decrease brain levels of the protein, started to be developed (Panza et al., 2009), with 
Aβ immunotherapy being one of the most promising strategies for disease modifying 
treatment (Panza et al., 2012; Li et al., 2013; Sarazin et al., 2013). Importantly, data 
from clinical trials indicates that Aβ immunotherapy constitutes a potential treatment 
for AD patients (see section 1.1.10). 
 
Although active immunisation with various Aβ peptide antigens failed to stimulate 
Aβ clearance in transgenic mouse models of AD due to impairment of the antibodies 
to cross the BBB (Vasilevko et al., 2007), passive peripheral administration of 
several antibodies including 10D5 and 3D6 has shown to reduce Aβ pathology (Bard 
et al., 2000; Bard et al., 2003). However, numerous reports demonstrating increased 
incidence of degenerative processes including haemorrhages in different transgenic 
mice following passive immunisation, have generated some concern (Pfeifer et al., 
2002b; Wilcock et al., 2004; Racke et al., 2005; Wilcock et al., 2006; Burbach et al., 
2007; Karlnoski et al., 2008; Schroeter et al., 2008). Hence, more research is needed 
before this approach can safely and successfully be applied in humans. 
 
CAA is present in almost all cases of AD (Weller et al., 2009) and, as discussed in 
the previous chapter of the present thesis, leads to the deterioration of the 
cerebrovascular system, which constitutes a risk factor for cognitive decline and may 
contribute to neurodegenerative processes in AD. The Tg-SwDI mouse model 
accumulates Aβ in the brain parenchyma and predominantly in the 
cerebrovasculature as the animals age, modelling this key pathology associated with 
AD (Davis et al., 2004). The results of the previous chapter also demonstrated that 
MIs are present subcortically in these mice thus providing a link between amyloid 
aggregation and degenerative processes. 
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Hence, although passive immunisation has proven successful in reducing 
parenchymal and vascular Aβ in transgenic mouse models of AD, its efficacy in a 
model with robust vascular amyloid, at a stage when amyloid load is relatively low 
has not been tested.  
 
5.1.1. Hypothesis and aim of study. 
 
It was hypothesised that treatment with 10D5 and 3D6 antibodies decreases Aβ 
accumulation, reducing the MI load and improving the cognitive performance of the 
Tg-SwDI mouse model. 
 
The specific aim of this study was to investigate the effects of passive immunisation 
with both 10D5 and 3D6 antibodies on Aβ40/42 levels in the parenchyma and 
cerebrovasculature of young heterozygous Tg-SwDI mice, at a time when amyloid 
burden is low, following 3 months of weekly intraperitoneal injections. Microglial 
burden in response to the therapy was also studied. A further aim was to determine 
whether treatment with these antibodies induces changes in the number of MIs and 





















Young male Tg-SwDI mice, on a heterozygous background were used. Controls, n = 
8 (age = 5 ± 0.2 months); 10D5, n = 9 (age = 4.7 ± 0.2 months) and 3D6, n = 10 (age 




The antibodies were obtained from Janssen Pharmaceutical Companies. Antibody 
solutions were diluted with sterile PBS and intraperitoneal injections were done as 
described in section 2.3. 
 
5.2.3. Barnes maze. 
 
Upon completion of the treatment, spatial learning and memory performance were 
tested by using the Barnes maze, as described in section 2.13. 
 
5.2.4. Perfusion and tissue processing. 
 
Following 3 months of treatment, animals underwent saline perfusion as described in 
section 2.4.1. The left hemi-brain was divided into 4 mm thick coronal sections and 
then processed for paraffin embedding. Coronal sections were produced as described 
in section 2.5.2. The right hemi-brain was used to generate parenchymal and vessel 
enriched fractions as described in section 2.9. Guanidine protein extraction (second 
step of sequential protein extraction) and quantification were performed as described 






Immunohistochemistry was carried out as described in section 2.6. Tissue sections at 
anatomical level corresponding to -1.70 mm from bregma (Franklin and Paxinos, 
1997) were used. Iba1 immunostaining was performed using immunoperoxidase 
labelling.  
 
5.2.6. Histological detection of MIs and haemorrhages. 
 
The detection of MIs was done by using H&E staining, which was performed as 
previously described in section 2.7.1. The detection of haemorrhages was done by 
using Prussian blue staining as described in section 2.7.2. Tissue sections at 
anatomical level corresponding to -1.70 and -2.18 mm from bregma (Franklin and 
Paxinos, 1997) were used. 
 
5.2.7. Image analysis. 
 
For the analysis of microglial load one image from the thalamus was acquired as 
described in section 2.8, at 4x magnification. Quantitative measurement of the 
staining was assessed by quantifying the number of positive Iba1 cells in the total 
area. 
 
For the study of MIs, two sections per brain were analysed and one image of the 
thalamus per section was acquired as described in section 2.8, at 10x magnification. 
MIs were defined as sharply delimited areas of tissue pallor that were accompanied 
by microglial proliferation identified by Iba1 immunostaining in adjacent sections. 
The area covered by infarcted tissue was measured. 
 
For the analysis of haemorrhages, two sections per brain were scanned. 
Haemorrhages were identified by the presence of ferric iron deposits on Perls stained 






5.2.8. Enzyme-linked immunosorbent assay. 
 
Levels of both Aβ1-40 and Aβ1-42 were determined by ELISA (Invitrogen) in 
protein samples extracted from the parenchymal and the vessel enriched fractions. In 
all experiments, manufacturer’s instructions were used to perform the assays. 
 
5.2.9. Statistical analysis.  
 
The data obtained from the ELISA, Iba1 immunostaining and MI studies, were 
analysed for statistical significance using one-way ANOVA followed by the 
Bonferroni post-test. For the behaviour study statistical comparison was carried out 
using two-way repeated measures ANOVA (with training and treatment as factors), 


























5.3.1. Effects of 10D5 and 3D6 treatment on Aβ levels in the parenchyma and 
cerebrovasculature of Tg-SwDI mice. 
 
To investigate whether administration of 10D5 or 3D6 antibodies may have had an 
effect on Aβ40/42 levels within the parenchyma and cerebrovasculature, amyloid 
levels were quantified by ELISA. Although lower levels of the protein were observed 
in the 10D5 and 3D6 treated groups, this was not significantly different from the 
control mice either in the parenchyma (p = 0.20 Aβ40, p = 0.26 Aβ42; Figure 5.1, a, 
c) or in the vasculature (p = 0.08 Aβ40, p = 0.09 Aβ42; Figure 5.1, b, d). 
 
5.3.2. Treatment with 10D5 and 3D6 does not affect microglial burden. 
 
In order to assess the microglial load following Aβ immunotherapy, Iba1 
immunostaining was used to visualise microglial proliferation, and the number of 
microglial cells was quantified with ImageJ (Figure 5.2). As shown in the graph, no 
significant differences were observed between control and treated groups (Figure 5.3, 
2). 
 
5.3.3. Effects of 10D5 and 3D6 treatment on the development of MIs and 
haemorrhages. 
 
The effect of Aβ immunotherapy on the development of MIs was studied by 
histological examination of tissue sections using H&E staining, and quantitative 
analysis of the area covered by MIs was done. Representative images of infarcted 
tissue in control, 10D5 and 3D6 groups are shown (Figure 5.3, a, b, c, respectively). 
Although the area covered by MIs in the 10D5/3D6 treated mice was not 
significantly different from the control group, it was noted that overall there was a 
tendency for the area of tissue damage to be reduced. The area of MIs was 0.0064 ± 
0.0032 mm2 (10D5 group) and 0.012 ± 0.0039 mm2 (3D6 group) as compared to the 









Figure 5.1. Effects of passive Aβ immunotherapy on cerebrovascular and 
parenchymal Aβ levels. Tg-SwDI animals were injected for 3 months with control, 
10D5 or 3D6 antibodies and sacrificed 1 week after the last injection. Following 
protein extraction, the levels of Aβ40/42 were quantified in the parenchymal (a, c) 
and vessel enriched (b, d) fractions by ELISA. Graphs represent the levels of the 
protein normalised to total protein concentration. The data presented are the means ± 
S.E.M. There were no statistical differences determined using one-way ANOVA, p > 




















Figure 5.2. Microglia burden following Aβ immunotherapy. Representative 
images showing Iba1 staining, which was used to visualise microglial proliferation in 
controls (a), 10D5 (b) and 3D6 (c) treated mice (scale bar = 100 µm). The number of 
microglial cells was quantified with ImageJ and is represented in the graph (d). The 
data presented are the means ± S.E.M. There were no statistical differences 
determined using one-way ANOVA, p > 0.05 (control: n = 8, 10D5: n = 9 and 3D6: 























Figure 5.3. Microinfarct load following Aβ immunotherapy. Representative 
images showing infarcted tissue in controls (a), 10D5 (b) and 3D6 (c) treated mice 
(scale bar = 100 µm). Histopathological analysis was performed using H&E staining, 
the area covered by infarcted tissue was measured with ImageJ and is represented in 
the graphs. The data presented are the means ± S.E.M. There were no statistical 
differences determined using one-way ANOVA, p > 0.05 (control: n = 8, 10D5: n = 










The analysis revealed no haemorrhages either in control or treated mice. 
 
5.3.4. Assessment of spatial learning and memory performance following Aβ 
immunotherapy. 
 
The impact of 10D5 and 3D6 administration on cognitive performance was explored 
using the Barnes maze, as described in section 2.13. Mice were trained over a period 
of 5 days, where they had to learn the relationship between distal cues to find the 
pathway to the escape box. 48 hours after the last training trial, animals were tested 
in a 90 seconds probe trial to assess long-term spatial memory.  
 
Firstly, in order to define whether administration of 10D5 or 3D6 antibodies may 
have had an effect on the locomotor activity of the mice, the speed, distance travelled 
and the time that the mice spent immobile during the training were determined 
(Figure 5.4, a, b and c, respectively). As shown in the graphs, no significant 
differences were observed between control and 10D5 or 3D6 groups. This result 
indicates that if any changes in cognitive performance were to be found, this would 
not be influenced by locomotor alterations that the treatment might have potentially 
induced. 
 
As shown in Figure 5.5, the mice in the three groups learnt the task, as it took less 
time to all of them to locate and enter the escape box as the training progressed. 
Accordingly, the graphs show a decreased numbers of primary and total errors the 
last training day, compared to the first day, in the three groups (Figure 5.5, c and d, 
respectively). However, statistical analysis revealed that neither the 10D5 nor 3D6 
groups differed significantly from the control group, in terms of primary latency, 
latency to escape, primary errors and total errors, at all the time points analysed (all 
training days).  
 
Assessment of long term spatial memory showed no significant changes in the 
number of primary and total errors between the controls and treated mice (Figure 5.6, 






Figure 5.4. Locomotor activity following Aβ immunotherapy. The locomotor 
performance of Tg-SwDI mice following treatment, was assessed by using the 
Barnes maze. Graphs represent the speed (a), distance travelled (b) and time 
immobile (c) during the training. The data presented are the means ± S.E.M., two-
way repeated measures ANOVA: significant effect of training (F(4,96) = 23.36, ***p < 
0.0001) (a); significant effect of training (F(4,96) = 9.492, ***p < 0.0001) (b); 












Figure 5.5. Spatial learning performance following Aβ immunotherapy. The 
learning performance following treatment was tested using the Barnes maze. Graphs 
represent the primary latency (a), latency to escape (b) primary errors (c) and total 
errors (d) recorded during the training. The data presented are the means ± S.E.M., 
two-way repeated measures ANOVA: significant effect of training (F(4,96) = 29.52, 
***p < 0.0001) (a); significant effect of training (F(4,96) = 55.59, ***p < 0.0001) (b); 
significant effect of training (F(4,96) = 3.978, ***p = 0.005) (c); significant effect of 


















Figure 5.6. Long term spatial memory following Aβ immunotherapy. The 
memory performance following treatment was tested using the Barnes maze. Graphs 
represent the primary errors (a), total errors (b), and % of time spent on each 
quadrant, where Q2 correspond to the target quadrant (c) recorded during the probe 
trial. The data presented are the means ± S.E.M. There were no statistical differences 
between control and 10D5/3D6 groups determined using one-way ANOVA, p > 0.05 











four zones containing five holes each, and the time spent exploring the zones was 
determined. As shown in the graph, all groups spent higher percent time exploring 
the target zone compared to the other zones (Figure 5.6, c). However, no significant 













































5.4. Discussion.  
 
To date, the majority of studies have focussed on clearing amyloid at stages when 
amyloid load is considerable and this has led to exacerbation of degenerative 
processes including haemorrhages. This study sought to examine the effects of 
passive amyloid immunisation at the early stages when amyloid burden is low.  
 
Although there were no significant changes between control and 10D5/3D6 treated 
mice in amyloid levels, appearance of MIs and cognitive performance, it was noted 
that there was a trend towards a reduction in amyloid levels and MI area in the 
10D5/3D6 treated mice compared to the control animals. Furthermore, there was no 
evidence of microhaemorrhages in response to the immunisation.  
 
5.4.1. Immunotherapy mediated Aβ clearance. 
 
The outcome of different passive amyloid immunotherapy studies on transgenic mice 
has shown variable results depending on different factors including the age of the 
animal when treatment was started, the amyloid load and the antibody used. The first 
passive Aβ immunotherapy experiments were performed in 2000 using PDAPP 
mice, which develop extensive accumulation of extracellular Aβ plaques. The results 
demonstrated that peripheral administration of 10D5 and 3D6 antibodies, which were 
able to reach the CNS, promoted Aβ clearance through Fc-dependant phagocytosis 
by microglia (Bard et al., 2000). Following studies performed in young PDAPP mice 
treated with m266 antibody, which recognises Aβ13–28, showed a decrease in 
soluble and insoluble amyloid levels, and the treatment also prevented the formation 
of plaques (DeMattos et al., 2001). However, studies in older PDAPP mice, 
demonstrated that only antibodies directed to n-terminal epitopes of the protein 
including 10D5 (which recognises Aβ3-7) and 3D6 (which recognises Aβ1-5), were 
able to clear the pre-existent amyloid deposits (Bard et al., 2003). 
 
In the present study, although no significant differences were determined between 
control and treated groups, a trend towards decreased Aβ40 and Aβ42 levels in 
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parenchyma and in the cerebrovasculature of young Tg-SwDI mice was found 
following treatment with both 3D6 and 10D5 antibodies, markedly in the vessel 
fraction. In contrast, several studies have shown that although reduced parenchymal 
Aβ levels were found following immunisation, increased vascular amyloid was 
observed (Wilcock et al., 2004; Wilcock et al., 2006; Karlnoski et al., 2008). For 
example, it was reported that in Tg-SwDI mice, intracranial injection anti-Aβ 
antibodies purified from previously immunised mice with Aβ, efficiently cleared 
diffuse parenchymal plaques, but did not clear vascular amyloid (Vasilevko et al., 
2007). Considering the intracranial delivery, it is unlikely that the lack of efficiency 
was due to inadequate concentration of the antibody in the brain. Therefore, this 
raised the concern that the particular biochemical or structural properties of the 
mutant Aβ generated in the Tg-SwDI model, which accumulates in the vasculature, 
makes it resistant to antibody mediated clearance. Indeed, there is evidence that 
suggests that vascular and parenchymal aggregates differ in composition (Herzig et 
al., 2004). Nevertheless, several differences can be found between the current study 
and the one performed by Vasilevko and colleagues, which need to be considered 
when comparing the results. For example, different antibodies and delivery route 
were used. Furthermore, the mice used in the published report were 14 months old at 
the moment of the injection and differently, in the present study, the first injection 
was performed when animals were ~4 months old, and therefore exhibited low levels 
of Aβ (Davis et al., 2004; Xu et al., 2007). Thus, it is possible that, in the present 
study, the treatment was able to induce the clearance of existent amyloid but also to 
prevent its accumulation in the vasculature. Future studies using an extra group of 
aged mice, are required to test this hypothesis.  
 
It is important to note that the limited sample size used in the current study might 
have negatively influenced the sensitivity of the study; hence, by increasing the 
power, a more robust body of data would be obtained. Another main issue to be 
considered, is that, due to a delay in acquisition of the antibody and mice availability, 
the 3D6 group was set up later than the other two groups, and the average age of 
these animals was lower compared to the control mice (~3 weeks younger), which 
might have influenced the outcome of the experiment. For instance, as 3D6 was 
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injected in a younger cohort, it is not possible to rule out the fact that the overall 
reduction of Aβ observed in this group may be the result of the already lower levels 
of amyloid at the initiation of the experiment. Nonetheless, the 10D5 group was 
matched to the control group and this also showed a tendency towards a reduction in 
amyloid levels. 
 
5.4.2. Microhaemorrhages and MIs following Aβ immunotherapy. 
 
The development of cerebral microhaemorrhages has been described in numerous 
preclinical studies of Aβ immunotherapy (Pfeifer et al., 2002; Wilcock et al., 2004; 
Racke et al., 2005; Wilcock et al., 2006; Burbach et al., 2007; Karlnoski et al., 2008; 
Luo et al., 2010). Due to the observation of increased CAA in some of these mice, it 
has been suggested that clearance of parenchymal amyloid may increase vascular 
accumulation of the protein, which could be linked to the development of 
microhaemorrhages (Wilcock and Colton, 2009). It has also been suggested that the 
mechanism by which these lesions occurs is related to the removal of vascular 
amyloid from the vessel wall, which may expose the pre-existing vascular pathology 
associated with CAA and contribute to the leakage of the vasculature and the 
appearance of microbleeds (Zago et al., 2013). Indeed, a 3D6 dose-response study 
performed in 12 months old PDAPP mice revealed evidence of microhaemorrhage in 
a subset of vessels, specifically at sites where Aβ was partially or completely 
removed (Schroeter et al., 2008). Interestingly, in the current study no microbleeds 
were observed following 3 months of treatment. As previously mentioned, vascular 
Aβ levels in the mice used in the present study were low when the treatment was 
initialised, therefore it is likely that rather than removal of vascular amyloid deposits, 
immunisation with 3D6 and 10D5 antibodies prevented further accumulation of the 
protein in the vasculature. Consequently, this might have also prevented the 
development of vascular alterations associated either with the accumulation or 
removal of Aβ in the vessel wall. The vessel integrity in Tg-SwDI mice at this age of 
immunisation is also likely to be intact and thus be more resistant to the effects of 




As demonstrated in a previous chapter of the present thesis, accumulation of amyloid 
in the brain is associated with the development of MIs. Hence, it seems logical to 
hypothesise that decreased Aβ levels induced by amyloid immunisation would 
reduce the development of this type of lesions. However, some reports have shown 
evidence of microinfarction as part of the secondary effects of Aβ immunotherapy in 
AD patients and have attributed this to the exacerbation of CAA post treatment (Uro-
Coste el at., 2010; Sakai and Yamada, 2013). Interestingly, although the data 
presented in the current study did not achieve statistical significance, there was a 
tendency for MI load to be reduced in the mice receiving the 10D5 and 3D6 
antibodies as compared to the control animals. A possible explanation for this finding 
may relate to the decreased levels of Aβ with no further build-up of deposits in the 
vasculature following the treatment, as lower amyloid levels in the immunised mice 
might have prevented an oxidative as well as an inflammatory response that could 
have contributed to the development of MIs. However future studies would be 
required to clarify this premise. 
 
5.4.3. Cognitive performance following Aβ immunotherapy. 
 
Both active and passive amyloid immunotherapy strategies have proven to attenuate 
cognitive deficits in transgenic models (Janus et al., 2000; Dodart et al., 2002; 
Hartman et al., 2005; Wilcock et al., 2006). However this has not been reflected in 
humans and therefore, with a limited effect in clinical trials, the approach has not 
been translated into a treatment for AD (see section 1.1.10).  
 
As demonstrated in previous reports, the Barnes maze task has been successfully 
used to determine cognitive deficits in the Tg-SwDI mice (Xu et al., 2007; Xu et al., 
2014). Therefore, in the current study, this test was used to determine spatial learning 
and memory performance in Tg-SwDI mice following treatment with 3D6 and 10D5 
antibodies. All mice learnt the task and showed a marked preference for exploring 
the target quadrant during the probe trial. However, no significant differences were 
found between control and 10D5/3D6 treated groups. A possible explanation for this 
result may be attributable to the minimal differences observed between control and 
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treated groups in amyloid burden following the therapy, as it might be possible that a 
certain threshold of amyloid levels needs to be reached in order for this to be 
translated into cognitive changes. Indeed, in the previously mentioned study by Xu 
and colleagues, where behavioural alterations were detected with the Barnes maze 
even in very young mice compared to wild-type controls, the animals used were 
homozygous, which develop more extensive Aβ pathology and at an earlier age than 
heterozygous mice. Hence, considering the heterozygous background of the animals 
used in the current study, and the low reduction in Aβ levels post-treatment, it is not 
surprising that no behavioural changes were found.  
 
An important weakness of this study is the lack of a wild-type group as comparative 
controls. This would have allowed to determine whether there are behavioural 
alterations in the Tg-SwDI mice compared to the wild-type mice that could be 
reversed following the immunotherapy. 
  
As shown previously in the present thesis, amyloid deposition is associated with 
microglial activation. Moreover, amyloid related cognitive alterations in Tg-SwDI 
mice have been shown to be associated with microglial activation and 
neuroinflammation (Xu et al., 2007). Therefore considering the trend towards 
reduced Aβ observed in the present study, it was reasonable to expect a similar trend 
of decreased microglial burden. However, no change in microglial cell number was 
found. This result supports the idea that the reduction in amyloid levels induced by 
the treatment was probably not sufficient to reduce the underlying inflammation that 
could have been reflected in a cognitive improvement. 
 
Interestingly, a study looking at synapsis integrity in Tg2576 mice following 
immunotherapy with 6G1 and A-887755 antibodies, showed improved synaptic 
pathology even when no effect on fibrillar amyloid load was observed (Dorostkar et 
al., 2014). Furthermore, there is evidence of reduced memory impairment without 
lowering Aβ burden following immunotherapy with the m266 antibody in PDAPP 
mice (Dodart et al., 2002). In this study, it is discussed that reversal of memory 
impairment was probably associated to reductions in soluble Aβ species. Indeed, it 
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has been suggested that the failure to reach clinical endpoint in human trials of Aβ 
immunotherapy is probably due to clearance of the non-pathological Aβ species, 
instead of using conformational antibodies directed to the most cytotoxic amyloid 
pools (Murakami, 2014). 
 
5.4.4. Summary and conclusions. 
 
The results presented in the current chapter demonstrate that Aβ immunotherapy with 
the antibodies 3D6 and 10D5 may potentially decrease parenchymal and vascular 
amyloid accumulation, reducing the appearance of MIs and notably without 
triggering the development of microhaemorrhages. Further studies are needed to 
confirm this evidence. This is of particular importance, as Bapineuzumab, which 
constitutes the humanised form of the 3D6 antibody, was the first antibody tested in 
humans, as a potential strategy to reverse the cognitive impairment in AD patients. 
The treatment showed decreased Aβ burden, but it was associated with high 
incidence of amyloid related imaging abnormalities, and therefore the program was 
ended in phase III due to failure of the treatment to reach clinical endpoint (Panza et 
al., 2011; Tayeb et al., 2013).  
 
Aβ aggregation constitutes a slow process that takes decades to develop. An effective 
treatment before the symptoms are visible seems to be a more reasonable strategy 
than attempting to reverse the pathology when the damage is already present and 
irreversible due the complexity of the pathological pathways triggered. Hence, the 
use of Aβ immunotherapy in the early stages of disease, as a preventive measure, 
might be more effective. This might also prevent further development of vascular 
alterations associated either with the accumulation or removal of Aβ in the vessel 
wall. For this reason, we aimed to carry out the intervention studies in young mice, 
before Aβ starts to accumulate. In contrast, as no diagnostic method has been 
successfully developed in order to allow the early detection of the disease in humans, 
clinical trials have been designed to test Aβ immunotherapy in AD patients when the 
clinical symptoms are present and amyloid burden is very high, and this is likely the 
176	
	
reason of the high incidence of degenerative processes such as haemorrhages post-
treatment.   
 
The results presented here are relevant not only for the implications in AD but also 
has ramifications for CAA, as no treatment is currently available for this pathology 


















































The findings presented in this thesis provide insights into the events that are initiated 
by chronic cerebral hypoperfusion and culminate with degenerative processes that 
may lead to cognitive decline in AD. Initially, Aβ pathology was temporally 
characterised in the transgenic mouse model of amyloidosis Tg-SwDI. In this model, 
mild cerebral hypoperfusion modified APP metabolism, triggering an early increase 
in the levels of soluble Aβ in the parenchyma followed by aggregation of the protein 
into insoluble fibrils, with the subsequent build-up of aggregates in the 
cerebrovasculature. Furthermore, a model of mixed injury was studied by inducing 
chronic cerebral hypoperfusion in Tg-SwDI mice, in order to explore the 
contribution of both hypoperfusion and Aβ deposition to cerebrovascular alterations. 
It was demonstrated that Aβ pathology is associated with the development of MIs 
and the alteration of specific elements of the NVU, and that hypoperfusion 
exacerbated these changes. Finally amyloid immunotherapy showed a trend towards 
decreased Aβ accumulation without further development of the commonly seen 
associated pathological processes, supporting the view of this therapy as a potential 
treatment for AD.  
 
Collectively, these findings provide evidence of a detrimental interaction between 
chronic cerebral hypoperfusion and Aβ pathology that contributed to the onset of the 
observed alterations. Thus, a mechanistic pathway is proposed, in which the cascade 
of events including inflammation and oxidative stress, triggered synergistically by 
chronic cerebral hypoperfusion and Aβ, results in the disruption of the NVU and the 
widespread development of MIs which may further induce the alteration of cognition 
networks. In parallel, vascular Aβ accumulation may contribute to perpetuate 





























Figure 6.1. Proposed mechanistic pathway leading to cognitive decline in AD.  
Vascular risk factors promote cardiovascular alterations that lead to reduced cerebral 
perfusion, which in turn triggers metabolic changes in the cerebrovasculature. These 
changes increases amyloid production leading to inflammation and oxidative stress, 
promoting degenerative processes including MIs and NVU disruption, which may 
contribute to cognitive deterioration in AD. The findings of this thesis are 



















6.2. Clinical implications and future studies. 
 
It is likely that in a healthy individual, the brain is able to react following different 
types of injuries, by inducing compensatory responses such as changes in APP 
metabolism to induce neuroprotection or adaptive NVU modifications to maintain or 
re-establish brain homeostasis. However, in the context of pathological conditions 
induced by VRFs, such as ageing-related cerebrovascular deterioration, it is possible 
that the system loses its capability of adaptation. In this case, the changes that 
initially occurred as part of a transient compensatory response, such as the increased 
APP metabolism, turn into permanent alterations that contribute to the damage and 
act to self-perpetuate the degenerative processes, for instance, by inducing Aβ 
accumulation due to faulty clearance of the protein. 
 
As demonstrated in the current thesis, enhanced APP and APP cleavage occurred 
following chronic cerebral hypoperfusion in the Tg-SwDI mice, probably as part of 
an adaptive response triggered in order to induce neuroprotection or recovery. Yet, 
considering the pathological environment of this model (Davis et al., 2004; Searcy et 
al, 2014), which display underlying genetic predisposition to develop amyloidosis, it 
cannot be ruled out that this might have influenced the results, potentiating the 
induction of metabolic and tissue damage.  
 
The events leading to chronic cerebral hypoperfusion during the normal ageing 
process may take decades. The evidence has shown a reduction of the CBF of 
approximately 20% at 60 years of age as compared to age 20, and a continuous rate 
of dropping of 0.5% per year until age 80 (Leenders et al., 1990; Zou et al., 2009; 
Chen et al., 2011a). Previous characterisation of the mouse model of chronic cerebral 
hypoperfusion induced by BCAS used in the present thesis, has shown an initial 
reduction of CBF of about 30%, which is gradually recovered to approximately 10% 
following 1 month (Shibata et al., 2004). Therefore, although it represents an 
extremely useful model to study the implications of modest reductions of CBF on 
different aspects related to the aetiology and treatment of cognitive decline, the 
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model does not recapitulate the gradual and progressive process that occurs with 
increasing ageing in humans.  
 
Similarly, it is widely accepted that pathological changes such as Aβ misfolding and 
oligomerisation constitute a slow process and may initiate decades before clinical 
symptoms are evident in AD patients (Braak et al., 1999; Buchhave et al., 2012). 
This represents another limitation of the model used in the present study, as the 
genetic mutations in APP predispose these mice to early and robust amyloid 
accumulation (Davis et al., 2004).  
 
Considering the issues addressed above, it would be interesting to perform a similar 
study as the one presented in this thesis, using a different model that could replicate 
more closely the conditions that occurs in the context of the human pathology. This 
could be achieved by inducing a more gradual reduction of CBF (Kitamura et al., 
2012), in a mouse model expressing the human APP without any mutations (Mucke 
et al., 2000). Thus, the gradual reduction of CBF would prevent the initial acute 
hypoxic condition and inflammatory response triggered by the severe blood flow 
drop. On the other hand, the use of a model expressing the wild-type human APP 
would avoid the genetic predisposition to develop Aβ aggregates spontaneously, 
although maintaining the possibility of studying experimentally-induced Aβ 
aggregation (which is not possible by using wild-type mice that expresses non 
amyloidogenic Aβ). 
 
The experimental design of the present thesis was aimed at modelling the early 
events that may contribute to degenerative processes that occur in AD, therefore 
young mice were subjected to chronic brain hypoperfusion. However, it would be 
interesting to carry out a similar study using aged mice in an attempt to determine the 
repercussion that reduced CBF would have in the aging brain. This would mirror 
more closely the course of the pathology in humans. Interestingly, age has been 
previously demonstrated to be an important factor when studying the effects of 




As research in the AD field progresses, it becomes evident that when the disease is 
clinically manifested, a complex combination of molecular and cellular alterations 
has already occurred (McGeer et al., 1989; Delacourte et al., 1999; Smith et al., 
2000; Cordonnier and van der Flier, 2011; van Rooden et al., 2014). For this reason, 
many potential targets have been the focus of different studies in an attempt of 
finding a successful treatment or cure for the disease (McGeer and McGeer, 1995; 
Sadowski et al., 2006; Greig et al., 2001; Corona et al., 2011; Deane et al., 2012; 
Herrmann and Spires-Jones, 2014; Hook et al., 2014; Iqbal et al., 2014).  
 
However, considering some key aspects that were studied in the present thesis, it 
becomes reasonable to focus on a mixed intervention targeting brain hypoperfusion 
and Aβ. The key findings supporting this premise include: the evidence reinforcing 
the view of chronic cerebral hypoperfusion as the initial triggering factor that leads to 
AD pathology; the fact that Aβ represents a key contributor to the onset and 
progression of the disease; and that the independent or combined presence of 
hypoperfusion and Aβ can lead to most of the molecular, cellular and structural 
disturbances present in the AD brain, amongst them WM alterations, axon-gial 
disruption, microinfarction, microbleeds, tau hyperphosphorylation, NVU changes, 
CAA, neurodegeneration and synapse loss, some of which were addressed in this 
thesis (Shankar et al., 2007; Palop and Mucke, 2010; Coltman et al., 2011; 
Cordonnier and van der Flier, 2011; Reimer et al., 2011; Okamoto et al., 2012; Zhao 
et al; 2014). 
 
As previously discussed, the events leading to chronic cerebral hypoperfusion, as 
well as the initial steps in Aβ aggregation, constitute slow processes that take 
decades to develop. Therefore, early diagnosis has become crucial and considerable 
efforts have been made to address this matter. Indeed, the detection of Aβ oligomers 
in biological fluids of AD patients constitutes a promising tool for the early diagnosis 
of AD (Salvadores et al., 2014). Of similar importance is the early identification of 
VRFs that could potentially lead to cerebral hypoperfusion, to stop the progression of 
underlying disease (Solomon et al., 2009). Thus, early diagnosis, in order to allow 
effective treatment before the symptoms become obvious seems to be more 
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reasonable than attempting to reverse the pathology when the damage is already 
present and irreversible due the complexity of the pathological pathways triggered.  
 
The findings described in this thesis highlight the importance of vascular care in 
midlife, which means to have a healthy life that could be achieved by having a 
healthy diet, exercising regularly, avoiding smoking, alcohol, and all vascular risk 
factors (hypercholesterolemia, hypertension, etc.) that could lead to damage of the 
cardiovascular system. This could potentially prevent reduced cerebral perfusion 
during the ageing process and this in turn would prevent the initiation of Aβ 
pathology. Additionally, amyloid immunisation aimed at preventing Aβ 
accumulation by clearing any excess of the protein before the process of 
oligomerisation is initiated, would also decrease the likelihood of developing AD in 
later life. A combined, early intervention targeting hypoperfusion and amyloid 
appears to be crucial, as both pathologies have shown to be able to self-perpetuate 






















By 2050, the number of cases of AD will triple and at present there is no effective 
treatment for the disease. Even more devastating is that it seems that there is no 
consensus regarding the aetiology of the disease. The present thesis builds on the 
discovery of the close resemblance between VaD and AD, and further finding of 
chronic cerebral hypoperfusion as a potential contributor to cognitive decline. 
Together, the results outlined in this study add to the role of reduced cerebral 
perfusion as a trigger in the initial steps of the chain of events leading to degenerative 
processes that may lead to cognitive deterioration. Moreover, the participation of Aβ 
is emphasised. These findings could be extended by future studies aiming at the 
investigation of a combined intervention strategy for the prevention of AD 
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Figure A1. Aβ levels are increased after chronic cerebral hypoperfusion in wild-
type mice. Animals were sacrificed after 1 (a, c) and 3 (b, d) months of chronic 
cerebral hypoperfusion. Following protein extraction, the levels of Aβ40/42 were 
quantified in the parenchymal fraction by ELISA. Graphs represent the levels of the 

























Figure A2. Chronic cerebral hypoperfusion does not affect APP metabolism in 
wild type animals. Western blot analysis of brain protein extracts after 1 (a, c, d) 
and 3 (b, e, f) months of hypoperfusion was performed to determine the expression 
levels of APP and CTFα. Specific bands were quantified by densitometric analysis 
and expressed relative to total tubulin protein, represented in the graphs. The data 



















Figure A3. Cerebral hypoperfusion increases vascular LRP-1 levels in wild-type 
animals. Western blot analysis of proteins extracts from vessels enriched fractions 
after 1 (a, c) or 3 (b, d) months of hypoperfusion was performed to determine the 
expression levels of LRP in wild-type mice; specific bands were quantified by 
densitometric analysis and expressed relative to total tubulin protein, represented in 




























Figure A4. MI load does not correlate either with vascular or with parenchymal 
Aβ. Scatter plot show no correlation between MI area and vascular (r = 0.05611, p = 
0.7415) (a) or parenchymal (r = 0.06368, p = 0.7122) (b) amyloid. 
 
 
 
 
 
 
 
 
 
